TMF-14449557  CONFIDENTIAL  206713  
The GlaxoSmithKline group of companies   Protocol Amd 02  
1 TITLE PAGE  
Protocol Title: A 52 -week, randomised, double -blind, placebo -controlled, parallel -
group, multi -centre study of the efficacy and safety of [COMPANY_004]3511294 adjunctive therapy 
in adult and adolescent participants with severe uncontrolled asthma with an eosinophilic 
phenotype  
Protocol Number : 206713 /Amendment 0 2 
Compound Number or Name:  [CONTACT_23983]3511294  
Brief Title: Placebo -controlled efficacy and safety study of [COMPANY_004]3511294  
(depemokimab)  in participants with severe asthma with an eosinophilic phenotype  
Study Phase:  Phase 3A  
Sponsor Name [CONTACT_29560]:  
GlaxoSmithKline Research & Development Limited  
[ADDRESS_31088] Information  can be found in the Study Reference 
Manual (SRM).  
Sponsor Signatory:  
David Lipson  
Vice President  and Disease Area Lead, Respi[INVESTIGATOR_31728]: GlaxoSmithKline   
Regulatory Agency Identifying Number(s):   
IND: [ADDRESS_31089]: 2020 -003632 -25 
Approval Date:  [ADDRESS_31090]-2020  TMF-2125331  
(2020N439965 _00) 
Amendment 02: 08 Apr 2022  
This amendment is considered to be substantial based on the criteria set forth in Article 
10(a) of Directive 2001/20/EC of the European Parliament and the Council of the 
European  Union.  
Overall Rationale for the Amendment :  
Amendment 02 is a global amendment to include details about  
 
 and the use of blinded interim data to complete a psychometric ana lysis 
of the Asthma Daily/Nightly Symptom Diary ( ADSD/ANSD ) and . 
Additional changes include repeated spi[INVESTIGATOR_31729]/or additional lab test if 
randomi sation criteria are not met during screening, change in the ratio of medium /high 
ICS dose, allowance/permittance of authorized COVID -19 treatments, Global Initiative 
for Asthma (GINA) inhaled corticosteroid (ICS) doses update, and QT prolongation 
clarifications. Added note for exclusion of adolescents in [LOCATION_013], [LOCATION_008] 
([LOCATION_006]), Russia. Text added related to special procedure for the urinalysis in China sites . 
Section # and Name  [CONTACT_9353] 1.3 Schedule of 
Activities  (SoA)  Added new footnote “h” 
spi[INVESTIGATOR_31730] a patient fails 
the protocol -specified reversibility 
criterion or FEV 1 inclusion criteria  
 
Added text to clarify that 
pregnancy text should be done at 
screening Visit 1 and Exit 
Visit/Withdraw from study visit  
 
Updated text in footnote “e” the 
Screening Visit laboratory 
assessment can be repeated 
during the run in period if a 
patient does not meet the blood To add flexibility in screening 
tests; c urrent information 
suggests this change is expected 
to result in improved screening 
while maintaining the integrity of 
the patient population  
 
Clarification  
 
 
 
 
To add flexibility in screening 
tests; current information 
suggests this change is expected 
to result in improved screening 
CCI
CCI
TMF-14449557  CONFIDENTIAL  206713  
 Protocol Amd 02  
 2 Section # and Name  [CONTACT_31877], 
electrocardiogram ( ECG ) must 
be perform ed and assessed pre -
dose  
 
Added text to clarify that 12 -lead 
ECG central over -read values 
should be used at all visits with 
the exception of Visit 2 and Visit 
10 where 12 -lead ECG machine 
read values should be used   while maintaining the integrity of 
the patient population  
 
 
 
Clarification  
 
 
Clarification  
Section 1.3 Schedule of 
Activities SoA 
(Urinalysis)  
 
10.2 Appendix 2: Clinical 
Laboratory Tests  
 
Section 10.11 Appendix 
11: Recommended 
measures Related to 
COVID -19 Pandemic 
(Table 6)  Text added to clarify that for 
China sites the urine specimen 
may be sent to the central 
laboratory for routine  urinalysis 
instead of performing a local 
urine dipstick.  Urinalysis should 
be performed at Visit 1 so that 
results are available befor e 
randomis ation at Visit 2 . Country specific procedure  
Section 2.3.1 Risk 
Assessment (QTc 
prolongation)  Removed text related to post -
baseline QTcF value of potential 
clinical importance from first time 
in human ( FTIH ) study (205722)  
 
Updated text related to ECG 
parameters including corrected 
QT interval using Fridericia’s 
formula (QTcF) for depemokimab 
treatment groups in the FTIH 
study (205722)  
 
Updated wordings related to 
analysis of the relationship 
between depemokimab plasma 
concentrations and change from 
baseline QTcF data collected in 
FTIH 205722 study  
 Modified text related to ECG 
parameters in the FTI H study 
(205722) for better clarity. No 
new safety information.  
TMF-14449557  CONFIDENTIAL  206713  
 Protocol Amd 02  
 3 Section # and Name  [CONTACT_9353] 4.1 Overall  
Design  
 
Section 6.4.1 Treatment 
Assignment  Changed the ratio of 
medium/high ICS dose from 25% 
medium ICS dose and 75% high 
ICS dose to aiming up to 50% 
approximately of participants on 
medium ICS dose  To better reflect dosing in clinical 
practice while maintaining the 
integrity of the patient population  
Section 5.1 Inclusion 
Criteria  Added note to clarify that, in [LOCATION_006], 
Russia and [LOCATION_013] only adult 
partic ipants (≥18 years) are to be 
included in this clinical trial  
 Clarification  
Section 5.2 Exclusion 
Criteria 
(Prior/Concomitant 
therapy)  Text added in exclusion criteria 
no. 12 to clarify that Authorized 
monoclonal antibodies ( mAbs ) 
treatments for COVID -[ADDRESS_31091] the overall interpretability 
of the data generated from this 
study or lead to any safety 
concern with concomitant use of 
IMP 
 
Section 5.2 Exclusion 
Criteria (Diagnostic 
Assesme nts) Text added in exclusion criteria 
no.15 to clarify that the 12 -lead 
ECG central over -read QTcF 
value is to be used  Clarification  
 
Section 5.3.2 
Randomi sation 
Exclusion Criteria  Text added in randomi sation 
exclusion criteria no. 3 to clarify 
that the 12-lead ECG machine 
read QTcF value is to be used at 
Visit 2. The central over -read of 
the Screening Visit 1 12 -lead 
ECG should be used to review 
ECG findings at Visit 2.  Clarification  
 
Section 6.9.1 Permitted 
Medications and Non -
Drug  Therapi[INVESTIGATOR_014]  “Additional asthma medications 
such as theophyllines and anti -
leukotrienes will be permitted as 
maintenance  provided that they 
have been taken regularly in the 
3 months prior to screening (Visit 
1)”. 
 Clarification  
 
 
 
 
 
 
 
Repeated text removed  
CCI
TMF-14449557  CONFIDENTIAL  206713  
 Protocol Amd 02  
 4 Section # and Name  [CONTACT_31878] -
CoV-2 infection using authorized 
COVID -19 vaccines  
 
Text added to clarify that 
participants can be treated for 
SARS -CoV-2 infection using 
authorized COVID -19 treatments 
(including mAbs ) in line with 
local/national guidelines.  
Experimental COV ID-[ADDRESS_31092] the overall interpretability 
of the data generated from this 
study or lead to any safety 
concern with concomitant use of 
IMP 
Section 7.1.2 QTc 
Stoppi[INVESTIGATOR_31731] 12 -lead 
ECG central over -read at 
randomisation Visit 2 should be 
used as baseline QTcF value for 
any changes from baseline 
calculations during the study  
 
Text adde d to clarify that after 
randomis ation 12 -lead ECG 
central over -read value s should 
be used to assess QTc stoppi[INVESTIGATOR_31732], with the exception of Visit 
10 (Week 26) where 12 -lead 
ECG machine read values 
should be used  Clarification  
 
 
 
 
 
 
 
Clarification  
Section 8.1.2 Critical 
Assessment performed 
at Screening (Visit 1)  Added new  text to clarify that if 
the Screening Visit test result 
does not meet the blood 
eosinophil count eligibility criteria, 
the laboratory  assessment may 
be repeated, at the discretion of 
the investigator  
 
Added text for spi[INVESTIGATOR_31733] a patien t fails the 
protocol -specified reversibility 
criterion or FEV1 inclusion 
criteria, spi[INVESTIGATOR_31734] -in period  
 To add flexibility in screening 
tests; current information 
suggests this change is expected 
to result in improved sc reening 
while maintaining the integrity of 
the patient population  
 
 
To add flexibility in screening 
tests; current information 
suggests this change is expected 
to result in improved screening 
while maintaining the integrity of 
the patient population  
TMF-14449557  CONFIDENTIAL  206713  
 Protocol Amd 02  
 5 Section # and Name  [CONTACT_31879] 8.3.3 
Electrocardiograms 
(ECGs)  Updated text related to additional 
ECGs to be performed if an ECG 
demonstrates a prolonged QTcF 
interval  Revised wording for clarification  
Section 9.2.1 Sample 
Size Assumptions  Added text regarding the 
possibility that greater than 375 
participants will be randomised in 
the study due to local country 
requests or requirements  Clarification  
Section 9.2.3  Sample 
Size Re -estimation or 
Adjustment  Text related to the data to be 
used for clinical study report has 
been deleted.   All data (pre and post - target 
enrolment) would be used for 
clinical study report  
Section 9.3 Analysis 
Sets Updated text related to screened, 
enrolled, randomised, full 
analysis set, and safety 
population  Revised description of Analysis 
sets 
 
 
Sectio n 9.4.5 Safety 
Analyses  Safety population used for Safety 
analyses instead of mITT  To provide clarification that all 
safety analyses will be performed 
on the Safety Population  
Section 9.6  
  
 
 
 
 
 
 
Added  text to describe that  
blinded interim data will be used 
to complete a psychometric 
analysis of the ADSD/ANSD and 
 
  
 
 
 
 
 
 
As part of the validation of the 
ADSD/ANSD and  
 a blinded, data cut 
off will be used to complete a 
psychometric analysis of the 
measures  
10.7.4 Recording and 
Follow -up of AE and/or 
SAE and Device 
Deficiencies 
(Assessment of Intensity)  Text deleted “other measures to 
evaluate AEs and SAEs may be 
utilised”.  Clarification  
Appendix 10 Medium 
and High Daily Doses of 
Inhaled Corticosteroids  Footnote added to clarify GINA 
2021 guidelines updates  Update as per GINA 2021 
guidelines  
Section 11 References  Added and updated the 
reference  
 Updated the references  
Throughout  Minor editorial and document 
formatting revisions  
 Minor, therefore hav e not been 
summarized  
CCI
CCI
CCI
CCI
CCI
TMF-14449557  CONFIDENTIAL  206713  
 Protocol Amd 02  
 6 TABLE OF CONTENTS  
PAGE  
PROTOCOL AMENDMENT S UMMARY OF CHANGES TA BLE ................................ ..... 1 
1. PROTOCOL SUMMARY  ................................ ................................ ........................  10 
1.1. Synopsis  ................................ ................................ ................................ ..... 10 
1.2. Schema  ................................ ................................ ................................ ...... 12 
1.3. Schedule of Activities (SoA)  ................................ ................................ ........  13 
2. INTRODUCTION  ................................ ................................ ................................ .... 22 
2.1. Study Rationale  ................................ ................................ ..........................  22 
2.2. Background  ................................ ................................ ................................  22 
2.3. Benefit: Risk Assessment  ................................ ................................ ...........  23 
2.3.1.  Risk Assessment  ................................ ................................ .........  24 
2.3.2.  Benefit Assessment  ................................ ................................ ..... 30 
2.3.3. Overall Benefit: Risk Conclusion  ................................ ..................  30 
3. OBJECTIVES AND ENDPO INTS  ................................ ................................ ...........  31 
3.1. Primary Estimand  ................................ ................................ .......................  33 
3.2. Secondary Estimands  ................................ ................................ .................  34 
4. STUDY DESIGN  ................................ ................................ ................................ .... 35 
4.1. Overall Design  ................................ ................................ ............................  35 
4.1.1.  Study Phases, Duration and Treatment Arms  ..............................  36 
4.1.2.  Treatment after the End of Study  ................................ .................  37 
4.1.3.  Independent Data Monitoring Committee (IDMC)  ........................  37 
4.2. Scientific Rationale for Study Design  ................................ ..........................  38 
4.2.1.  Participant Input into Design  ................................ ........................  39 
4.3. Justification for Dose  ................................ ................................ ..................  39 
4.4. End of Study and Study Completer Definition  ................................ .............  40 
5. STUDY POPULATION  ................................ ................................ ...........................  41 
5.1. Inclusion Criteria  ................................ ................................ .........................  41 
5.2. Exclusion Criteria  ................................ ................................ ........................  43 
5.3. Randomisation Criteria  ................................ ................................ ...............  45 
5.3.1.  Randomisation Inclusion Criteria  ................................ .................  45 
5.3.2.  Randomisation Exclusion Criteria  ................................ ................  47 
5.4. Lifestyle Considerations  ................................ ................................ ..............  47 
5.5. Pre-screen/Screen/Run -in Failures  ................................ .............................  48 
5.6. Criteria for Temporarily Delaying Randomisation  ................................ ........  48 
6. STUDY INTERVENTION A ND CONCOMITANT THERA PY ................................ .. 49 
6.1. Study Intervention Administered  ................................ ................................ . 49 
6.1.1.  Medical Devices  ................................ ................................ ...........  50 
6.2. Packaging and Labelling  ................................ ................................ .............  50 
6.3. Preparation/Handling/Storage/Accountability  ................................ ..............  50 
6.4. Measures to Minimise Bias: Randomisation and Blinding  ...........................  51 
6.4.1.  Treatment Assignment  ................................ ................................ . 51 
6.4.2.  Blinding  ................................ ................................ ........................  51 
  
6.5. Study Intervention Compliance  ................................ ................................ ... 52 
CCI
TMF-14449557  CONFIDENTIAL  206713  
 Protocol Amd 02  
 7 6.6. Dose Modification  ................................ ................................ .......................  52 
6.7. Continued Access to Study Intervention after the End of the Study  ............  53 
6.8. Treatment of Overdose  ................................ ................................ ...............  53 
6.9. Concomitant Therapy ................................ ................................ ..................  54 
6.9.1.  Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014]  ..........................  54 
6.9.2.  Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014]  .........................  55 
6.9.3.  Rescue Medicine  ................................ ................................ .........  55 
7. DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL  ................................ ................................ ..... 56 
7.1. Discontinuation of Study Intervention  ................................ ..........................  56 
7.1.1.  Liver Chemistry Stoppi[INVESTIGATOR_2121]  ................................ ................  57 
[IP_ADDRESS].  Study Intervention Restart or Rechallenge after 
liver stoppi[INVESTIGATOR_31735]  ................................ ............  58 
7.1.2.  QTc Stoppi[INVESTIGATOR_2121]  ................................ ................................ .. 58 
7.1.3.  Temporary Discontinuation  ................................ ..........................  59 
7.2. Participant Discontinuation/Withdrawal from t he Study  ...............................  [ADDRESS_31093] to Follow -Up ................................ ................................ ........................  60 
7.4. Reasons for Study Intervention Discontinuation and/or Study 
Withdrawal  ................................ ................................ ................................ .. 60 
7.5. Criteria for Follow -up of Potential Type III Hypersensitivity (Immune 
Complex Disease /Vasculitis)  ................................ ................................ ...... 60 
8. STUDY ASSESSMENTS AN D PROCEDURES  ................................ .....................  62 
8.1. Screening and Critical Baseline Assessments  ................................ ............  62 
8.1.1.  Pre-screening Visit (Visit 0)  ................................ ..........................  62 
8.1.2.  Critical Assessments performed at Screening (Visit 1)  .................  63 
8.1.3.  Critical Assessments performed at Randomisation (Visit 2)  .........  64 
8.2. Efficacy Assessments  ................................ ................................ .................  65 
8.2.1.  Efficacy Endpoints  ................................ ................................ ....... 65 
8.2.2.  Asthma Exacerbations  ................................ ................................ . 65 
8.2.3.  Pulmonary Function Testing/ Spi[INVESTIGATOR_038]  ................................ ..... 66 
[IP_ADDRESS].  Reversibility using the Maximum Post -
Bronchodilator Method  ................................ ...............  [ADDRESS_31094]. George’s Respi[INVESTIGATOR_31736] (SGRQ)  .........................  66 
8.2.5.  Asthma Control Questionnaire -5 (ACQ -5) ................................ .... 67 
  
8.2.10.  Asthma Daily Symptom Diary/Asthma Nightly Symptom 
Diary (ADSD/ANSD)  ................................ ................................ .... 68 
  
8.3. Safety Assessments  ................................ ................................ ...................  69 
8.3.1.  Physical Examinations  ................................ ................................ . 69 
8.3.2.  Vital Signs  ................................ ................................ ....................  69 
8.3.3.  Electrocardiograms (ECGs)  ................................ .........................  70 
8.3.4.  Clinical Safety Laboratory Assessments  ................................ ...... 70 
8.3.5.  Pregnancy Testing  ................................ ................................ ....... 71 
8.4. Adverse Events (AEs), Serious Adverse Events (SAEs) and Other 
Safety Reporting  ................................ ................................ .........................  [ADDRESS_31095]  ................................ ..............  74 
8.4.8.  Medical Device Deficiencies  ................................ ........................  75 
[IP_ADDRESS].  Time Period for Detecting Medical Device 
Deficiencies  ................................ ................................  75 
[IP_ADDRESS].  Follow -up of Medical Device Deficiencies  ...................  75 
[IP_ADDRESS].  Prompt Reporting of Medical Device 
Deficiencies to Sponsor  ................................ ..............  75 
[IP_ADDRESS].  Regulatory Reporting Requirements for Medical 
Device Incidents  ................................ .........................  75 
8.5. Pharmacok inetics  ................................ ................................ .......................  76 
8.6. Genetics and Pharmacogenomics  ................................ ..............................  76 
  
  
9. STATISTICAL CONSIDER ATIONS  ................................ ................................ ........  78 
9.1. Statistical Hypotheses ................................ ................................ .................  78 
9.2. Sample Size Determination  ................................ ................................ ........  78 
9.2.1.  Sample Size Assumptions  ................................ ...........................  78 
[IP_ADDRESS].  Primary Endpoint  ................................ ........................  78 
[IP_ADDRESS].  Secondary Endpoints  ................................ .................  79 
9.2.2.  Sample Size Sensitivity  ................................ ................................  79 
9.2.3.  Sample Size Re -estimation or Adjustment  ................................ ... 79 
9.3. Analysis Sets  ................................ ................................ ..............................  80 
9.4. Statistical Analysis  ................................ ................................ ......................  80 
9.4.1.  General Considerations  ................................ ...............................  80 
9.4.2.  Primary Endpoint  ................................ ................................ .........  81 
[IP_ADDRESS]. Main Estimand  ................................ ............................  81 
9.4.3.  Secondary Endpoints  ................................ ................................ ... 82 
[IP_ADDRESS].  Main Estimands  ................................ ..........................  82 
9.4.4.  Other Endpoints  ................................ ................................ ...........  83 
9.4.5.  Safety Analyses  ................................ ................................ ...........  83 
9.5. Multiple Testing Strategy  ................................ ................................ ............  84 
9.6.  
10. SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  ................................ ................................ ...............................  85 
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  ................................ ................................ ............................  85 
10.1.1.  Regulatory and Ethical Considerations  ................................ ........  85 
10.1.2.  Financial Disclosure  ................................ ................................ ..... 85 
10.1.3.  Informed Consent Process  ................................ ..........................  86 
CCI
CCI
CCI
TMF-14449557  CONFIDENTIAL  206713  
 Protocol Amd 02  
 9 10.1.4.  Data Protection  ................................ ................................ ............  86 
10.1.5.  Committees Structure  ................................ ................................ .. 87 
10.1.6.  Dissemination of Clinical Study Data  ................................ ...........  87 
10.1.7.  Data Quality Assurance  ................................ ...............................  88 
10.1.8.  Source Documents  ................................ ................................ ...... 88 
10.1.9.  Study and Site Start and Closure  ................................ .................  89 
10.1.10.  Publication Policy  ................................ ................................ .........  90 
10.2.  Appendix 2: Clinical Laboratory Tests  ................................ .........................  91 
10.3.  Appendix 3: AEs and SAEs: Definitions and Procedures for 
Recording, Evaluati ng, Follow -up, and Reporting  ................................ ....... 93 
10.3.1.  Definition of AE  ................................ ................................ ............  93 
10.3.2.  Definition of SAE  ................................ ................................ ..........  94 
10.3.3.  Definition of Cardiovascular Events  ................................ .............  95 
10.3.4.  Recording and Follow -Up of AE and SAE  ................................ .... 96 
10.3.5.  Reporting of SAE to [COMPANY_004]  ................................ .............................  98 
10.4.  Appendix 4: Contraceptive and Barrier Guidance  ................................ ....... 99 
10.4.1.  Definitions:  ................................ ................................ ...................  99 
10.4.2.  Contraception Guidance:  ................................ ...........................  100 
10.5.  Appendix 5: Genetics  ................................ ................................ ................  102 
10.6.  Appendix 6: Liver Safety: Required Actions, Monitoring and Follow -
up Assessments  ................................ ................................ .......................  103 
10.7.  Appendix 7: AEs, ADEs, SAEs, SAD Es, [LOCATION_003]DEs and Device 
Deficiencies: Definition and Procedures for Recording, Evaluating, 
Follow -up, and Reporting in Medical Device Studies  ................................  107 
10.7.1.  Definition of Medical Device AE and ADE  ................................ .. 107 
10.7.2.  Definition of Medical Device SAE, SADE and [LOCATION_003]DE  ...............  108 
10.7.3.  Definition of Device Deficiency  ................................ ...................  108 
10.7.4.  Recording and Follow -Up of AE and/or SAE and Dev ice 
Deficiencies  ................................ ................................ ...............  109 
10.7.5.  Reporting of SAEs  ................................ ................................ ..... 111 
10.7.6.  Reporting of SADEs  ................................ ................................ ... 112 
10.8.  Appendix 8: Anaphylaxis Criteria  ................................ ..............................  113 
10.9.   
10.10.  Appendix 10: Low, Medium and High Daily Doses of Inhaled 
Corticosteroids  ................................ ................................ ..........................  115 
10.11.  Appendix 11: Recommended Measures Related to COVID -19 
Pandemic ................................ ................................ ................................ .. 116 
10.12.  Appendix 12: Country -specific requirements  ................................ .............  129 
10.13.  Appendix 13: Abbreviations and Trademarks  ................................ ............  130 
10.14.  Appendix 14: Protocol Amendment History  ................................ ...............  134 
10.14.1.  Amendment 1: 17 -Aug-2021  ................................ ......................  134 
11. REFERENCES  ................................ ................................ ................................ ..... 138 
  
CCI
TMF-14449557  CONFIDENTIAL  206713  
 Protocol Amd 02  
 10 1. PROTOCOL SUMMARY  
1.1. Synopsis  
Protocol Title:  A 52 -week, randomised, double -blind, placebo -controlled, parallel -group, 
multi -centre study of the efficacy and safety of [COMPANY_004]3511294 adjunctive therapy in adult 
and adolescent participants with severe uncontrolled asthma with an eosinophilic 
phenotype  
Brief Title: Placebo -controlled efficacy and safety study of [COMPANY_004]3511294  (depemokimab)  
in participants with severe asthma with an eosinophilic phenotype  
Rationale:  
[COMPANY_004]3511294 is being developed as a long -acting (LA) subcutaneous (SC) injectable anti -
interleuk in-5 (anti -IL-5) therapy and is expected to deliver an efficacy and safety profile 
similar to current anti -IL-5 therapi[INVESTIGATOR_15128] a reduced dosing frequency (once every 26 
weeks). The aim of this study is to investigate the efficacy and safety, over a 52 -week  
treatment period, of [COMPANY_004]3511294 100 mg SC given once every 26 weeks as adjunctive 
therapy in participants with uncontrolled severe asthma with an eosinophilic phenotype.  
Objectives and Endpoints:   
Objectives  Endpoints  
Primary   
• To evaluate the efficacy of [COMPANY_004]3511294 
100 mg (SC) every 26 weeks versus 
placebo in participants with severe 
uncontrolled asthma with an eosinophilic 
phenotype  on top of existing asthma 
therapy  • Annualised rate of clinically significant 
exacerbationsa over 52 weeks  
Secondary   
• To evaluate [COMPANY_004]3511294 100  mg (SC) 
every 26 weeks versus placebo on health -
related quality of life (HRQoL) and 
additional efficacy assessments on top of 
existing asthma therapy  • Change from baseline in St. George's 
Respi[INVESTIGATOR_6015] (SGRQ) total 
score at Week 52  
• Change from baseline in Asthma Control 
Questionnaire -5 (ACQ -5) score at Week 52  
• Change from baseline in pre -bronchodilator 
forced expi[INVESTIGATOR_31737] 
(FEV 1) at Week 52  
• Annualised rate of exacerbations requiring 
hospi[INVESTIGATOR_31738] d/or Emergency 
Department (ED) visit over 52 weeks  
a. Clinically significant exacerbations will be defined as worsening of asthma requiring the use 
of systemic corticosteroids (IM, IV or oral) and/or hospi[INVESTIGATOR_31739]/or ED visit (see Section 
8.2.2 ). For all participants, IV or oral steroids (e.g., prednisone) for at least [ADDRESS_31096] 3 days is required.   
TMF-14449557  CONFIDENTIAL  206713  
 Protocol Amd 02  
 11 Overall Design:  
This study employs a multi -centre, randomised, placebo -controlled, double -blind, parallel 
group design to assess the efficacy and safety of [COMPANY_004]3511294 in participants with severe 
uncontrolled asthma with an eosinophilic phenotype despi[INVESTIGATOR_31740] o f care (SoC) 
treatment with medium to high dose inhaled corticosteroid (ICS) plus at least one  
additional controller. All participants will receive study intervention as an adjunct therapy 
while remaining on their existing asthma therapy throughout the stu dy. 
Brief Summary:  
The purpose of this study is to assess the efficacy and safety of [COMPANY_004]3511294 as an 
adjunctive therapy in participants with severe uncontrolled asthma with an eosinophilic 
phenotype. During the 52 -week treatment period, participants will receive two doses (at 
Week 0 and Week 26) of add -on study intervention  ([COMPANY_004]3511294 100 mg or matching 
placebo) by [CONTACT_10530], while remaining on their existing maintenance asthma therapy 
(that excludes biologics) throughout the study. Assessments will in clude the annuali sed 
rate of clinically significant exacerbations and measures of lung function, asthma control, 
and safety.  
Number of Participants:  
Approximately 540 participants with severe uncontrolled asthma with an eosinophilic 
phenotype will be scree ned to ensure the randomisation of 375 participants in a 2:1 ratio 
to [COMPANY_004]3511294 (n=250) and matching placebo (n=125).  
Intervention Groups and Duration:  
The study will consist of a pre -screen period (0 -2 weeks), a run -in period (1 -6 weeks), and 
a study in tervention period (52 weeks). After the run -in period, participants will be 
randomised in a 2:1 ratio using  an interactive response technology (IRT) system in a 
blinded manner to receive either [COMPANY_004]3511294 100 mg or placebo by [CONTACT_10530]. 
Randomisation wi ll be stratified based on baseline ICS dose (medium or high dose ). Two 
doses of study intervention will be administered in the clinic: the first at randomisation 
Visit 2 (Week 0) and the second at Visit 10 (Week 26). Participants will be assessed at 
each s cheduled visit (a total of 17 study visits) during the 52 -week treatment phase.  Study 
visits may be conducted remotely (by a home healthcare professional) or virtually, 
however, in -person clinic visits are required for the following: pre -screening Visit 0,  
screening Visit 1, randomisation Visit 2, Visit 3, Visit 10, Visit 11  Exit Visit 17, and WS 
Visit (if applicable).   
Participants who receive both doses of study intervention  and complete the Exit Visit will 
be eligible to participate in an open -label extension (OLE) study (Study 212895), during 
which they will receive two doses of open -label [COMPANY_004]3511294 [ADDRESS_31097] a follow -up visit/call at 
Week 56.  
 
Independent Data Monitoring Committee:  Yes 
TMF-14449557  CONFIDENTIAL  206713  
 Protocol Amd 02  
 12 1.2. Schema  
 
 

TMF-14449557  CONFIDENTIAL  206713  
  Protocol Amd 02  
 13 1.3. Schedule of Activities (SoA)  
Protocol Activity  Pre-
Screenin
g Screenin
g/Run -in Intervention Period and Exit Visit (visit window is 7 days)  Follow -
up 
/Withdra
w  
(7 days)  Notes  
Visit  V0 a Visit 1 a V2b 
R* V3 V4 V5 V6 V7 V8 V9 V1
0 V1
1 V1
2 V1
3 V1
4 V1
5 V1
6 Exit 
V17 WSc  FU R* =Randomisation  
WS=Withdraw from study visit  
(see footnote c) 
FU=Follow -up visit/call (only required for 
participants not entering OLE study)  Study Week  -8 to -6 -6 to -1 0 2 4 8 12 16 20 24 26 28 32 36 40 44 48 52 26 
or 
52 56 
Study Day  -56 to -
42 -42 to -7 1 14 28 56 84 112 140 168 182 196 224 252 280 308 336 364  392 
General Eligibility Assessments  
Informed consent 
a X (X)                   Conduct at Visit 1 if not completed at Visit 
0; See footnote a.  
Genetic sample 
informed consent 
d X (X)                   Conduct  at Visit 1 if not completed at Visit 
0; See footnote d.  
Demography data 
collection  X (X)                   Conduct  at Visit 1 if not completed at Visit 
0; All females must be assessed at Visit  1 
to determine childbearing potential.  
Inclusion/Exclusio
n criteria  X X                    
Historical blood 
eosinophil count   X                   See footnote e.  
Medical history   X                   Include cardiovascular (CV), CV risk 
factors, asthma, exacerbations, 
vasculitis, allergies and anaphylaxis.  
Smoking status   X                    
TMF-14449557  CONFIDENTIAL  206713  
  Protocol Amd 02  
 14 Protocol Activity  Pre-
Screenin
g Screenin
g/Run -in Intervention Period and Exit Visit (visit window is 7 days)  Follow -
up 
/Withdra
w  
(7 days)  Notes  
Visit  V0 a Visit 1 a V2b 
R* V3 V4 V5 V6 V7 V8 V9 V1
0 V1
1 V1
2 V1
3 V1
4 V1
5 V1
6 Exit 
V17 WSc  FU R* =Randomisation  
WS=Withdraw from study visit  
(see footnote c) 
FU=Follow -up visit/call (only required for 
participants not entering OLE study)  Study Week  -[ADDRESS_31098]. For details 
refer to study reference manual (SRM).  
eDiary registration 
and training   X                   Conduct thorough eDiary training at 
Screening Visit 1 and throughout the 
study on as -needed basis.   
Randomisation 
criteria    X                  Assess prior to randomisation; see 
footnote  e. 
Efficacy Assessments  
Review for 
exacerbations   X X X X X X X X X X X X X X X X X X X Collection of exacerbations at Visit 1 is 
historical data.  
Spi[INVESTIGATOR_038] (pre - 
and post -
bronchodilator 
FEV 1)h  X X        X       X X  FEV 1=Forced expi[INVESTIGATOR_3741] 1 
second ; Spi[INVESTIGATOR_31741]/suspected COVID -19 (see 
Section 8.2.3 ). 
ACQ -5   X X X X X X X X X X X X X X X X X  ACQ -5=Asthma Control Questionnaire -5 
TMF-14449557  CONFIDENTIAL  206713  
  Protocol Amd 02  
 15 Protocol Activity  Pre-
Screenin
g Screenin
g/Run -in Intervention Period and Exit Visit (visit window is 7 days)  Follow -
up 
/Withdra
w  
(7 days)  Notes  
Visit  V0 a Visit 1 a V2b 
R* V3 V4 V5 V6 V7 V8 V9 V1
0 V1
1 V1
2 V1
3 V1
4 V1
5 V1
6 Exit 
V17 WSc  FU R* =Randomisation  
WS=Withdraw from study visit  
(see footnote c) 
FU=Follow -up visit/call (only required for 
participants not entering OLE study)  Study Week  -8 to -6 -6 to -1 0 2 4 8 12 16 20 24 26 28 32 36 40 44 48 52 26 
or 
52 56 
Study Day  -56 to -
42 -42 to -7 1 14 28 56 84 112 140 168 182 196 224 252 280 308 336 364  392 
HRQoL: PRO and Health Outcomes Assessments  
SGRQ    X  X  X    X    X   X X  SGRQ=St. George’s Respi[INVESTIGATOR_31742]/ANSD   =========   daily   
========= → X X X X X X X X X X   ADSD/ANSD=Asthma Daily/Nightly 
Symptom Diary; To be completed daily 
during Run -in phase through Week 16, 
then to be  complete d for 1 full week 
during the week  preceding each visit 
thereafter.  
CCI
CCI
CCI
CCI
TMF-14449557  CONFIDENTIAL  206713  
  Protocol Amd 02  
 16 Protocol Activity  Pre-
Screenin
g Screenin
g/Run -in Intervention Period and Exit Visit (visit window is 7 days)  Follow -
up 
/Withdra
w  
(7 days)  Notes  
Visit  V0 a Visit 1 a V2b 
R* V3 V4 V5 V6 V7 V8 V9 V1
0 V1
1 V1
2 V1
3 V1
4 V1
5 V1
6 Exit 
V17 WSc  FU R* =Randomisation  
WS=Withdraw from study visit  
(see footnote c) 
FU=Follow -up visit/call (only required for 
participants not entering OLE study)  Study Week  -8 to -6 -6 to -1 0 2 4 8 12 16 20 24 26 28 32 36 40 44 48 52 26 
or 
52 56 
Study Day  -56 to -
42 -42 to -7 1 14 28 56 84 112 140 168 182 196 224 252 280 308 336 364  392 
Safety Assessments  
Concomitant 
Medication 
Assessment  X X X X X X X X X X X X X X X X X X X  Ensure maintenance asthma medications 
from the year prior to Screening Visit 1, 
all medications within the 3 months prior 
to Screening Visit 1 and all current 
medications are reviewed.  
Physical 
Examination   X                X X  Include height and weight for the 
complete physical exam at Screening 
Visit 1. Height can be omitted for 
subsequent visits.  
Vital Signs   X X   X   X  X X   X  X X X   
CCI
CCI
TMF-14449557  CONFIDENTIAL  206713  
  Protocol Amd 02  
 17 Protocol Activity  Pre-
Screenin
g Screenin
g/Run -in Intervention Period and Exit Visit (visit window is 7 days)  Follow -
up 
/Withdra
w  
(7 days)  Notes  
Visit  V0 a Visit 1 a V2b 
R* V3 V4 V5 V6 V7 V8 V9 V1
0 V1
1 V1
2 V1
3 V1
4 V1
5 V1
6 Exit 
V17 WSc  FU R* =Randomisation  
WS=Withdraw from study visit  
(see footnote c) 
FU=Follow -up visit/call (only required for 
participants not entering OLE study)  Study Week  -[ADDRESS_31099] be performed and assessed 
pre-dose . Twelve -lead ECG central over -
read values should be used at all visits 
with the exception of Visit 2 and Visit 10 
where 12 -lead ECG machine read values 
should be used.  
AE/SAE 
Assessment  X g X g X X X X X X X X X X X X X X X X X X AE=Adverse events; SAE=Serious 
adverse events; see footnote g. 
Laboratory Assessments  
Total IgE    X                   
Pregnancy Test 
(WOCBP only)   X X  X X X X X X X  X X X X X X X X Serum pregnancy test should be done at 
screening Visit 1 and Exit Visit / Withdraw 
from study visit ; urine pregnancy tests 
should be done for all other 
assessments; WOCBP=Women of 
childbearing potential; See Section 8.3.5  
for additional information.  
CCI
CCI
TMF-14449557  CONFIDENTIAL  206713  
  Protocol Amd 02  
 18 Protocol Activity  Pre-
Screenin
g Screenin
g/Run -in Intervention Period and Exit Visit (visit window is 7 days)  Follow -
up 
/Withdra
w  
(7 days)  Notes  
Visit  V0 a Visit 1 a V2b 
R* V3 V4 V5 V6 V7 V8 V9 V1
0 V1
1 V1
2 V1
3 V1
4 V1
5 V1
6 Exit 
V17 WSc  FU R* =Randomisation  
WS=Withdraw from study visit  
(see footnote c) 
FU=Follow -up visit/call (only required for 
participants not entering OLE study)  Study Week  -8 to -6 -6 to -1 0 2 4 8 12 16 20 24 26 28 32 36 40 44 48 52 26 
or 
52 56 
Study Day  -56 to -
42 -42 to -7 1 14 28 56 84 112 140 168 182 196 224 252 280 308 336 364  392 
CCI
TMF-14449557  CONFIDENTIAL  206713  
  Protocol Amd 02  
 19 Protocol Activity  Pre-
Screenin
g Screenin
g/Run -in Intervention Period and Exit Visit (visit window is 7 days)  Follow -
up 
/Withdra
w  
(7 days)  Notes  
Visit  V0 a Visit 1 a V2b 
R* V3 V4 V5 V6 V7 V8 V9 V1
0 V1
1 V1
2 V1
3 V1
4 V1
5 V1
6 Exit 
V17 WSc  FU R* =Randomisation  
WS=Withdraw from study visit  
(see footnote c) 
FU=Follow -up visit/call (only required for 
participants not entering OLE study)  Study Week  -8 to -6 -6 to -1 0 2 4 8 12 16 20 24 26 28 32 36 40 44 48 52 26 
or 
52 56 
Study Day  -56 to -
42 -42 to -7 1 14 28 56 84 112 140 168 182 196 224 252 280 308 336 364  392 
Immunogenicity 
sample    X X X X X    X X X X X   X X   
Genetics sample    =============  The genetics sample can be 
collected at Visit 2 or any visit 
after ============= →   See footnote d.  
Study intervention  
Administer study 
intervention    X        X          Study intervention will only be 
administered in the clinic. Any scheduled 
assessments or sample draws should be 
performed before hand . Monitor 
participant for at least 2h  after 
administration  (see Section 6.5). 
eCRF/worksheets/other  
CCI
CCI
TMF-14449557  CONFIDENTIAL  206713  
  Protocol Amd 02  
 20 Protocol Activity  Pre-
Screenin
g Screenin
g/Run -in Intervention Period and Exit Visit (visit window is 7 days)  Follow -
up 
/Withdra
w  
(7 days)  Notes  
Visit  V0 a Visit 1 a V2b 
R* V3 V4 V5 V6 V7 V8 V9 V1
0 V1
1 V1
2 V1
3 V1
4 V1
5 V1
6 Exit 
V17 WSc  FU R* =Randomisation  
WS=Withdraw from study visit  
(see footnote c) 
FU=Follow -up visit/call (only required for 
participants not entering OLE study)  Study Week  -8 to -6 -6 to -1 0 2 4 8 12 16 20 24 26 28 32 36 40 44 48 52 26 
or 
52 56 
Study Day  -56 to -
42 -42 to -7 1 14 28 56 84 112 140 168 182 196 224 252 280 308 336 364  392 
Provide 
worksheet   X X X X X X X X X X X X X X X X    The worksheet is a medical problems and 
healthcare utili sation worksheet.  Review worksheet    X X X X X X X X X X X X X X X X X  
eDiary close out                   X X   
Complete eCRF  X X X X X X X X X X X X X X X X X X X  eCRF=electronic Case Report Form  
                      
a. Informed Consent must be obtained prior to initiating any study assessments. Pre -screening Visit [ADDRESS_31100] be available for review of randomisation criteria.  
c. If a participant withdraws from t he study, then the Withdraw from Study (WS) Visit should be conducted [ADDRESS_31101] administered dose of study inte rvention, i.e., at 
Week 26 if the second dose of study intervention was not received, or at Week 52 if the second dose of study int ervention was received. A follow -up visit/call should also be 
conducted [ADDRESS_31102] dose of study intervention for AE/SAE assessments and pregnancy testing.  
d. Informed Consent for optional genetics research must be obtained before collecting a s ample. China only:   Genetic Informed Consent will not be collected from participants in 
China.  Genetic blood samples will not be collected from participants in China.  
e. To be randomised, participants without a historical blood eosinophil count of ≥300 cells/ µL in the [ADDRESS_31103] a blood eosinophil count of ≥150 
cells/µL at Screening Visit 1. If the Screening Visit test result does not meet the blood eosinophil count eligibility criter ia, the laboratory  assessment may be re peated, at the 
discretion of the investigator, if it is judged to be likely in the eligible range for study inclusion within the run -in period prior to Visit 2.  
f. 
CCI
CCI
TMF-[ADDRESS_31104] an established efficacy and long-term safety profile and are a 
cornerstone of severe asthma management for patients with an eosinophilic phenotype 
[GINA , 2020]. Three antagonists of IL -5 (mepolizumab and reslizumab) or its receptor 
(IL-5R) (benralizumab) are approved for severe asthma  with an eosinophilic phenotype , 
as an add -on treatment administered every 4 to 8  weeks.  
[COMPANY_004]3511294  (depemokimab)  is being developed as a LA SC injectable anti -IL-5 therapy 
and is anticipated to deliver an efficacy and safety profile similar to current anti -IL-5 
therapi[INVESTIGATOR_15128] a reduced dosing frequency (once every 26 weeks). The aim of this study 
is to investigate t he efficacy and safety, over a 52 -week treatment period, of 
[COMPANY_004]3511294 100  mg SC given once every 26 weeks as adjunctive therapy to 
participants with uncontrolled severe asthma with an eosinophilic phenotype.  
2.2. Background  
Persistent eosinophil inflammation i s a feature of more than 50% of patients with severe 
asthma [ Chung , 2014]. Several monoclonal antibodies (mAbs) targeting eosinophil 
inflammation have receive d marketing authori sation for asthma with an eosinophilic 
phenotype, including 3 targeting either interleukin -5 (IL -5) or its receptor (IL -5R): 
mepolizumab (Nucala), reslizumab (Cinqair/Cinqaero), and benralizumab (Fasenra). All 
three, by [CONTACT_31804] e osinophils as a biomarker to predict patients likely to respond to 
therapy, have been shown to reduce asthma exacerbations, and improve lung function and 
health -related quality of life (H RQoL), in patients with asthma with an eosinophilic 
phenotype [ Haldar , 2009; Castro , 2011; Pavord , 2012; Bel, 2014; Ortega , 2014; Castro , 
2015; Bleecker , 2016; FitzGerald , 2016; Chupp , 2017].  
Evidence supporting the tolerability of targeting IL -5/5R is provided by [CONTACT_7419] -term 
extension studies  for mepo lizumab  [Lugogo , 2016; Khatri , 2019; Khurana , 2019] , 
reslizumab [ Murphy , 2017 ], and benra lizumab [ Busse , 2019] as well as efficacy data in 
real-world evidence settings  for mepo lizumab  [Harrison , 2020; Bagnasco , 2019; Pertzov , 
2019; Schleich , 2020]. Clinical trial data over more than [ADDRESS_31105] are both 
highly effective and well -tolerated. Based on this established efficacy and safety, anti -IL-
5/5R therapi[INVESTIGATOR_31743] a cornerston e of severe asthma management and are endorsed by 
[CONTACT_31805][INVESTIGATOR_31744] 4 or Step 5 treatment (medium and high dose ICS) [GINA , 
2020].  
[COMPANY_004]3511294 is a humanised , affinity matured mAb that blocks human IL -5 binding to 
its receptor and belongs to the established class of anti -IL-5 therapi[INVESTIGATOR_31745].  
 
. The resulting 
antibody has increased affinit y and half -life. Evidence to date indicate that these amino 
acid changes extend the pharmacokinetics (PK) and pharmacology of [COMPANY_004]3511294 to 
CCI
TMF-14449557  CONFIDENTIAL  206713  
 Protocol Amd 02  
 23 enable less frequent dosing with an anticipated similar efficacy  and safety  profile relative 
to mepolizumab (adminis tered chronically).  
Long -acting alternatives that can be administered on a less frequent basis are recognised 
as successful approaches for chronic indications. As a LA anti -IL-[ADDRESS_31106] an efficacy and safety profile that is similar to those 
of the currently -approved therapi[INVESTIGATOR_31746] , but with a single administration every 
26 weeks, as opposed to the current regimen of every 4 weeks for mepolizumab and 
reslizumab, or every 8 weeks for benralizumab (every [ADDRESS_31107] 3 doses).  
A detailed description of the chemistry, pharmacology, and safety of [COMPANY_004]3511294 is 
provided in the current Investigator’s Brochure ( IB) [GlaxoSmithKline Document 
Number 2016N295843_03  or later].  
2.3. Benefit:  Risk Assessment  
Summaries of findings from non -clinical studies conducted with [COMPANY_004]3511294 and 
completed FTIH study 205722 can be found in the current IB [GlaxoSmithKline 
Document Number 2016N295843_03  or later] . The following section outlines the risk 
assessment and mitigation strategy for this protocol : 
 
TMF-14449557  CONFIDENTIAL  206713  
 Protocol Amd 02  
24 2.3.1.  Risk Assessment  
Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Study Intervention [COMPANY_004]3511294  
• Allergic reactions including anaphylaxis.  • Allergic reactions with the most severe form 
being anaphylaxis (see Appendix 8 ), are 
potential risks associated with mAbs.  
• No allergic reactions or anaphylaxi s have 
been reported with [COMPANY_004]3511294 in FTIH 
study 205722 in participants  with mild to 
moderate asthma. One participant  reported 
an event under Hypersensitivity SMQ with 
preferred term of rash verbatim “locali sed 
rash both bends of arms”, [ADDRESS_31108] 30 
mg SC dose of [COMPANY_004]3511294. The event 
was non -serious, of mild intensity, resolved 
within 10 days and was considered 
unrelated to the study intervention  by [CONTACT_1275] . 
 • Daily monitoring of serious adverse events 
(SAEs) by [CONTACT_25290]/SAE 
coordinator ; regular systematic review of 
adverse event (AE)/SAE data from ongoing 
studies by a [COMPANY_004] safety review team.  
• Use of Joint NIAID/FAAN 2nd 
Symposium on Anaphylaxis to collect data 
on reports of anaphylaxis (see Appendix 8 ). 
• Participants will be monitored in clinic for 
immediate hypersensitivity and any other 
untoward effects for a minimum of [ADDRESS_31109]-injection  (both at randomisation and at 
Week 26) . In the event of an acute severe 
reaction (e.g., anaphylaxis) following 
administration of study intervention , there 
are personnel/staff onsite at the treatment 
facility who are appropriately trained in 
basic life support to manage the participant  
includin g administration of medications 
(e.g., epi[INVESTIGATOR_238]), and have access to a 
system that can promptly transport the 
participant  to another facility for additional 
care if appropriate.  
• An independent data monitoring committee 
(IDMC ) will review unblinded safet y data 
at regular intervals . 
TMF-14449557  CONFIDENTIAL  206713  
 Protocol Amd 02  
25 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
• Participants with severe allergic 
reaction/anaphylaxis with no alternative 
explanation  after the first dose will not 
receive another dose.  
• Type III Hypersensitivity (Immune complex 
disease/vasculitis)  • Adverse effects of vascul ar inflammation 
consistent with immune complex disease 
were observed in 1  female monkey in the 
1-month toxicity study after administration 
of 10  mg/kg. A further monkey had a 
minimal focal inflammation after 
administration of 100  mg/kg.  Immune 
complex dise ase was not observed in the 
6-month repeat dose (2  doses) study at the 
same doses. It is unknown if this will 
translate to humans as preclinical models 
are not necessarily predictive of clinical 
findings in humans.  
• No AEs of Type III hypersensitivity have 
been reported with [COMPANY_004]3511294 in FTIH 
study 205722 in participants with mild to 
moderate asthma (3 6 participants received 
[COMPANY_004]3511294; 12 participants received 
placebo).  • Participants with current diagnosis of 
vasculitis will be excluded. Participants 
with high clinical suspi[INVESTIGATOR_31747]  (Section 5.2). 
• Daily monitoring of SAEs will be done by 
[CONTACT_25290]/SAE coordinator; regular 
systematic review of adverse event 
(AE)/SAE data from ongoing studies will be 
performed by a [COMPANY_004] safety review team.  
• IDMC will review unblinded safety data at 
regular interva ls; any events suggestive of 
immune complex disease will be reviewed 
by a rheumatologist (member of the IDMC).   
• Protocol guidance on early identification of 
vasculitis events is provided (see 
Section  7.5). 
• Participants with confirmed vasculitis or 
suspected vasculitis with no alternative 
explanation after the first dose will not 
receive another dose of study intervention 
(see Section 7.1). 
TMF-14449557  CONFIDENTIAL  206713  
 Protocol Amd 02  
26 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
• Immunogenicity, anti -drug antibodies 
(ADAs)  • Biopharmaceutical products may elicit 
ADAs and neutralising antibodies (NAb), 
which have the potential to modulate PK or 
pharmacodynamics ( PD), or to produce 
adverse reactions.  
• In FTIH study 205722, none of the 
participants tested positive for ADA at 
baseline. Overall, 9 participants (25%) had 
confirmed positive results for ADA at any 
time post -baseline, primarily in the 
[COMPANY_004]3511294 30 mg dose group (5 
participants), which was also the group with 
the highest total serum IL -5 concentrations. 
This apparent co rrelation warrants further 
investigation. There were no major 
differences observed in the [COMPANY_004]3511294 
plasma concentration  profiles  and blood 
eosinophil count -time profiles as well as AE 
reporting between ADA -positive and ADA -
negative participants. Neutrali sing 
antibodies were not tested in this study.  • Blood samples will be collected for 
detection of both ADA and N Ab (see 
Section 8.8). 
• Local injection  site reactions  • A potential risk of any drug delivered via 
injection.  
• No injection site reactions were noted in the 
preclinical studies.  
• In the [COMPANY_004]3511294 FTIH study 205722, 
injection site reactions were reported by [CONTACT_31806] 
(3%) participant who received • Daily monitoring of SAEs by [CONTACT_31807]/SAE coordinator; regular 
systematic review of AE/SAE data from 
ongoing studies by [CONTACT_31808]/or 
[COMPANY_004] safety review team.  
• The IDMC will review unblinded safety 
data at regular intervals.  
TMF-14449557  CONFIDENTIAL  206713  
 Protocol Amd 02  
27 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
[COMPANY_004]351 1294 and one (8%) participant who 
received placebo.  
• QTc prolongation  • Four monkeys in the 6 -month repeat dose 
monkey study administered 100  mg/kg 
every 3 months (2 doses) were observed to 
have QTc prolongation (mean change of 18 
msec relative to vehicle control value) 
durin g Week 14.  
• In the [COMPANY_004]3511294 FTIH study (205722), 
no treatment effect for ECG parameters 
including corrected QT interval (QTcF) 
was observed across the [COMPANY_004]3511294 
treatment groups (n=36). No participants 
met QTcF protocol specified criteria (QTcF 
>500 msec  or increase from baseline >60 
msec, or uncorrected QT >600 msec) that 
would require additional monitoring.  
• Analysis of the relationship between 
[COMPANY_004]3511294  plasma concentrations and 
change from baseline QTcF data collected 
in FTIH 205722 study did not reve al any 
clinically or statistically significant trends of 
concern with increasing [COMPANY_004]3511294  dose 
up to 300 mg. The predicted increase in 
mean QTcF change from baseline with 
[COMPANY_004]3511294  plasma concentrations point 
estimates remained below 10 msec [ FDA , 
2005] up to concentrations of 100 ug/mL, 
with a 95% lower CI consistent with zero 
change from baseline (i.e. the 95% lower • ECGs will be performed according to 
timepoints specified in the SoA 
(Section  1.3) and the assessment will be 
done as specified in Section 8.3.3 . 
• Participants with  QTc prolongation on 
screening will be excluded (criterion 15, 
Section 5.2). 
• Participants with a pre -existing clinically 
significant cardiac medical condition are 
excluded (criterion 7, Section 5.2). 
• Participants who meet QT stoppi[INVESTIGATOR_31748] 7.1.2  will not receive 
another dose of study intervention.  
• The IDMC will review unblinded safety 
data at regular intervals.  
TMF-14449557  CONFIDENTIAL  206713  
 Protocol Amd 02  
28 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
bound of the CI is below zero) [[COMPANY_004] 
Docume nt Number: 2020N457410_00 ]. 
• Risk of [COMPANY_004]3511294 affecting an unborn 
baby.  • Reproductive studies have no t been 
conducted with [COMPANY_004]3511294; however, in 
the [ADDRESS_31110] to their stage in the 
spermatogenic cycle and the integrity of the 
various cell types present within the 
different stages in sexually mature males. 
No cell or stage specific abnormalities were 
noted.   
• In addition, there is a low reproductive risk 
associated with the IL -5 target mechanism 
(as shown in pre -clinical reproductive 
toxicology studies of mepolizumab and  
reslizumab), a low genotoxic concern for 
mAbs in general, and a low transfer of 
mAbs into semen due to the inability of 
large molecular weight proteins such as 
[COMPANY_004]3511294 to access pi[INVESTIGATOR_31749] [ Setchell , 1975; Pollanen , 1995; 
Pollanen , 1989; Setchell , 2001; Sohn , 
2016], the risk of adverse effects on 
spermatogenesis is considered minimal. 
Therefore, male participants are not required 
to use contraception.  • Participants who are pregnant, 
breastfeeding, or p lan to become pregnant at 
Screening are excluded (criterion 19, 
Section 5.2). Participants who become 
pregnant during the study will not receive 
another dose of study intervention (see 
Section 7.1).  
• All female participants will be assessed at 
screening to determine childbearing status. 
Female participants of childbearing 
potential must be using a highly effective 
contraceptive method from at least [ADDRESS_31111] administered dose as described in 
Section 10.4.2 . 
TMF-14449557  CONFIDENTIAL  206713  
 Protocol Amd 02  
29 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Study Procedures  
• Potential risk for injury with phlebotomy.  • Risks with phlebotomy include bruising, 
bleeding, infection, nerve damage.  • Procedures to be performed by [CONTACT_31809] (i.e., study nurse).  
 
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
30 2.3.2.  Benefit Assessment  
Current clinical data from approved anti -IL-5/5R mAbs ( mepolizumab , reslizumab, and 
benralizumab)  demonstrate clinical utility  in the treatment of conditions associated with 
elevated eosinophil levels, such as  severe asthma with an eosinophilic phenotype. 
Mepolizumab 100  mg SC (every 4 weeks) is approved as an add -on maintenance 
treatment for severe asthma  with an eosinophilic phenotype . The safety profile of 
mepolizumab is favourable.  
As a LA anti -IL-5 mAb, GS K3511294 is anticipated to provide the same clinical benefit 
with a similar safety profile compared with mepolizumab and others in its class and with 
the added benefit of an extended duration of action requiring  less frequent SC dosing 
(once every 6 months ). As such, [COMPANY_004]3511294 may offer the convenience of an improved 
dosing schedule.  
2.3.3.  Overall Benefit: Risk Conclusion  
Taking into account the measures being implemented to minimi se risk to participants in 
this study, the potential risks of participating in th is study  are justified by [CONTACT_31810]; therefore, the Sponsor considers that the investigation of the 
efficacy, and safety of [COMPANY_004]3511294 is jus tified in this study  with a positive benefit:  risk 
ratio.  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
31 3. OBJECTIVES AND ENDPO INTS  
Objectives  Endpoints  
Primary   
• To evaluate the efficacy of [COMPANY_004]3511294 
100 mg (SC) every 26 weeks versus 
placebo in participants with severe 
uncontrolled asthma with an eosinophilic 
phenotyp e on top of existing asthma 
therapy  • Annuali sed rate of clinically significant 
exacerbationsa over 52 weeks  
Secondary   
• To evaluate [COMPANY_004]3511294 100  mg (SC) 
every 26 weeks versus placebo on health -
related quality of life (H RQoL) and 
additional efficacy assessments  on top of 
existing asthma therapy  • Change from baseline in St. George's 
Respi[INVESTIGATOR_6015] (SGRQ) total 
score at Week 52  
• Change from baseline in Asthma Control 
Questionnaire -5 (ACQ -5) score at Week 52  
• Change from baseline in pre -bronchodilator 
forced expi[INVESTIGATOR_31737] 
(FEV 1) at Week 52  
• Annuali sed rate of exacerbations requiring 
hospi[INVESTIGATOR_31739]/or Emergency 
Department (ED) visit  over 52 weeks  
Other   
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
32 Objectives  Endpoints  
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
33 Objectives  Endpoints  
Safety  
• To evaluate the safety and tolerability of 
[COMPANY_004]3511294 100 mg (SC) every 26 weeks 
versus placebo in participants with severe 
uncontrolled asthma with an eosinophilic 
phenotype  on top of existing asthma 
therapy  • Incidence of AEs/SAEs  
• Laboratory parameters, including 
haematological and clinical chemistry 
parameters  
• Vital signs including blood pressure (BP), 
body temperature, and pulse rate  
• ECG assessments  
• Incidence of immunogenicity as measured 
by [CONTACT_31811]/NAb to 
[COMPANY_004]351129 4  
  
a. Clinically significant exacerbations will be defined as worsening of asthma requiring the use 
of systemic corticosteroids (IM, IV or oral) and/or hospi[INVESTIGATOR_31739]/or ED visit (see Section 
8.2.2 ). For all participants , IV or oral steroids (e.g., prednisone) for at least [ADDRESS_31112] 3 days is required.   
3.1. Primary Estimand  
Population:  Adult and adolescent participants with severe uncontrolled asthma with an 
eosinophilic phenotype following the strategy outlined below for dealing with the main 
intercurrent events that are anticipated . 
Treatment comparison:  [COMPANY_004]3511294 + SoC compared with placeb o + SoC  
Endpoint:  Annuali sed rate of clinically significant exacerbations  over 52 weeks  
Main intercurrent events anticipated:  
• Study intervention discontinuation due to reasons unrelated to the COVID -19 
pandemic:  
 
• Study intervention discontinuation due to reasons related to the COVID -19 
pandemic:  
 
CCI
CCI
CCI
CCI
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
34 • Change in maintenance therapy or use of prohibited medications (listed in 
Section  6.9.2 ):  
 
Summary measure:  Ratio of the rates of clinically significant exacerbations between 
[COMPANY_004]3511294 + SoC and placebo  + SoC  
For further details, see (Section  9.4 
3.2. Secondary Estimand s 
Population : Adult and adolescent participants with severe uncontrolled asthma with an 
eosinophilic phenotype following the strategy outlined below for dealing with the main 
intercurrent events that are anticipated.  
Treatment comparison:  [COMPANY_004]3511294 + SoC compared with placebo  + SoC  
Endpoints:  
• Change from baseline in SGRQ at Week 52  
• Change from baseline in ACQ -5 at Week 52  
• Change from b aseline in pre-bronchodilator FEV 1 at Week 52  
• Annuali sed rate of clinically significant exacerbations requiring hospi[INVESTIGATOR_31750]/or ED  visit over 52 weeks  
Main intercurrent events anticipated:  
• Study intervention discontinuation due to reasons unrelated to the COVID -19 
pandemic:  
 
• Study intervention discontinuation due to reasons related to the COVID -19 
pandemic:  
 
• Change in maintenance therapy or use of prohibited medications (listed in 
Section  6.9.2 ):  
 
Summary measures:  
• Difference in mean change from baseline in SGRQ at Week 52  
• Difference in mean change from baseline in ACQ -5 at Week 52  
• Difference in mean change from baseline in pre -bronchodilator FEV 1 at Week 52  
• Ratio of the rates of clinically significant exacerbations requiring hospi[INVESTIGATOR_31750]/or ED  visit  
between [COMPANY_004]3511294  + SoC  and placebo  + SoC . 
For further details , see (Section 9.4) 
CCI
CCI
CCI
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
35 4. STUDY DESIGN  
4.1. Overall Design  
This study employs a multi -centre, randomised, placebo -controlled, double -blind, parallel 
group design. The study will recruit adults and adolescents ( 12 years) with a confirmed 
diagnosis of severe asthma with an eosinophilic phenotype and who are on a regimen of 
medium to high dose ICS ( 440 mcg fluticasone propi[INVESTIGATOR_16847] [FP]  hydrofluoroalkane 
product [HFA]  daily , or clinical ly comparab le [GINA , 2020 ; see Appendix 10 ]) plus at 
least one  additional con troller medication, with evidence of bronchodilator reversibility 
or airway hyperresponsiveness as measured by [CONTACT_31812]/histamine challenge. 
Eligible participants must have uncontrolled asthma with a history of repeat 
exacerbations ( 2 exacerbations in  the previous 12 months) while  on their existing 
maintenance asthma therapy that excludes any biologics. Participants will be required to 
have a blood eosinophil count of 150 cells/µL at screening or 300 cells/µL 
documented in the [ADDRESS_31113] received any anti -
IL-5/5R mAb therapy within the last 12 months will be excluded from this study.  
Participants will attend a Pre -screen Visit (Visit 0) to sign consent and a Screening Visit 
(Visit 1; may be done on the same day  as Visit 0) for eligibility assessments (see Section 
8.1). At the conclusion of the run -in period (Visit 2), participants who meet the pre -
defined criteria (see Section 5.1 and Section 5.3) will be randomised in a 2:1 ratio to 
receive either [COMPANY_004]3511294 100  mg or placebo, administered SC (at Week 0 and Week 
26) in the clinic via a pre -filled safety syringe ( PFS) as an adjunct therapy. 
Randomisation will be stratified based on baseline ICS dose ( aiming to up to 50% 
approximately of participants on medium ICS dose ; see Appendix 10 ). Participants will 
remain on their existing stable maintenance asthma therapy throughout the study (See 
Section 6.9 for details on concomitant medications). See Section 4.1.1  for additional 
details on the study phases, duration, and treatment arms.  
The primary outcome measure will be the annuali sed rate of clinically significant 
exacerbations (i.e. exacerbations requiring systemic CSs and/or hospi[INVESTIGATOR_31739]/or ED  
visit [see Section 8.2.2 ]) measured over the 52 -week treatment period. Additional 
efficacy assessments will include lung function (pre - and post -bronchodilator FEV 1), 
asthma control (AC Q-5), HRQoL measured with SGRQ,   
 daytime and night -time asthma symptoms 
(ADSD/ANSD),  
 (see Section 8.2).  
The study will include safety ( see Section 8.3 and Section  8.4) and immunog enicity (see 
Section 8.8) assessments to characteri se the safety profile of [COMPANY_004]3511294 100  mg SC 
following repeat dosing.  
 
 
After randomisation, all participants will be encouraged to remain in the study and 
complete all scheduled visits, regardless of whether they receive the second dose of study 
intervention at Week 26. Participants who experience any of the stu dy intervention 
CCI
CCI
CCI
CCI
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
36 discontinuation conditions (listed in Section 7.1) will not receive another dose of study 
intervention.  
Study visits may be conducted remotely (by a home healthcare professional) or virtually , 
however, in -person clinic visits are required for the following: pre -screening Visit 0, 
screening Visit 1, randomisation Visit 2, Visit  3, Visit 10, Visit 11  Exit Visit  17, and WS 
Visit (if applicable). Participants who are unable to attend their scheduled clinic visits due 
to COVID -19 restrictions or other unexpected events may complete some visits at home 
(see Appendix 11 ). Note : study intervention will only be administered in the clinic (at 
Week 0 and Week 26 visits).  
4.1.1.  Study Phases, Duration and Treatment Arms  
At pre -screening, participants will be requested to participat e in the study for a maximum 
of 60 weeks (Visit 0 to the Exit Visit, inclusive) or 64 weeks if not continuing into the 
OLE Study 212895 (Visit 0 to the Follow -up Visit, inclusive).  
During the study, participants will remain on their existing maintenance as thma therapy 
whilst completing all phases of the study described in Table 1.  
Table 1 Study Phases  
Phase  Phase Title  Duration  Description  
1 Pre-screening 
(Visit 0)  0-2 weeks  Details about the study and procedures will be 
explained through the informed consent process. The 
Pre-screening Visit (Visit 0) can occur on the same day 
as the Screening Visit (Visit 1) but must be completed 
prior to initiating any Visit 1 procedures  
2 Screening 
(Visit  1) and 
Run-in 1-6 weeks  Participants who meet all the eligibility criteria at 
Screening (Visit 1) will enter the run -in period for a 
minimum of 1 week and a maximum of 6 weeks.  
The run -in is intended to assess the participant’s 
compliance with study -related procedures and 
continued eligibility for the stu dy as well as to collect 
baseline eDiary data.  
Participants who experience an asthma exacerbation 
during the run -in period should receive treatment for 
their exacerbation and remain in the run -in period until 
the investigator considers that the participant  has 
returned to their baseline asthma status for at least one 
week.  
The participants that are not eligible to continue in the 
study at the end of the run -in period will be deemed 
run-in failures, but may be rescreened after 
consultation with the Medical Monitor (Section 5.5). 
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
37 Phase  Phase Title  Duration  Description  
3 Study 
Intervention 
(Visit 2 -Visit 
17) 52 weeks  Participants who meet the randomisation criteria will 
enter the 52 -week trea tment period and will be 
randomised to receive either add -on [COMPANY_004]3511294 
(100 mg) or matching placebo in a 2:1 ratio.  
During the treatment phase, a total of 2 doses of study 
medication will be administered SC via PFS: at 
Week  0 (Visit 2) and Week 26 (Visit  10).a 
Study  visits will occur at Week 0, Week 2, Week 4 and 
every 4 weeks  thereafter with an additional study visit 
at Week 26 for the administration of the second dose 
of study intervention. The study intervention period will 
conclude with the Exit Visit  at Week 52 (Visit 17).  
Only participants who choose not to enter the OLE study will complete the phase below:  
4 Follow -up 4 weeks  Participants will complete a Follow -up visit/call 4 weeks 
after the Exit Visit; this visit/call will capture AE/SAE 
assessments and a urine pregnancy test result.  
At the end of the Follow -up visit/call, participants will be 
prescribed appropriate alternat ive asthma therapy at 
the physician’s discretion, if required.  
a. Participants who experience any of the study intervention discontinuation conditions listed in 
Section 7.1 will not receive another dose of study intervention but will be encouraged to 
remain in the study and complete their remaining scheduled visits/assessments.  
4.1.2.  Treatment after the End of Study  
Participants who receive both doses of double -blind treatment and complete the Week 52 
Exit Visit will be eligible to participate in the OLE study 212895. See Section 6.7 for 
details.  
Participants who are not entering the OLE study 212895 will enter a 4 -week follow -up 
period and complete the study with a Follow -up visit/call at Week 56. After study 
completion, appropriate alternative asthma therapy may  be prescribed at the physician’s 
discretion.  
4.1.3.  Independent Data Monitoring Committee  (IDMC)  
An IDMC will be utili sed in this study to ensure external objective review of the data in 
order to protect the ethical and safety interests of participants and to p rotect the scientific 
validity of the study (see Section 10.1.5 ).  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
38 4.2. Scientific Rationale for Study Design  
Population:  This study is designed to evaluate the efficacy and safety of [COMPANY_004]3511294 
[ADDRESS_31114] the requisite elevated blood eosinophil count (see randomisation 
criterion 1, Section 5.3) that is indicat ive of asthma with an eosinophilic phenotype. This 
population has been shown to benefit from add -on anti -IL-5 therapi[INVESTIGATOR_31751] [ Pavord , 2012, Ortega , 2014; Chupp , 2017] and is therefore anticipated to 
benefit from [COMPANY_004]3511294.  
Blood eosinophil count screening : A Screening blood eosinophil count threshold of 
150 cells/μL at Screening Visit 1 or 300 cells /µL in the previous 12 months has been 
selected as a criterion to identify participants likely to respond to treatment with anti -IL-5 
therapy, consistent with findings from previous trials with mepolizumab.  
Primary efficacy endpoint:  A primary efficacy end point of annuali sed rate of clinically 
significant exacerbations has been selected as a robust and clinically relevant measure of 
the direct benefit of [COMPANY_004]3511294 to a population with severe uncontrolled asthma with 
an eosinophilic phenotype. In the curren t study, the definition of clinically significant 
exacerbations (see Section 8.2.2 ), i.e. exacerbations treated with systemic CSs 
(intramuscular [IM] , intravenous [IV], or oral) for 3 or more days and/or hospi[INVESTIGATOR_31750]/or ED visit, is consistent with previous trials with mepolizumab [ Pavord , 2012; 
Ortega , 2014] and reslizumab [ Castro , 2015].  
Placebo -control design : An established randomised, double -blind and parallel -group 
study design will allow for a robust determination of participant  response to 
[COMPANY_004]3511294 as an adjunct therapy to their maintenance asthma therapy. As such, the 
comparator arm in this study will be placebo plus continued maintenance asthma 
treatment. A 2:1 randomisation will be used in order to limit the number of participants 
randomised to placebo treatmen t and to provide more safety information on 
[COMPANY_004]3511294.  All participants will continue to receive their optimised and stable 
maintenance asthma therapy throughout the entire duration of the study regardless of 
intervention arm assignment. The stable mainte nance asthma therapy (per the inclusion 
criteria) will consist of medium to high dose ICS (440 mcg FP HFA daily, or clinical ly 
comparab le [GINA , 2020 ; see Appendix 10 ]) with at least one  additional controller 
medication e.g., long -acting beta -2-agonist (LABA), with or without maintenance  oral 
corticosteroids  (OCS ). Participants who are treated with medium dose ICS will also need 
to be treated with LABA to qualify for inclusion.  
Study Duration : A 52 -week treatment period should allow sufficient time to assess 
whether [COMPANY_004]3511294 100 mg SC, administered as two repeat do ses 26 weeks apart (at 
Week 0 [randomisation] and at Week 26), can reduce the annuali sed rate of clinically 
significant exacerbations to a similar extent to that observed with other anti -IL-5 mAbs. 
The study will also provide 12 -month safety data with repe at dosing.  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
39 Run-in Period:  The one -week (maximum 6 weeks) Run -in period allows for the 
assessment of participant understanding and compliance with the daily eDiary, to 
establish Baseline symptoms, and to allow adequate time for receipt of results from 
assessments collected at Screening Visit 1.  
Open -label extension study:  Following study completion, all eligible participants will 
have the option to participate in the OLE study to provide additional safety data (see 
Section 6.7). 
Data collection after discontinuation from study intervention : The protocol objective 
is to collect data over the full study period, whether participants continue on study 
intervention  or in the case of premature discontinuation from study intervention.  
However, the decision to continue in the study after premature discontinuation from 
study intervention remains the prerogative of the participant. Participants who agree to 
continue in the study after premature discontinuation from study intervention (for any 
reason) will continue to be contact[CONTACT_9298], either through in clinic visits or by 
[CONTACT_31813] e as agreed with the participant, on a monthly basis (aligned to their study schedule) 
until the end of their planned [ADDRESS_31115] -intervention information.  
4.2.1.  Participant Input into Desi gn 
Participant involvement in the study design was obtained from 10 patients (6 in Italy, 1 in 
[LOCATION_006], and 3 in US [1 adolescent]) using 2 online qualitative surveys containing 
17 questions over a period of 2 weeks. Based on the participant feedback, the follo wing 
design elements will be implemented:  
• Reduced number of laboratory samples and patient -reported outcomes ( PRO ) 
assessments  
• A hybrid trial model, allowing for home visits and virtual/telemedicine visits at 
key assessments which will reduce the burden of onsite visits and offer some 
flexibility in visit timing for the participant’s schedule  
4.3. Justification for Dose  
The dose rationale for  this study is supported by [CONTACT_31814] 205722 
[GlaxoSmithKline Document Number 2019N411063_00 ] that investigated single SC 
doses of [COMPANY_004]3511294 ranging from [ADDRESS_31116] completed the study if he/she has completed the visit 
at Week 52, regardless of whether the second dose of study intervention (at Week 26) 
was received.  
CCI
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
41 5. STUDY POPULATION  
Prospective approval of protocol deviations to re cruitment and enrolment criteria, also 
known as protocol waivers or exemptions, is not permitted.  
5.1. Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following criteria 
apply:  
AGE 
1. Age:  Adults and adolescents ≥12 years of age, at the time of signing the informed 
consent /assent . 
TYPE OF PARTICIPANT AND DISEASE CHARACTERISTICS  
2. Asthma:  Participants must have a  documented physician diagnosis of asthma for 
≥2 years that meets the National Heart, Lung, and Blood Institute guidelines 
[NHLBI , 2007] or GINA guidelines [ GINA , 2020] AND  
a) Eosinophilic phenotype:  Have, or with high likelihood of having, asthma 
with an eosinophilic phenotype as per Randomisation Criteria 1 and 2 (see 
Section  5.3) 
AND  
b) Exacerbation history:  Have previously confirmed history of 2 
exacerbations requiring treatment with systemic CS (IM, IV, or oral), in the 
12 months prior to Visit 1, despi[INVESTIGATOR_31752] -dose ICS (see 
criterion 4). For participants receiving maintenance CS, the CS treatment for 
the exacerbations must have been a two -fold dose increase or greater.  
3. Airflow obstruction: Persistent airflow obstruction as indicated by:  
a) For participants 18 years of age at Visit 1, a pre -bronchodilator FEV 1 <80% 
predicted (NHANES III) recorded at Visit 1  
b) For participants 12 -17 years of age at Visit 1:  
• A pre -bronchodilator FEV 1 <90% predicted (NH ANES III) recorded at 
Visit 1  
OR 
• FEV 1:Forced Vital Capacity (FVC) ratio <0.8 recorded at Visit 1  
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
42 ASTHMA MAINTENANCE T HERAPY  
4. Inhaled Corticosteroid: A well -documented requirement for regular treatment 
with medium to high dose ICS (in the 12 months prior to Visit 1 with or without 
maintenance OCS). The maintenance ICS dose must be 440 mcg FP HFA daily, 
or clinically comparable [ GINA , 2020; see Appendix 10 ]. Participants who are 
treated with medium dose ICS will a lso need to be treated with LABA to qualify 
for inclusion.  
5. Additional Controller Medication:  Current treatment with at least one 
additional controller medication, besides ICS, for at least 3 months [e.g., LABA, 
long-acting muscarinic antagonist (LAMA), leukotriene receptor antagonist 
(LTRA), or theophylline].  
 
SEX 
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
43 SEX 
INFORMED CONSENT  
7
5.2. Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply:  
MEDICAL CONDITIONS  
1. Concurr ent Respi[INVESTIGATOR_31753]:  Presence of a known pre -existing, clinically 
important lung condition other than asthma. This includes (but is not limited to) 
current infection, bronchiectasis, pulmonary fibrosis, bronchopulmonary 
aspergillosis, or diagnoses of emphysema or chronic bron chitis (chronic 
obstructive pulmonary disease other than asthma) or a history of lung cancer.  
2. Eosinophilic Diseases: Participants with other conditions that could lead to 
elevated eosinophils such as hyper -eosinophilic syndromes including (but not 
limited to) Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly 
known as Churg -Strauss Syndrome) or Eosinophilic Esophagitis.   
3. Parasitic infection: Participants with a known, pre -existing parasitic infestation 
within 6 months prior to Visit 1.  
4. Immunodef iciency: A known immunodeficiency (e.g. human immunodeficiency 
virus – HIV), other than that explained by [CONTACT_31815].  
5. Malignancy: A current malignancy or previous history of cancer in remission for 
less than 12 months prior to screening (Participants that had locali sed carcinoma 
of the skin which was resected for cure will not be excluded).  
6. Liver Disease: Cirrhosis or current unstable liver or biliary disease per 
investigator assessment defined by [CONTACT_31816], en cephalopathy, 
coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, persistent 
jaundice.  
CCI
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
44 MEDICAL CONDITIONS  
NOTE: Stable non -cirrhotic chronic liver disease (including Gilbert’s syndrome, 
asymptomatic gallstones, and chronic stable hepatitis B or C) are acceptable  if 
participant otherwise meets entry criteria.  
 
7. Other Concurrent Medical Conditions:  Participants who have known, pre -
existing, clinically significant cardiac, endocrine, autoimmune, metabolic, 
neurological, renal, gastrointestinal, hepatic, haematological or any other system 
abnormalities that are uncontrolled with standard treatment.  
8. Vasculitis:  Participants with current diagnosis of vasculitis. Participants with 
high clinical suspi[INVESTIGATOR_31754].  
9. COVID -19: Participants that, according to the investigator's medical judgment, 
are likely to have active COVID -[ADDRESS_31117] 14 days following the exposure during which the par ticipant 
should remain symptom -free. 
 
PRIOR/CONCOMITANT THERAPY  
10. Monoclonal antibodies targeting IL -5/5R:  Participants who have received 
mepolizumab (Nucala), reslizumab (Cinqair/Cinqaero), or benralizumab 
(Fasenra) within [ADDRESS_31118] a previous documented 
failure with anti -IL-5/5R therapy.  
11. Other mAbs in the treatment of asthma : Participants who have received 
omalizumab (Xolair) or dupi[INVESTIGATOR_12458] (Dupi[INVESTIGATOR_12460]) within 130 days prior to Visit 1.  
12. Other mAbs not used for the treatment of asthma:  Participants who have 
received any mAb within 5 half -lives of Visit 1.  Authorized treatments for 
COVI D-19 are permitted.  
13. Investigational Medications:  Participants who have received treatment with an 
investigational drug within the past 30 days or five terminal phase half -lives of 
the drug whichever is longer, prior to Visit 1 (this also includes investiga tional 
formulations of marketed products).  
 
PRIOR/CONCURRENT CLI NICAL STUDY EXPERIEN CE 
14. Previous participation:  Previously participated in any study with mepolizumab, 
reslizumab, or benralizumab and received study intervention  (including placebo) 
within 12 months prior to Visit 1.   
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
45  
DIAGNOSTIC ASSESSMEN TS 
15. ECG Assessment:  QTcF ≥450 msec or QTcF ≥480 msec for participants with 
Bundle Branch Block in the 12 -lead ECG central over -read from screening Visit 
1.   
 
OTHER EXCLUSIONS  
16. Smoking history:  Current smokers or former smokers with a smoking history of 
10 pack years (number of pack years = (number of cigarettes per day / 20) x 
number of years smoked). A former smoker is defined as a participant who quit 
smoking at least 6 mont hs prior to Visit 1.  
17. Alcohol/Substance Abuse:  A history (or suspected history) of alcohol misuse or 
substance abuse within 2 years prior to Visit 1.  
18. Hypersensitivity:  Participants with allergy/intolerance to the excipi[INVESTIGATOR_31755]3511294 in Section 6.1 or any  mAb or biologic.  
19. Pregnancy:  Participants who are pregnant or breastfeeding. Participants  should 
not be enrolled if they plan to become pregnant dur ing the time of study 
participation. Requirements for pregnancy testing are located in Section 8.3.5 . 
20. Adherence:  Participants who have known evidence of lack of adherence to 
controller medications and/or ability to follow physician’s recommendations.  
5.3. Randomisation Criteria  
At the end of the run -in period, study participants must fulfil all of the randomisation 
inclusion/exclusion criteria below in order to be randomised to study intervention .  
5.3.1.  Randomisation Inclusion Criteria  
RANDOMISATION INCLUSION CRITERIA  
1. Blood eosinophil count:  
a) An elevated peripheral blood eosinophil count of 300 cells/ L demonstrated 
in the past 12 months prior to Visit 1 that is related to asthma  
OR 
b) An elevated peripheral blood eosinophil count of 150 cells/ L at Screening 
Visit 1  that is related to asthma . 
2. Asthma: Evidence of airway reversibility or responsiveness as documented by 
[CONTACT_5640]:  
a) Airway reversibility (FEV 112% and 200 ml) demonstrated at Visit [ADDRESS_31119] Bronchodilator Procedure OR 
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
46 RANDOMISATION INCLUSION CRITERIA  
b) Airway reversi bility (FEV 112% and 200ml) documented in the 24  months 
prior to Visit 2 (randomisation visit) OR  
c) Airway hyperresponsiveness (methacholine:  PC20 of <8 mg/mL, histamine: 
PD 20 of <7.8 mol, mannitol: decrease in FEV [ADDRESS_31120] 
instruction s) documented in the 24 months prior to Visit 2 (randomisation 
visit)  
3.  
 
 
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
47 5.3.2.  Randomisation Exclusion Criteria  
RANDOMISATION EXCLUSION CRITERIA  
1. Laboratory abnormality:  Evidence of clinically significant abnormality in the 
haematological, biochemical or urinalysis screen at Visit 1, as judged by [CONTACT_1275].  
2. Liver chemistry test: Participants who meet the following based on results from 
sample taken at Screening Visit 1:  
a) Alanine aminotransferase (ALT) >2x upper limit of normal (ULN)  
b) Total b ilirubin >1.5x ULN (isolated bilirubin >1.5xULN is acceptable if 
bilirubin is fractionated an d direct bilirubin <35%)  
c) Cirrhosis or current unstable liver or biliary disease per investigator 
assessment defined by [CONTACT_31816], encephalopathy, coagulopathy, 
hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice.  
NOTES: Stable non -cirrhotic chronic liver disease (including Gilbert’s 
syndrome, asymptomatic gallstones, and chronic stable hepatitis B or C) is 
acceptable if the participant otherwise meets entry criteria.  
3. ECG:  QTcF ≥450msec, or QTcF ≥[ADDRESS_31121] the participant’s participation during 
the study, based on the evaluation of the Investigator . 
4. Unstable  Asthma: Participants with a clinically significant asthma exacerbation 
in the [ADDRESS_31122] their randomisation visit delayed 
until the investigator considers the participant's asthma to be stable (see 
Section  5.6).  
5. Maintenance Asthma Therapy: Any changes in the dose or regimen of baseline 
ICS and/or additional controller medication (except for treatment of an 
exacerbation) during the run -in period.  
5.4. Lifestyle Considerations  
No lifestyle restrictions are required  for this study . 
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
48 5.5. Pre-screen/Screen/Run -in Failures  
Pre-screen/screen/run -in failures are defined as participants who consent to participate in 
the clinical study but are not subsequently randomised. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participants to 
meet the Consolidated Standards of Reporting Trials (CONSORT) publishing 
requirements and to respond to queries from regulatory authorities. Minimal information 
inclu des demography, screen failure details, eligibility criteria, any protocol deviations 
and any SAEs.  
For the purposes of this study, pre -screen/screen/run -in failures will be defined as 
follows:  
Pre-screen Failures  Screen Failures  Run-in Failures  
Participants who are assigned 
a study number at the time of 
signing the informed consent 
(pre-screen visit) but do not 
progress to the screening 
visit. Participants who complete at 
least one additional Visit 1 
(Screening) procedure but do 
not enter the run -in period.  Participants who enter the 
run-in period but are not 
subsequently randomised.  
Re-screening of participants will be permitted; however, advance written approval to 
proceed with re -screening a participant must be obtained from the Medical Monito r. 
Re-screened participants should be assigned a new participant number for every 
screening/rescreening event.  
5.6. Criteria for Temporarily Delaying Randomisation  
Participants who experience a clinically significant asthma exacerbation during the run -in 
period should receive treatment for their exacerbation, have their randomisation visit 
delayed and remain in the run -in period (up to 6 weeks) until the investigator  considers 
the participant to have returned to their baseline asthma status for at least 7 days.  
A clinically significant exacerbation is defined as worsening of asthma requiring the use 
of systemic CS and/or hospi[INVESTIGATOR_31739]/or ED visit (Section 8.2.2 ). 
A participant who is not eligible to continue in the study at  the end of the run-in period , 
should be considered a run -in failure  but may be rescreened after consultation with the 
Medical Monitor  (Section 5.5).  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
49 6. STUDY INTERVENTION A ND CONCOMITANT THERA PY 
Study intervention is de fined as any investigational intervention(s)/ product (s) (IP), 
marketed product (s), placebo, or medical device(s) intended to be administered to a study 
participant according to the study protocol.  
Study intervention will only be administered in the clinic;  hence Visit 2 (Week 0) and 
Visit 10 (Week 26) are re quired to be in -clinic visits.  
6.1. Study Intervention Administered  
[COMPANY_004]3511294 is a humanised IgG antibody (IgG1, kappa) with human heavy and light 
chain frameworks. [COMPANY_004]3511294 liquid drug product will be sup plied by [CONTACT_31817] a Type I 
glass syringe 
 The drug product and syringe will be assembled in a single use, 
disposable safety syringe to enable delivery of the dru g product. Each device enables SC 
delivery of 100 mg [COMPANY_004]3511294  sterile liquid formulation.  
 
  
The placebo in this study will be 0.9% sodium chloride solution contained in a PFS also 
supplied by [CONTACT_23983].  
An overview of study intervention is provided in Table 2. 
Table 2 Overview of Study Intervention  
ARM Name  [CONTACT_23983]3511294 100 mg  Placebo  
Intervention Name  [CONTACT_23983]3511294 100 mg SC  Placebo  
Type  Biologic  N/A 
Dose Formulation  Sterile liquid formulation in 
single -use PFS  Sterile 0.9% (w/v) sodium 
chloride solution in single -use 
PFS 
Unit Dose Strength(s)  100 mg/mL; 1.0 mL (deliverable)  N/A, 1.0 mL (deliverable)  
Dosage Level(s)  100 mg once every 26 weeks 
(Week 0 and Week 26)  Placebo once every 26 weeks 
(Week 0 and Week 26)  
Route of 
Administration  SC injection  SC injection  
Use Experimental  Placebo  
IMP and NIMP  IMP IMP 
Sourcing  Provided centrally by [CONTACT_31818]-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
50 ARM Name  [CONTACT_23983]3511294 100 mg  Placebo  
Packaging and 
Labelling  
 Study Intervention will be 
provided in PFS. Each PFS will 
be labelled as required per 
country requirement.  Study Intervention will be 
provided in PFS. Each PFS will 
be labelled as required per 
country requirement.  
PFS=Pre -filled safety syringe, IMP=Investigational Medicinal Product, N/A=not applicable  
6.1.1.  Medical Devices  
The [COMPANY_004] manufactured medical devices (or devices manufactured for [COMPANY_004] by a third 
party) provided for use in this study are injection devices:  
• A pre -filled syringe contained within a safety syringe.  
. 
• The components that comprise the pre -filled syringe (glass barrel with pre -staked 
needle and plunger)  
 
 
•  
 
 
The Instruction for use (IFU) of the i njection device will be provided.  
 
  
All device deficiencies, (including malfunction , use error and inadequate labelling) shall 
be documented, and reported by [CONTACT_31819] (see 
Section 8.4.8 ) and appropriately managed by [CONTACT_23983].  
6.2. Packaging and Labelling  
The contents of the label will be in accordance with all applicable regulatory 
requirements.  
6.3. Preparation/Handling/Storage/Accountability  
• The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study intervention received and any 
discrepancies are reported and resolved before use of the study intervention.  
• Only participants enrolled in the study may receive study intervention and only 
authori sed site staff may supply or administer study intervention.  
• All study interventions must be stored in a secure, environmentally controlled, and 
monitored (manual or automated) area in accordance with the labelled  storage 
conditions with access  limited to the investigator and authorised site staff.  
CCI
CCI
CCI
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
51 • The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for study intervention accountability, reconciliation, and record 
maintenance (i.e., receipt, re conciliation, and final disposition records).  
• Further guidance and information for the final disposition of unused study 
intervention are provided in the SRM .  
• Under normal conditions of handling and administration, study intervention is not 
expected to pose significant safety risks to site staff . Take adequate precautions to 
avoid direct eye or skin contact [CONTACT_23968]. In the case of 
unintentional occupational exposure notify the monitor, Medical Monitor and/or [COMPANY_004] 
study cont act. 
• A Material Safety Data Sheet (MSDS)/equivalent document describing occupational 
hazards and recommended handling precautions either will be provided to the 
investigator, where this is required by [CONTACT_1207], or is available upon request from 
[COMPANY_004].  
6.4. Meas ures to Minimi se Bias: Randomisation and Blinding  
6.4.1.  Treatment Assignment  
• Eligible participants will be centrally randomised using an IRT system.   
•  
 Separate  randomisation schedules will be created for each 
country. Participants will be assigned to study intervention  in accordance with the 
randomisation schedule. Once a randomisation number has been assigned to a 
participant, it cannot be reassigned to any oth er participant in the study.  
• Randomisation will be stratified according to the participant’s baseline ICS dose 
(aiming to up to  50% approximately of participants  on medium ICS dose ; see 
Appendix 10 ). 
• At Visit 2 (Week 0), those participants who meet the randomisation criteria will be 
randomised in a 2:1 ratio to receive one of the following study treatments in addition 
to their stable maint enance asthma treatment:  
o [COMPANY_004]3511294 100 mg SC  
o Placebo SC  
• Study intervention will be administered in the clinic at Visit 2 (Week 0) and Visit 10 
(Week 26) as per the SoA (Section 1.3).  
6.4.2.  Blinding  
• The IRT system  will be programmed with blind -breaking instructions. In case of an 
emergency, the investigator has the sole responsibility for determining if unblinding 
of a participant’s intervention assignment i s warranted. Participant safety must always 
be the first consideration in making such a determination. If the investigator decides 
that unblinding is warranted, the investigator should make every effort to contact 
[CONTACT_31820] a participant’s in tervention assignment unless this could 
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
52 delay emergency intervention of the participant. If a participant’s intervention 
assignment is unblinded, [COMPANY_004] must be notified within [ADDRESS_31123] be recorded in the source 
documentation and case report form  (CRF) , as applicable.  
• Investigators will remain blinded to each participant’s assigned study intervention 
throughout the course of the study.  
. 
• If a participant’s intervention code is unblinded by [CONTACT_28807], that participant will continue with all study visits but will not receive the 
second dose of stu dy intervention at Week 26. The primary reason for the event or 
condition which led to the unblinding will be recorded in the CRF  (see Section 7.1).  
•  
 
.  
• [COMPANY_004]’s Global Clinical Safety and Pharmacovigilance (GCSP) staff may unblind the 
intervention assignment for any participant with an SAE. If the SAE requires that an 
expedited regulatory report be sent to one or more regul atory agencies, a copy of the 
report, identifying the participant’s intervention assignment, may be sent to 
investigators in accordance with local regulations and/or [COMPANY_004] policy.  
6.5. Study Intervention Compliance  
Both doses of [COMPANY_004]3511294 or placebo will be administered under medical supervision 
via SC injection to participants by [CONTACT_1720] d esignee at the study site. Dose 
administration details (date and time) will be recorded in the source documents and 
reported in the CRF . 
Participants will be monitored in clinic for a minimum of [ADDRESS_31124] effects. In the event of an acute 
severe reaction (e.g., anaphylaxis) following administration of [COMPANY_004]3511294, there are 
personnel/staff onsite at the treatment facility who are appropriately trained in basic life 
support to manage the  participant  including administration of medications (e.g., 
epi[INVESTIGATOR_238]), and have access to a system that can promptly transport the participant  to 
another facility for additional care if appropriate.  
6.6. Dose Modification  
Dose modification is not allowed.  
CCI
CCI
CCI
TMF-[ADDRESS_31125] -
study care of the participan t’s medical condition whether or not [COMPANY_004] is providing 
specific post -study  treatment.  
At the end of the study, participants will be eligible to screen to enter the OLE Study 
[ADDRESS_31126] continued access to open -label [COMPANY_004]3511294 if he/she:  
• has received both doses of study intervention (at Week 0 and Week 26), AND  
• completed the scheduled Exit Visit at Week 52, AND  
• did not meet any of the study intervention discontinuation conditions (Section 7.1) 
during the study.  
For par ticipants who enrol into the 12 -month OLE study, the Day 1 visit of the OLE 
study can occur on the same day as the Exit Visit of the current study. Specific details on 
the OLE study will be documented separately . 
Participants who do not enter the OLE study  will complete a follow -up visit/call and be 
prescribed alternative asthma therapy if needed and as determined by [CONTACT_31821].  
6.8. Treatment of Overdose  
The dose of [COMPANY_004]3511294 that is considered to be an overdose has not been defined. 
There are no known antidotes and there is no specific treatment for a suspected overdose. 
In FTIH study 205722 (refer to the current  IB [GlaxoSmithKline Document Number 
2016N295843_03  or later] ),  single SC doses of [COMPANY_004]3511294 up to 300 mg were  well 
tolerated by [CONTACT_31822]/moderate asthma (6 participants received a 
300 mg SC dose).  
 (see Section 6.1). 
In the event of an overdose, the investigator should:  
• Contact [CONTACT_27465].  
• Treat the participant  with active supportive care  as dictated by [CONTACT_31823] t’s 
clinical status in the knowledge of the long half -life ( approximately 41 days) of 
[COMPANY_004]3511294.  
• Closely monitor the participant for AE/SAE and laboratory abnormalities for 
[ADDRESS_31127] administered dose.  
• Docu ment the quantity of the excess dose as well as the duration of the 
overdosing in the CRF.  
Decisions regarding discontinuation or delay of another dose of study intervention will be 
made by [CONTACT_31824].  
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
54 6.9. Concomitant Therapy  
At pre -screening and/or screening, information on the participant’s baseline maintenance 
asthma therapy will be collected and recorded in the eCRF.  
Any medication or vaccine (including over -the-counter or prescription medicines, 
vitamins, and/or herbal supplements) that the participant is receiving at the time of 
enrolment or receives during the study must be recorded in the eCRF along with:  
• reason for use 
• dates of administration including start and end dates  
• dosage information including dose and frequency (any dose changes are to be 
recorded for OCS)  
The Medical Monitor should be contact[CONTACT_31825] y. 
6.9.1.  Permitted Medications and Non -Drug Therapi[INVESTIGATOR_31756], participants are to be maintained on their baseline maintenance 
asthma treatment consisting of ICS plus at least one other controller, e.g. LABA, LAMA , 
with or without maintenance OCS (see inclusion criteria 4 and 5, Section 5.1). It is 
recognised that in a year -long study, changes may need to be ind ividualised if clinically 
crucial for a participant. The investigator is encouraged to discuss any cases with the 
Medical Monitor before initiating changes to a participant’s maintenance asthma 
medication.  
Additional asthma medications such as theophylline s and anti-leukotrienes  will be 
permitted as maintenance provided that they have been taken regularly in the 3 months 
prior to screening (Visit 1). If uncertain whether a medication is permitted, please 
confirm with the Medical Monitor.  
Albuterol/salbutam ol is permitted throughout the study but should be withheld in the 
6-hour period prior to spi[INVESTIGATOR_31757], if possible. Study -provided 
albuterol/salbutamol should not be recorded in the eCRF, only in the eDiary.  
LABAs , LAMAs,  and fixed dose combina tions of ICS/LABA  or ICS/LABA/LAMA 
should be withheld for [ADDRESS_31128] Pressure (CPAP) or Bilevel Positive Airway Pressure 
(BiPAP) for the treatment of obstructive sleep apn oea is permitted, if ini tiated prior to the 
Screening Visit (Visit 1). This treatment must be captured in the eCRF.  
Allergen -specific immunotherapy is permitted provided that it has been taken regularly in 
the 6 months prior to screening (Visit 1).  
Participants can be vaccinated  against SARS -CoV -2 infection using authorized COVID -
19 vaccines in line with local/national guidelines for COVID -19 vaccines. Experimental 
COVID -19 vaccines are not permitted.  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
55 COVID -19 vaccine administration and the administration of the study interventio n should 
be separated by 14 days if possible, in order to be able to properly assess study injection 
site/treatment reactions.  
Participants can be treated for SARS -CoV -2 infection using authorized COVID -19 
treatments (including monoclonal antibodies) in li ne with local/national guidelines.  
Experimental COVID -19 treatments are not permitted.  
6.9.2.  Prohibited Medications and Non-Drug Therapi[INVESTIGATOR_31758] (Visit 1), according to the 
following schedule, or during the  study:  
Medication  Washout Time  
Prior to Screening Visit  
Investigational drugs  1 month or 5 half -lives whichever is 
longer  
Omalizumab [Xolair], dupi[INVESTIGATOR_12458] [Dupi[INVESTIGATOR_12460]]  130 days  
Mepolizumab [Nucala], reslizumab [Cinqair/Cinqaero], 
benralizumab [Fasenra]  12 months  
Other monoclonal antibodies  5 half -lives 
Experimental anti -inflammatory drugs (non biologicals)  3 months  
 
Immunosuppressive medications such as those listed below (not all inclusive)  
Corticosteroids if used to treat a condition other than asthma  
• Intramuscular, long -acting depot  
• Regular systemic (oral or parenteral)  
Methotrexate, cyclosporin, azathioprine  
Oral gold  
Chemotherapy used for conditions other than asthma  
Additionally, Bronchial Thermoplasty and Radiotherapy are excluded for 12 months 
prior to Visit 1 and throughout the study. CPAP, BiPAP, and oxygen therapy should not 
be initiated during the run -in period.  
6.9.3.  Rescue Medicine  
Trade label albuterol/salbutamol m etered dose inhalers (MDIs) will be provided as rescue 
medication throughout the study. Albuterol/salbutamol will be sourced for all cent res. 
Use of low dose ICS -formoterol as rescue medication is not allowed during the study.  
Participants will be dispense d an MDI at Screening Visit 1 to be used primarily to treat 
asthma symptoms on an as needed basis and also during the reversibility assessments (see 
Section [IP_ADDRESS] ). The MDI should be replaced as needed.  
Although the use of rescue medications is allowable (at any time during the study), the 
use of rescue medications should be withheld , if possible, for at least 6 hours prior to the 
spi[INVESTIGATOR_31759]. Rescue medication usage will be recorded in the eDiary . 
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
56 7. DISCONTINUATION OF S TUDY INTERVENTION AN D 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL  
7.1. Discontinuation of Study Intervention  
No further doses of study intervention will be administered to participants  who meet any 
of the following permanent treatment discontinuation conditions at any time during the 
study treatment period:  
• Liver Chemistry: Meets any of the protocol -defined liver chemistry stoppi[INVESTIGATOR_31732] (see Section 7.1.1 ) 
• ECG : Meets any of the protocol -defined QTc stoppi[INVESTIGATOR_3418] (see Section 7.1.2 ) 
• Pregnancy: Positive pregnancy test (see Section 8.4.5 ) 
• Severe allergic reaction/anaphylaxis: Participants with severe allergic 
reaction /anaphylaxis with no clear alternative cause  (see Appendix 8 ) 
• Vasculitis: Participants with confirmed vasculitis or suspected vasculitis with no 
alternative e xplanation (see Section 7.5). 
• Study treatment unblinded: Unblinding of the study treatment assigned to a 
participant  (see Section 6.4.2 ). 
If a participant meets any of the treatment discontinuation conditions or chooses (for any 
reason) not to receive another dose of study intervention before the end of the protocol 
specified randomised intervention period:  
• The investigator will make every effort to encourage the participant to remain in 
the study and to continue with all remaining study visits, including the Exit and 
Follow -up Visits.  
• The primary reason for discontinuation of study intervention (e.g., AE, lack of 
efficacy, protocol deviation, investigator discretion, consent withdrawn etc.) must 
be recorded in the eCRF.  
• Participants will be provided with the option to continue their scheduled  visits  
in-clinic , at home,  or by [CONTACT_648]. The required study assessments wil l depend on 
whether the participant is attending the visit in-clinic , at home, or by [CONTACT_648] . At a 
minimum, an assessment of exacerbations, AEs, SAEs, and concomitant 
medications will be completed.  
• If for any reason, the participant later chooses to withdraw from the study, a 
Withdraw from Study Visit (see Section 7.2) should be conducted accordi ng to 
the SoA (Section 1.3). 
TMF-[ADDRESS_31129] been 
design ed to assure participant safety and evaluate liver event aetiology.  
Discontinuation of study intervention for abnormal liver tests is required when:  
• a participant meets one of the conditions outlined  in the algorithm or  
• in the presence of abnormal liver c hemistry not meeting protocol -specified 
stoppi[INVESTIGATOR_004], the investigator believes that it is in the best interest of the 
participant.  
Liver Chemistry Stoppi[INVESTIGATOR_31760]: ALT = alanine transaminase; INR = international normali sed ratio; SAE = 
serious adverse event; ULN = upper limit of normal, Tbili = Total bilirubin  
Refer to Appendix 6  for required Liver Safety Actions, Monitoring , and Follow -up 
Assessments.  

TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
58 Liver Chemistry Increased Monitoring Algorithm with Continued Study 
Intervention for Participants with ALT 3xULN but <8xULN and do not meet any 
of the liver stoppi[INVESTIGATOR_31761]: ALT = alanine transaminase; Tbili = to tal bilirubin; INR = international 
normali sed ratio; SAE = serious adverse event; ULN = upper limit of normal, Tbili = 
Total bilirubin.  
Refer to Appendix 6  for required Liver Safety Actions, Monitoring and Follow -up 
Assessments.  
[IP_ADDRESS].  Study Intervention Restart or Rechallenge after liver stoppi[INVESTIGATOR_31762] 
a participant in this study will not be permitted.  
7.1.2.  QTc Stoppi[INVESTIGATOR_31763] 8.3.3 .  
The QT interval corrected using Fridericia’s formula (QTcF) must be used for each 
individual participant  to determine eligibility for and discontinuation from the study 
intervention . Thi s formula may not be changed or substituted once the  participant has 
been enrolled.  

TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
59 For this study, the following QTc stoppi[INVESTIGATOR_31764]:  
• QTcF >500 msec OR uncorrected  QT >600 msec  
• Change from baseline of QTcF >60 msec  
For participants  with unde rlying bundle branch block, follow the discontinuation criteria 
listed below:  
Baseline QTcF with Bundle Branch 
Block  Discontinuation QTcF with Bundle 
Branch Block  
<450 msec  >500 msec  
450 – 480 msec  ≥530 msec  
The QTcF value from the 12 -lead ECG central over-read at randomisation Visit 2 should 
be used as baseline QTcF value for any changes from baseline calculations during the 
study . After randomis ation 12 -lead ECG central over -read values should be used to 
assess QTc stoppi[INVESTIGATOR_3418], with the exceptio n of Visit 10 (Week 26) where 12 -lead 
ECG machine read values should be used.  
7.1.3.  Temporary Discontinuation  
For this study, a temporary discontinuation refers to a delayed administration of the 
second dose of study intervention at Week 26.  
If a participant be comes infected (parasitic infection) during the study intervention period 
before receiving the second dose of study intervention and does not respond to anti -
helminth treatment, a delayed administration of the study intervention may be considered 
in consul tation with the [COMPANY_004] Medical Monitor.  
7.2. Participant Discontinuation/Withdrawal from the Study  
• Participants are strongly encouraged to remain in the study for the entire duration but 
may prematurely withdraw from the study at any time at his/her own request, at the 
request of their legally authori sed representative (LAR), or may be withdrawn at any 
time at the discretion of the investigator for safety, behavioural, or compliance 
reasons. This is expected to be uncommon.  
• Participants who prematurely withdraw fr om the study should attend:  
o a Withdraw from Study (WS) Visit, [ADDRESS_31130] administered dose of 
study intervention (at Week 26 or Week 52) AND  
o a Follow -up visit/call, [ADDRESS_31131] administered dose of study 
intervention for AE/SAE and  pregnancy assessment s.  
Note: t his includes any participants who initially discontinue study intervention  and 
remain in the study (Section 7.1) but later decide to withdraw from the study.  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
60 • If the participant withdraws consent for disclosure of future information, the Sponsor 
may retain and continue to use any data collected before s uch a withdrawal of 
consent.  
• If a participant withdraws from the study, he/she may request destruction of any 
samples taken and not tested, and the investigator must document this in the site study 
records.  
7.3. Lost to Follow -Up 
A participant  will be considere d lost to follow -up if he/she repeatedly fails to return for 
scheduled visits (or scheduled phone calls, if applicable) and is unable to be contact[CONTACT_31826].  
The following actions must be taken if a participant fails to return to the clinic for  a 
required study visit:  
• The site must attempt to contact [CONTACT_31827]/or should continue in the study.  
• Before a participant is deemed lost to follow -up, the investigator or designee must 
make every effort to regain contact [CONTACT_6635] (where possible, 
3 telephone calls and, if necessary, a certifie d letter to the participant’s last known 
mailing address or local equivalent methods). These contact [CONTACT_19425]’s medical record.  
• Should the participant continue to be unreachable, he/she will be considered to 
have wit hdrawn from the study. A final attempt will be made to contact [CONTACT_31828] a safety follow -up [ADDRESS_31132] administered dose of 
study intervention.  
Discontinuation of specific sites or of the study as a whole are handled as part of 
Appendix 1 . 
7.4. Reasons for Study Intervention  Discontinuation and/or Study 
Withdrawal  
The primary reason for study intervention  discontinuation and/or study withdrawal will 
be recorded in the eCRF. When a participant withdraws consent, the investigator must 
document the reason (if specified by [CONTACT_2299]) in the eCRF.  
7.5. Criteria for Follow -up of Potential Type III Hypersensiti vity (Immune 
Complex Disease /Vasculitis)  
Owing to the adverse findings of arterial inflammation that were observed in the 
1-month, but not 6 -month, nonclinical toxicology studies, events potentially representing 
type III hypersensitivity/immune complex di sease/vasculitis should be promptly reported 
to [COMPANY_004], and consultation with the Medical Monitor is encouraged. Treatment for the 
event will be given as medically required.  
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
61  
  
Symptoms potentially suggestive of vasculitis include but are not limited to:  
• persistent* fever (*where persistent is considered to be a duration of 2 days)  
• persistent* muscle and joint pain   
• persiste nt* rash  
• persistent* fatigue  
• symptoms of peripheral neuropathy, like numbness or weakness  
• laboratory abnormalities, e.g., decreased platelets, elevated creatinine, decrease 
in complement C3/C4, abnormal urinary albumin/creatinine ratio  
Participants who experience any of the above events should be monitored until the event 
resolves and/or a diagnosis is established.  
The symptoms and clinical features are often non -specific and heterogenous with respect 
to the time course over which they develop, organ involvement and the constellation of 
symptoms and severity. Early recognition of potential events of vasculitis is important to 
timely diagnosis and subsequent treatment.  
The precise management will depend on the clinical evaluation at the time of presentation 
and ongoing assessment including consideration of relevant differential diagnoses. Given 
that there is often a differential for presenting symptoms such as infection, and indeed 
such factors may also precipi[INVESTIGATOR_31765], the se factors (infectious, 
neoplastic, metabolic, toxic) should be given due consideration and ruled out.  
Serological, immunological, and histological (biopsy) data should be considered to 
support the diagnosis and consultation with the [COMPANY_004] Medical Monitor, and an 
appropriate medical specialist should be considered when investigating a possible 
immune related AE.  
If clinically indicated, the participant  may be referred to a specialist for further 
management, which may include organ biopsy.  
CCI
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
62 8. STUDY ASSESSMENTS AN D PROCEDURES  
• Study procedures and their timing are summari sed in the SoA (Section 1.3).  
• As detailed in the SoA (Section 1.3), participants who are not entering the OLE st udy 
212895 should make every effort to complete the Week 56 follow -up visit/call on the 
scheduled day. The visit may be completed within 7 days of the scheduled time -point.  
• Every effort should  be made to reduce missing data throughout the study.  
• Protocol w aivers or exemptions are not allowed.  
• Immediate safety concerns should be discussed with the Medical Monitor 
immediately upon occurrence or awareness to determine if the participant should 
continue to receive the second scheduled dose of study intervention , if applicable.  
• Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.  
• All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligib ility criteria. The investigator will maintain a screening log 
to record details of all participants screened and to confirm eligibility or record 
reasons for screening failure, as applicable.  
• Procedures conducted as part of the participant’s routine clin ical management (e.g., 
blood count) and obtained before signing of ICF may be utili sed for screening or 
baseline purposes provided the procedure met the protocol -specified criteria and was 
performed within the time frame defined in the SoA.  
•  
 
 
 
• Repeat or unscheduled samples may be taken for safety reasons or for technical issues 
with the samples.  
• Participants  should be provided a quiet space in which to complete patient -reported 
outcomes ( PRO ), prior to other assessments and procedures. S ite staff can provide 
limited advice if required, however participants  should not be guided or directed in 
answering questions. Family or friends should not influence the answers. Site staff 
should encourage participants to complete all questions.  
8.1. Screenin g and Critical Baseline Assessments  
8.1.1.  Pre-screening Visit (Visit 0)  
Informed consent should be obtained at the Pre -screening Visit  or the Screening Visit , 
prior to initiating any study assessments . A participant number will be assigned at the 
time the ICF is  signed. Participants can conduct the Pre -screening Visit (Visit 0) up to 
2 weeks prior to the Screening Visit (Visit 1).  
The pre -screening procedures will include a review/assessment of:  
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
63 • Inclusion/exclusion criteria (see Section 5.1 and Section 5.2) 
• Demographic information including gender, ethni c origin, race, and year of birth 
(can be conducted at Visit 1  instead,  if necessary)  
• Childbearing status for all women  (can be conducted at Visit 1 instead, if 
necessary) ; for WOCBP, contraception should be started at least [ADDRESS_31133] dose of study intervention  (see Appendix 4 ) 
• Therapy history and concomitant medications including  maintenance asthma 
medications from the year prior to Screening Visit 1, all medications within the 
3 months prior to Screening Visit 1 and all current medications  
All clinic visits from Pre -screening Visit 0 to the Exit Visit (or if applicable, the WS Visit 
or the Follow -up Visit) should be completed in the relevant eCRF form. Visit 1, 2, [ADDRESS_31134] be collected from signing of Informed Consent if considered 
related to study procedures.  
8.1.2.  Critical Assessments performed at Screening (Visit 1)  
The following critical assessments will be conducted at Screening Visit 1:  
• Review inclusion /exclusion criteria (see Section 5.1 and Section 5.2) 
• Review therapy history and concomitant medications including maintenance 
asthma medications from the year prior to Screening Visit 1, all medications 
within the 3 months prior to Screening Visit 1 and all current medications.  
• Medical history inc luding:  
o Asthma including current treatment, duration of asthma, courses of rescue 
CSs, history of previous intubations, asthma exacerbation history  in previous 
year, asthma triggers  
o Cardiovascular (CV) medical history/risk factors (as detailed in the eCRF ) 
o Vasculitis, allergies and anaphylaxis history  
o Smoking history and current status  
o Historical blood eosinophil count - participants without a documented  blood 
eosinophil count ≥300 cells/µL in the [ADDRESS_31135] show a blood eosinophil count ≥150 cells/µL, based on the sample 
collected at Visit 1 (see randomisation criterion 1, Section 5.3.1 ). If the 
Screening Visit test result does not meet the blood eosinophil count eligibility 
criteria, the laboratory assessment may be repeated, at the discretion of the 
investigator, if it is judged to be likely in the eligible range for study inclusion 
within the run -in period prior to Visit 2.  
• Spi[INVESTIGATOR_31766] (see Section 8.2.3 ). If a patient fails the protocol -
specified reversibility criterion or FEV [ADDRESS_31136] is 
allowed during the run -in period.  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
64 •  
• Safety Assessments including:  
o Physical exam (see Section 8.3.1 ) 
o Vital signs (see Section 8.3.2 ) 
o Resting 12 -lead ECG  (see Section 8.3.3 ) 
o AE/SAE assessment  
• 
• eDiary registration and training  
• (see Section 8.9) 
• Complete ADSD/ANSD ( to be completed daily at home; see Section 8.2.10 ) 
8.1.3.  Critical Assessments performed at Randomisation (Visit 2)  
The following critical assessments will be conducted at randomisation Visit 2:  
• Review of randomisation criteria (see Section 5.3), and data collected at Visit 1, 
including, if applicable, verification that the asthma -related peripheral blood 
eosinophil count is 150 cells/ L, based on the sample collected at Visit 1  
• Review of concomitant medications  
• Spi[INVESTIGATOR_038] (if airway reversibility was not demonstrated at Visit 1, the Maximum 
Bronchodilator Procedure may be repeated at Visit 2) (see Section 8.2.3 ) 
• SGRQ (see Section 8.2.4 ) 
• ACQ -5 (see Section 8.2.5 ) 
•  
•  
•  
• Safety assessments including:  
o Vital signs (see Section 8.3.2 ) 
o Resting 12 -lead ECG  (see Section 8.3.3 ) 
CCI
CCI
CCI
CCI
CCI
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
65 o AE/SAE assessment  
•
o  
 
 
• Provide and review  (see 
Section 8.9) 
The following items will be completed at home:  
•  
• Complete ADSD/ANSD daily (see Section 8.2.10 ) 
8.2. Efficacy Assessments  
8.2.1.  Efficacy Endpoints  
Efficacy endpoints and estimands are provided in Section 3. 
8.2.2.  Asthma Exacerbations  
Clinically significant exacerbations  of asthma are defined by:  
[CONTACT_31829]1 and/or hospi[INVESTIGATOR_31739]/or 
Emergency Department (ED) visit.  
1For all participants , IV or oral steroids (e.g., prednisone) for at least [ADDRESS_31137] 3 days is required.  
Exacerbations separated by [CONTACT_21316] 7 days will be treated as a continuation of the same 
exacerbation.  
CCI
CCI
CCI
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
66 Details of each asthma exacerbation, includi ng medications used to treat exacerbations 
should be recorded in the eCRF.  
Asthma exacerbations should not be recorded as an AE unless they meet the definition of 
a SAE.  
The time period for collection of exacerbation information in the eCRF will be from th e 
start of study intervention  until the Exit Visit or Follow -up Visit if applicable.  
8.2.3.  Pulmonary Function Testing/ Spi[INVESTIGATOR_31767] 1. At least 3 valid spi[INVESTIGATOR_31768] (with no 
more than 8 attempts) using the ATS guidelines [ Miller , 2005]. Spi[INVESTIGATOR_31769] 1, percent predicted FE V1, Forced Vital Capacity (FVC) and FEV 1/FVC. Spi[INVESTIGATOR_31770] (Visit 1), randomisation (Visit 2), and at 
scheduled in -clinic visits according to the SoA (Section 1.3). At each visit, spi[INVESTIGATOR_31771] ( 1 hour) as the assessment performed at 
Visit 2 (the baseline assessment).  Participants should try to withhold short -acting beta -2-
agonists (SABAs) for 6 hours and LAMAs/ LABAs for 12 hours prior to the clinic 
visit, if possible.   
Spi[INVESTIGATOR_31772]/suspected 
COVID -19.  
[IP_ADDRESS].  Reversibil ity using the Maximum Post -Bronchodilator Method  
Pre-bronchodilator measurements will be taken at the clinic visits specified in the SoA 
(Section 1.3): at screening, randomisation, Week 26  Visit , and Exit Visit (or EW Visit) . 
In addition, post -bronchodilator values will be recorded following reversibility testing 
using the Maximum Post -Bronchodilator Method. Participants’ reversibility will be 
assessed at Visit 1 (Screening) . For participants unable to achieve 12% reversibility and 
200 mL change at Visit 1, reversibility can be repeated at Visit 2 to confirm eligibility for 
the study (see randomisation criterion 2, Section 5.3.1 ). The procedures involved in the 
Maximum Post -Bronchodilator Method are those generated by [CONTACT_31830]  [Tepper , 2012] . Additional details on the reversibility testing procedures 
using the Maximum Post -Bronchodilator Method can be found in the spi[INVESTIGATOR_31773] . 
8.2.4.  St. George’s Respi[INVESTIGATOR_6015] (SGRQ)  
The SGRQ  is a well -established instrument, comprising [ADDRESS_31138] obstruction [ Jones , 1992]. The 
questionnaire will be administered as per guidance from the measure developers and 
completed electronically according to the SoA (Section 1.3).  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
67 8.2.5.  Asthma Control Questionnaire -5 (ACQ -5) 
The ACQ -5 is a five -item questionnaire, which has been developed as a measure of 
participants’ asthma control that can be quickly and easily completed [ Juniper , 2005]. 
The questions are designed to be self -completed by [CONTACT_2299]. The five questions 
enquire about the frequency and/or severity of symptoms (nocturnal awakening on 
waking i n the morning, activity limitation, and shortness of breath, wheeze) over the 
previous week. The response options for all these questions consist of a zero (no 
impairment/limitation) to six (total impairment/ limitation) scale. This will be completed  
elect ronically according to the SoA ( Section 1.3). 
CCI
CCI
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
68 8.2.9.    
The evaluations will be completed electronically  at the visits specif ied in the SoA 
(Section 1.3). 
8.2.10.  Asthma Daily Symptom Diary/Asthma Nightly Symptom Diary 
(ADSD/ANSD)  
The ADSD/ANSD is a 6 -item self -administered patient -reported diary developed by [CONTACT_31831]’s Asthma Working Group (in accordance with the Food and Drug 
Administration’s PRO Guidance) to facilitate comprehensive and reliable assessment of 
asthma symptoms from a patient’s perspective [ Gater , 2016].  
The ADSD/ANSD is intended for use by [CONTACT_31832] (aged 12 years and older) 
who are diagnosed with asthma to rate the severity of their symptom s in the three core 
categories: breathing symptoms (wheezing, shortness of breath), chest symptoms (chest 
tightness, chest pain) and cough.  
The ADSD/ANSD must be completed twice daily by [CONTACT_2299]:  
• ADSD is to be completed before going to bed and ref ers to asthma  symptoms 
during the day.  
• ANSD is to be completed upon waking and refers to asthma symptoms during the 
previous night.   
Participants are required to rate the six symptoms at their worst during the respective 
timeframes using an 11 -point numeric rating scale (NRS) ranging from 0 (‘None’) to 10 
(‘As bad as you can imagine’). Responses will be captured electronically.  
The ADS D/ANSD questionnaire should only be administered to participants for whom 
an appropriate translation is available. Further details are contained in the SRM.  
CCI
CCI
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
69 8.3. Safety Assessments  
Planned time points for all safety assessments are provided in the SoA (Section 1.3) – 
where possible, these should be aligned with standard of care.  
8.3.1.  Physical Examinations  
• A complete physical examination will include, at a minimum, assessments of the 
Skin, Eyes, CV, Respir atory, Gastrointestinal and Neurological systems. Height 
(screening only) and weight will also be measured and recorded.  
• Investigators should pay special attention to clinical signs related to previous 
serious illnesses.  
8.3.2.  Vital Signs  
• Temperature, pulse rate, and blood pressure will be assessed.  
• Blood pressure and pulse measurements will be assessed in the resting state with a 
completely automated device. Manual techniques will be used only if an 
automated device is not available.  
CCI
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
70 • Blood pressure and pulse measurements should be preceded by [CONTACT_2669] [ADDRESS_31139] for the participant in a quiet setting without distractions (e.g., television, 
cell phones) and should be taken before blood collection for laboratory tests.  
8.3.3.  Electrocard iograms  (ECGs)  
• Twelve -lead ECGs will be obtained at the time points specified in the SoA (see 
Section 1.3) using  an ECG machine, provided by [CONTACT_31833] a  designated central 
laboratory, that automatically calculates the heart rate and measures PR, QRS, 
QT, and QTc intervals.  
• The QTcF formula must  be used for each  individual participant to determine 
eligibility. This formula may not be changed or substitute d once the participant 
has been enrolled.  Refer to Section 7.1.2  for the QTcF formula.  
• If an ECG demonstrates a prolonged QT interval, obtain two mor e ECGs over a 
brief period, and then use the averaged QTcF values of the three ECGs to 
determine whether the participant should be screened/ randomised/ discontinued 
from the study intervention (but not from the study). Refer to Section 5.2 and 
Section 5.3.2  for exclusion/ randomis ation exclusion  criteria related to ECG 
assess ment and Section 7.1.2  for QTc withdrawal criteria and additional QTc 
readings that may be necessary . 
• ECG measurements will be made after the partici pant has rested in the supi[INVESTIGATOR_31774] 5 minutes. The ECG should be obtained after the vital signs 
assessments but before lung function testing followed by [CONTACT_31834]. 
Collection shortly after a meal or during sleep should be avoided since QT 
prolongation can occur at these times.  
• Paper ECG traces will be recorded at a standard paper speed of 25 mm/sec and 
gain of 10 mm/mV, with a lead II rhythm strip. There will be electronic capture 
and storage of the data by a validated method.  
• Paper ECG traces are required to be maintained at the site with other source 
documents.  
8.3.4.  Clinical Safety Laboratory Assessments  
• See Appendix [ADDRESS_31140] of clinical la boratory tests to be performed and refer to 
the SoA (Section 1.3) for the timing and frequency.  
• The investigator must review the laboratory report, document this review, and 
record any clinically significant changes occurring during the study as an AE. The  
laboratory reports must be filed with the source documents.  
• Abnormal laboratory findings associated with the underlying disease are not 
considered clinically significant, unless judged by [CONTACT_31835]'s condition.  
• All laboratory tests with values considered clinically significantly abnormal 
during participation in the study until the Exit Visit (or Follow -up visit/call if 
applicable) should be repeated until the values return to normal or baseline or  are 
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
71 no longer considered significantly abnormal by [CONTACT_31836]. If clinically significant values do not return to normal/baseline within a 
period of time judged reasonable by [CONTACT_093], the aetiology should be 
identified,  and the Sponsor notified.  
• If laboratory values from non -protocol specified laboratory tests performed at the 
institution’s local laboratory require a change in participant management or are 
considered clinically significant by [CONTACT_093] (e.g., SAE or AE), then the 
results must be recorded.  
• All protocol -required laboratory assessments, as defined in Section 10.2, must be 
conducted in accordance wit h the laboratory manual and the SoA (Section 1.3). 
•  
 
 
 
8.3.5.  Pregnancy Testing  
• Refer to Section 5.1 Inclusion Criteria for pregnancy testing entry criteria.  
• A serum pregnancy test should be conducted for all WOCBP at the screening visit 
(Visit 1) and the Exit visit. In addition, a urine pregnancy test should be 
performed for all WOCBP prior to randomisation (Visit 2), on a monthly basis at 
the specified  schedu led study visit, and at the Follow -up Visit/call (if applicable) 
as per the SoA (Section 1.3). 
• A final urine pregnancy test should be conducted for a ll WOCBP, [ADDRESS_31141] administered dose of study intervention:  
o Participants who enter the OLE study will have a urine pregnancy test 
prior to receiving the first dose of open -label [COMPANY_004]3511294.  
o Participants who do not enter the OLE study should have a urine 
pregnancy test at the Follow -up Visit/call (Week 56). A self -reported 
home urine pregnancy test result is acceptable if the follow -up is 
conducted as a phone call visit.  
o Participants who with draw early from the study should have a urine 
pregnancy test, 4 weeks after the WS Visit (see Section 7.2). 
• Additional serum or urine pregnancy tests may be performed, as determined 
necessary by [CONTACT_31837], to establish the 
absence of pregnancy at any time during the participant’s participation in the 
study.  
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
72 8.4. Adverse Events (AEs), Serious Adverse Events (SAEs) and Ot her 
Safety Reporting  
The definitions of adverse events (AE) or serious adverse events (SAEs) can be found in 
Section 10.3. Asthma exacerbations should not be recorded in the AE section of the 
eCRF unless they meet the definition of a SAE.  
The definitions of device -related safety events, (adverse device effects [ ADEs] and 
serious adverse device effects [SADEs]), can be found in Section 10.7. Device 
deficiencies are covered in Section 10.7. 
AEs will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, surrogate, 
or the participant's legally authori sed representative).  
The investigator and a ny qualified designees are responsible for detecting, documenting, 
and reporting events that meet the definition of an AE or SAE and remain responsible for 
following up all AEs that are serious, considered related to the study intervention or the 
study, or  that caused the participant to discontinue the study (see Section 7).  
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Section 10.3. 
8.4.1.  Time Period and Frequency for Collecting AE and SAE 
Information  
• All SAEs will be collected from the start of intervention (Visit 2) until the Exit Visit 
or follow -up visit/call (if applicable) at the time points specified in the SoA 
(Section  1.3). However, any SAEs assessed as related to study participation (e.g., 
study intervention, protocol -mandated procedures, invasive tests, or change in 
existing therapy) or related to a [COMPANY_004] product will be recorded from the time a 
participant consents to participate in the study.   
• All AEs will be collected from the start of int ervention until the Exit Visit or the 
follow -up visit/call (if applicable) at the time points specified in the SoA 
(Section  1.3). 
• Medical occurrences that begin before the start of study intervention but after 
obtaining informed consent will be recorded as Medical History/Current Medical 
Conditions (in the eCRF) not as AEs.  
• All SAEs will be recorded and reported to the Sponsor or designee immediately an d 
under no circumstance should this exceed 24 hours,  as indicated in Appendix 3 . The 
investigator will submit any updated SAE data to [COMPANY_004] within 24  hours of it being 
available.  
• Investigators are not obligated to actively seek information on AEs or SAEs after the 
conclusion o f the study participation. However, if the investigator learns of any SAE, 
including a death, at any time after a participant has been discharged from the study, 
and he/she considers the event to be reasonably related to the study intervention or 
study par ticipation, the investigator must promptly notify [COMPANY_004].  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
73 8.4.2.  Method of Detecting AEs and SAEs  
Care will be taken not to introduce bias when detecting AE and/or SAE. Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inqui re about 
AE occurrence.  
8.4.3.  Follow -up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All SAEs and non -serious AEs of special 
interest (as defined in Section 8.4.7 ), will be followed until the event is resolved, 
stabili sed, otherwise explained, or the participant is lost to follow -up (as defined in 
Section 7.3). Further information on follow -up procedures is given in Appendix 3 . 
8.4.4.  Regulatory Reporting Requirements for SAEs  
• Prompt notification by [CONTACT_31838] a study intervention under clinical investigation are met.  
• [COMPANY_004] has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical 
investigation. The Sponsor will comply with country -specific regulatory requirements 
relating  to safety reporting to the regulatory authority, Institutional Review Boards 
(IRB)/Independent Ethics Committees (IEC), and investigators.  
• An investigator who receives an investigator safety report describing an SAE or other 
specific safety information (e .g., summary or listing of SAEs) from [COMPANY_004] will review 
and then file it along with the IB and will notify the IRB/IEC, if appropriate 
according to local requirements.  
• Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]R) according to local regulatory requirements and [COMPANY_004] policy and 
forwarded to investigators as necessary.  
8.4.5.  Pregnancy  
• Any female participant who becomes pregnant while participating in the study will 
not receive another dose of study intervention.  
• Details of all pregnancies in female participants will be collected from the start of 
study intervention and until [ADDRESS_31142] administered dose of study 
intervention .  
• If a pregnancy is  reported, the investigator will record pregnancy informa tion on the 
appropriate form and submit it to [COMPANY_004] within 24 hours  of learning of the female  
participant pregnancy. While pregnancy itself is not considered to be an AE or SAE, 
any pregnancy complication or elective termination of a pregnancy for medical 
reasons will be reported as an AE or SAE.  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
74 • Abnormal pregnancy outcomes (e.g., spontaneous abortion, f oetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs and will be reported 
as such.  
• The participant will be followed to determ ine the outcome of the pregnancy. The 
investigator will collect follow -up information on the participant and the neonate , and 
the information will be forwarded to the Sponsor.  
• Any post -study pregnancy -related SAE considered reasonably related to the study 
intervention by [CONTACT_31839] 8.4.4 . While the investigator is not obligated to actively s eek this information 
in former study participants, he or she may learn of an SAE through spontaneous 
reporting.  
8.4.6.  Cardiovascular and Death Events  
For any CV events detailed in Appendix 3  and all deaths, whether or not they are 
considered SAEs, specific CV and Death sections of the CRF will be required to be 
completed. These sections include questions regarding CV (including sudde n cardiac 
death) and non -CV death.  
The CV CRF pages are presented as queries in response to reporting of certain CV 
MedDRA terms. The CV information should be recorded in the specific CV section of 
the CRF within one week of receipt of a CV Event data que ry prompting its completion.   
The Death CRF page is provided immediately after the occurrence or outcome of death is 
reported. Initial and follow -up reports regarding death must be completed within  one 
week of when the death is reported.  
8.4.7.  Adverse Events of  Special Interest  
Adverse events of special interest (AESI) include:  
• Allergic reactions including anaphylaxis  
Note:  these events will be assessed by [CONTACT_31840] 2006 Joint NIAID/FAAN 
Second Symposium on Anaphylaxis [ Sampson , 2006] ( Appendix 8 ). 
• Type III hypersensitivity (immune complex disease/vasculitis) reactions  
• Local injection site reactions  
• QTc prolongation  
See Section 2.3.1  for additional details.  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
75 8.4.8.  Medical Device Deficiencies  
Medical devices (PFS) are being provided for use in this study as a delivery method for 
[COMPANY_004]3511294 or matching placebo injections. To fulfil regulatory reporting obligations 
worldwide, the investigator is responsible for the detection and documentation of events 
meeting the definitions of device deficiency that occur during the study with such 
devices.  
The definition of a Medical Dev ice Deficiency can be found in Section 10.7. 
NOTE: Deficiencies fulfilling the definition of an AE/SAE will also follow the processes 
outlined in Sect ion 10.3 of the protocol.  
[IP_ADDRESS].  Time Period for Detecting Medical Device Deficiencies  
• Medical device deficiencies that result in an incident will be detec ted, documented, 
and reported during all periods of the study in which the medical device is used.  
• The method of documenting Medical Device Incidents is provided in Section 10.7. 
[IP_ADDRESS].  Follow -up of Medical Device Deficiencies  
• Follow -up applies to all participants, including those who discontinue study 
intervention or the study.  
• The investigator is responsible for ensuring that follow -up includes any 
supplem ental investigations as indicated to elucidate the nature and/or causality of 
the deficiency.  
• New or updated information will be recorded on the originally  completed form with 
all changes signed and dated by [CONTACT_093].  
[IP_ADDRESS].  Prompt Reporting of Medical De vice Deficiencies to Sponsor  
• Device deficiencies will be reported to the Sponsor within 24 hours after the 
investigator determines that the event meets the protocol definition of a device 
deficiency.  
• The Medical Device Deficiency Report Form will be sent t o the Sponsor by [CONTACT_6968]. 
If email is unavailable, then fax should be utili sed. 
• The Sponsor will be the contact [CONTACT_31841].  
[IP_ADDRESS].  Regulatory Reporting Requirements for Medical Device Incidents  
• The investigator will promptly report all deficiencies occurring with any medical 
device provided for use in the study in order for the Sponsor to fulfil the legal 
responsibility to notify appropriate regulatory authorities and other entities about 
certain  safety information relating to medical devices being used in clinical studies.  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
76 • The investigator, or responsible person according to local requirements (e.g., the 
head of the medical institution), will comply with the applicable local regulatory 
requiremen ts relating to the reporting of device deficiencies to the IRB/IEC.  
8.5. Pharmacokinetics  
• Blood samples will be collected for measurement of plasma concentrations of 
[COMPANY_004]3511294 as specified in the SoA (Section 1.3).  
• The actual date and time (24 -hour clock time) of each sample will be recorded. 
Samples obtained at Visit 2 (Week 0) and Visit 10 (Week 26) should be drawn prior 
to dosing.  
• Collection, processin g, storage and shippi[INVESTIGATOR_31775].  
• Intervention concentration information that would unblind the study will not be 
reported to investigative sites or blinded personnel until the study has been 
unblinded.  
8.6. Genet ics and Pharmacogenomics  
China only: Genetic blood samples will not be collected from participants in China.  
A blood sample for DNA isolation will be collected from participants who have 
consented to participate in the genetics analysis component of the st udy. Participation is 
optional. Participants who do not wish to participate in the genetic research may still 
participate in the study.  
In the event of DNA extraction failure, a replacement genetic blood sample may be 
requested from the participant. Signed  informed consent will be required to obtain a 
replacement sample unless it was included in the original consent.  
See Section 10.[ADDRESS_31143] for the superiority of [COMPANY_004]3511294 100 mg SC 
+ SoC following two doses (at Week 0 and at Week 26) compared with placebo  + SoC , 
assessed by [CONTACT_31842] [ADDRESS_31144] at a 5% two -sided significance level the null hypothesis that there is 
no difference in annuali sed exacerb ation rate between [COMPANY_004]3511294 and placebo.  
9.2. Sample Size Determination  
Approximately  participants with severe uncontrolled asthma with an eosinophilic 
phenotype will be screened to ensure the randomisation of  participants in a ratio 
to [COMPANY_004]3511294   and matching placebo   
9.2.1.  Sample Size Assumptions  
A sample size of participants  [COMPANY_004]3511294 to placebo allocation ratio) is based 
on sufficient power to conclude superiority on primary and key secondary endpoints.  
There is a possibili ty that greater than  participants will be randomised in the study 
due to local country requests or requirements, for example, the local competent authority 
specifying a minimum number to be enrolled.  
[IP_ADDRESS].  Primary Endpoint  
The assumed true annuali sed rate of  exacerbations in the placebo arm is 1.18. Based on 
an assumed true treatment difference of a reduction in annuali sed exacerbation rate 
between [COMPANY_004]3511294 + SoC and placebo  + SoC , a sample size of  randomised 
participants (  to [COMPANY_004]3511294, to placebo) will provide 99% power for the 
primary endpoint at a 5% two -sided significance level [ PASS , 2020].  
The assumptions for the placebo rate and treatment effect are median values from an 
elicitation exercise which used Phase 3 anti -IL-5/5R historical data (~50% reduction in 
exacerbations) and expert opi[INVESTIGATOR_1649]. The sample size is based also on an assumption of  
for the dispersion parameter which was observe d in two mepolizumab studies [ Pavord , 
2012; Ortega , 2014] . It was assumed that  of participant -years data will be missing 
due to study withdrawal, which is also consistent with mepolizumab studies.  
Based on the assumptions above, the minimum observed treatment difference estimated 
to result in significance at  the 5% two -sided significance level is a  reduction in 
exacerbations for [COMPANY_004]3511294 + SoC compared with placebo + SoC (rate ratio of 0. 73). 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
79 [IP_ADDRESS].  Secondary Endpoints  
Table 3 describes the assumptions and power values for two key secondary endpoints. 
The assumptions are obtained from the Phase 3 mepolizumab studies [Pavord , 2012; 
Ortega , 2014; Chupp , 2017].  
Table 3 Power Calculations for Key Secondary Endpoints   
Endpoint  Assumed treatment 
difference ([COMPANY_004]3511294 + 
SoC vs. placebo + SoC)  Standard 
deviation  Power  
9.2.2.  Sample Size Sensitivity  
The sample size and power calculations are based on assumptions about the true values 
for parameters. The power of the study is dependent on changes in these assumptions, in 
particular the assumed annuali sed exacerbation rate s. Table 4 illustrates how changes in 
assumptions for two parameters (placebo + SoC annualised exacerbation rate and 
treatment effect) affect the power.  
Table 4 Estimates of Power for Assumed Placebo  + SoC  Exacerbation 
Rate and Assumed Percen t Reduction with [COMPANY_004]3511294 + SoC 
Compared with Placebo  + SoC  
Percent reduction in 
annuali sed exacerbation rate 
with [COMPANY_004]3511294 + SoC vs. 
placebo  + SoC  Placebo  + SoC  annuali sed exacerbation rate  
9.2.3.  Sample Size Re -estimation or Adjustment  
There will be no sample size re -estimation.  
CCI
CCI
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
80 9.3. Analysis Sets  
For the purpose of analyses, the following populations are defined  
Further populations to be used for other ass essments will be defined in the statistical 
analysis plan  (SAP). 
9.4. Statistical Analysis  
The SAP will be finalised prior to un -blinding and it will include a more technical and 
detailed description of the statistical analyses described in this section.  
This section is a summary of the planned statistical analyses of the most important 
endpoints including primary and key secondary endpoints.  
9.4.1.  General Considerations  
The study will test at a 5% two -sided significance level the null hypothesis that there is 
no difference in annualised exacerbation rate between [COMPANY_004]3511294 + SoC  and placebo 
+ SoC. Population  Description  
Screened  All participants who sign the ICF.  
Enrolled  All participants who entered the study.  
 
Note screening failures (who never passed screening even if 
rescreened) and participants screened but never enrolled into the 
study (Met eligibility but not needed) are excluded from the 
Enrolled analysis set as the y did not enter the study.  
 
Randomised  All participants who were randomly assigned to study 
intervention in the study.  
Full Analysis Set (FAS)  All randomised participants who receive at least one dose of 
study intervention. Participants will be analysed according to the 
intervention they are allocated at randomisation. This population 
will serve as the primary population for analyses of efficacy 
endpoints.  
Safety  All randomised participants who receive at least one dose of 
study intervention. Participant s will be analysed according to the 
intervention they are allocated at randomisation, unless a 
participant receives a different intervention to the randomised 
intervention at all protocol -defined administrations, in which case 
the participant will be analy sed according to the actual 
intervention they received. This population will serve as the 
primary population for analyses of safety endpoints.  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
81 9.4.2.  Primary Endpoint  
[IP_ADDRESS].  Main Estimand  
Target Participant  
Population  Adult and adolescent participants with severe uncontrolled asthma with 
an eosinophilic  phenotype following the strategy outlined below for 
dealing with the main intercurrent events that are anticipated.  
Primary Endpoint  Annuali sed rate of clinically significant exacerbations  over 52 weeks . 
Clinically significant exacerbations are defined in Section 8.2.2 . 
Intercurrent events 
and strategies  The anticipated key intercurrent events and corresponding strategies 
are: 
a) Study intervention discontinuation due to reasons unrelated to the 
COVID -19 pandemic:  
 
b) Study intervention discontinuation due to reasons related to the 
COVID -19 pandemic:  
 
c) Change in mainten ance therapy or use of prohibited medications 
(listed in Section 6.9.2 ):  
 
Summary measure  Ratio of the rates of exacerbations between [COMPANY_004]3511294 + SoC and 
placebo  + SoC . 
Analysis Metho d The primary analysis of the annuali sed rate of clinically significant 
exacerbations will use a negative binomial model. Covariates included 
will be baseline maintenance OCS therapy (OCS vs. no OCS), baseline 
ICS dose (medium or high dose, see Appendix 10 ), region , number of 
exacerbations in the year prior to the study, baseline % predicted FEV 1 
and treatment group with log e(time in study in years ) as an offset 
variable. The rate ratio and 95% confidence interval (CI) will be provided 
for the comparison between [COMPANY_004]3511294 + SoC and placebo  + SoC . 
Handling of 
missing data and 
intercurrent events 
leading to 
exclusion of data  Missing data or data excluded due to intercurrent events will be handled 
as follows:  
a)  
 
 
 
 
 
  
 
CCI
CCI
CCI
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
82  
 
Sensitivity analyses  will be conducted to investigate the conclusions 
from deviations from these assumptions regarding missing data for ( b) 
above .  
 
 
 
 
 
 
9.4.3.  Secondary Endpoints  
[IP_ADDRESS].  Main Estimands  
Target Participant  
Population  Adult and adolescent participants with severe uncontrolled asthma with 
an eosinophilic  phenotype following the strategy outlined below for 
dealing with the main intercurrent events that are anticipated.  
Secondary 
Endpoints  • Change from baseline in SGRQ total score at Week 52  
• Change from baseline in ACQ -5 score at Week 52  
• Change from baseline in pre -bronchodilator FEV 1 at Week 52  
Intercurrent events 
and stra tegies  The anticipated key intercurrent events and corresponding strategies:  
a) Study intervention discontinuation due to reasons unrelated to the 
COVID -19 pandemic:  
 
b) Study intervention discontinuation due to reasons related to the 
COVID -19 pandemic:  
 
c) Change in maintenance therapy or use of prohibited medications 
(listed in Section 6.9.2 ):  
 
Summary measure  Difference in means between [COMPANY_004]3511294  + SoC  and placebo  + SoC . 
Analysis Method  The analysis will be performed using a repeated measures mixed model. 
Covariates included will be baseline, region, baseline maintenance OCS 
therapy (OCS vs. no OCS) , baseline ICS dose (medium or high dose, 
see Appendix 10 ), number of exacerbations in the year prior to the 
study, baseline % predicted FEV 1,treatment group and visit, plus 
interaction terms for visit by [CONTACT_31843]. The 
difference in means and 95% CI will be provided for the comparison 
between [COMPANY_004]3511294 + SoC  and placebo  + SoC . 
CCI
CCI
CCI
CCI
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
83 Handling of 
missing data and 
intercurrent events 
leadi ng to 
exclusion of data  Missing data or data excluded due to intercurrent events will be handled 
as follows:  
a) 
b) 
Sensitivity analyses  will be conducted to investigate the conclusions 
from deviations from these assumptions regarding missing and excluded 
data for (b) above .  
 
 
 
 
 
The annuali sed rate of exacerbations requiring hospi[INVESTIGATOR_31739]/or ED visit over 
52 weeks will be evaluated using the same strategy as that described for the primary 
endpoint (see Section 9.4.2 ). 
9.4.4.  Other Endpoints  
Full details of analysis methods to be used for  other endpoints will be provided in the 
SAP.  
9.4.5.  Safety  Analyses  
All safety analyses will be performed on the Safety Population. Summaries of data will 
report data according to the nominal visit for which it was recorded. Occurrence of AEs, 
SAEs , AESIs, laboratory data, vital signs, and ECGs will be included in data displays in 
the form of listings, frequency tables, summary statistics, graphs, and statistical analyses 
where appropriate.  
Adverse Events (AEs) will be coded using the standard Medi cal Dictionary for 
Regulatory Activities (MedDRA) and will be grouped by [CONTACT_9313]  (SOC) . AEs 
will be summarised by [CONTACT_31844] , by [CONTACT_31845]. Separate summaries will be present ed for all AEs, 
drug-related AEs, serious AEs (SAEs), AEs leading to permanent discontinuation of 
study intervention  or withdrawal from study and for any AEs of special interest.  
CCI
CCI
TMF-[ADDRESS_31145] for the primary and secondary endpoints is 
[COMPANY_004]3511294 100 mg SC + SoC vs placebo  + SoC . A fixed sequence hierarchical testing 
procedure will be used to provide strong control of Type I error for multiplicity arising 
from the primary and multiple secondary endpoints. This will be carried out using a 
stepdown closed testing procedure where inference for an endpoint in the predefined 
hierarchy will be dependent on statistical significance having been achieved for the 
previo us endpoints in the hierarchy. For example, for the primary endpoint, [COMPANY_004]3511294  
+ SoC  will be compared to placebo  + SoC  at a two -sided 5% level. The next endpoint in 
the hierarchy (i.e. the first secondary endpoint) will be tested only if the test for the  
primary endpoint is significant at the two -sided 5% level. Testing will continue down the 
hierarchy for the remaining endpoints in an equivalent manner only if the previous 
endpoint in the hierarchy achieves statistical significance.  
The hierarchy of the primary and secondary endpoints to be tested is as follows:  
1. Annuali sed rate of clinically significant exacerbations over 52 weeks  
2. Change from baseline in SGRQ at Week 52  
3. Change from baseline in ACQ -5 at Week 52  
4. Change from baseline in clinic pre -bronchodil ator FEV 1 at Week 52  
5. Annuali sed rate of exacerbations requiring hospi[INVESTIGATOR_31739]/or ED visit over 
52 weeks  
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
85 10. SUPPORTING DOCUMENTA TION AND O PERATIONAL 
CONSIDERATIONS  
10.1.  Appendix 1: Reg ulatory, Ethical, and Study Oversight Considerations  
10.1.1.  Regulatory and Ethical Considerations  
• This study will be conducted in accordance with the protocol and with:  
• Consensus ethical principles derived from international guidelines 
including the Declaration o f Helsinki and Council for International 
Organizations of Medical Sciences (CIOMS) International Ethical 
Guidelines  
• Applicable ICH Good Clinical Practice (GCP) Guidelines  
• Applicable laws and regulations  
• The protocol, protocol amendments, ICF, IB, and other  relevant documents (e.g., 
advertisements) must be submitted to an IRB/IEC by [CONTACT_31846]/IEC before the study is initiated.  
• Any amendments to the protocol will require IEC/IRB approval before 
implementation of ch anges made to the study design, except for changes 
necessary to eliminate an immediate hazard to study participants.  
• Protocols and any substantial amendments to the protocol will require health 
authority approval prior to initiation except for changes necessary to eliminate an 
immediate hazard to study participants.  
• The investigator will be responsible for the following:  
• Providing written summaries of the status of the study to the IRB/IEC 
annually or more frequently in accordance with the requirements,  policies, 
and procedures established by [CONTACT_1201]/EC  
• Notifying the IRB/IEC of SAE or other significant safety findings as 
required by [CONTACT_1744]/IEC procedures  
• Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH  guidelines, the IRB/IEC, European 
regulation 536/2014 for clinical studies (if applicable), European Medical 
Device Regulation 2017/745 for clinical device research (if applicable), 
and all other applicable local regulations  
10.1.2.  Financial Disclosure  
Investiga tors and sub -investigators will provide [COMPANY_004] with sufficient, accurate financial 
information as requested to allow [COMPANY_004] to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests during the 
course of the study and for 1 year after completion of the study.  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
86 10.1.3.  Informed Consent Process  
• The investigator or his/her representative will explain the nature of the study to 
the pa rticipant or their legally authori sed representative  and answer all questions 
regarding the study.  
• Participants must be informed that their participation is voluntary. Participants or 
their legally authori sed representative will be required to sign a stat ement of 
informed consent that meets the requirements of [ADDRESS_31146] (HIPAA) 
requirements, where applicable, and the IRB/IEC or study cent re.  
• For participants [ADDRESS_31147] be obtained in 
addition to the legally authori sed representative(s)' consent. Assent will be 
obtained in accordance with applicable country or IRB/Ethics Committee 
regulations. Written informed consent will be obtain ed from participants turning 
18 years of age to continue participation in the study.  
• The medical record must include a statement that written informed consent/assent 
was obtained before the participant was enrolled in the study and the date the 
written co nsent/assent was obtained. The authori sed person obtaining the 
informed consent/assent must also sign the ICF.  
• Participants must be re -consented/re -assented to the most current version of the 
ICF(s) during their participation in the study.  
• A copy of the I CF(s) must be provided to the participant or their legally 
authori sed representative.  
Participants who are rescreened are required to provide consent/assent and sign a new 
ICF/assent form.  
[COMPANY_004] (alone or working with others) may use a participant’s coded s tudy data and 
samples and other information to carry out this study; understand the results of this study; 
learn more about [COMPANY_004]3511294 or about the study disease; publish the results of these 
research efforts; work with government agencies or insurers to h ave [COMPANY_004]3511294 
approved for medical use or approved for payment coverage.  
10.1.4.   Data Protection  
• Participants will be assigned a unique identifier by [CONTACT_23983]. Any participant records 
or datasets that are transferred to [COMPANY_004] will contain the identifier only; particip ant 
names or any information which would make the participant identifiable will not 
be transferred.  
• The participant must be informed that his/her personal study -related data will be 
used by [CONTACT_31847]. The level of di sclosure 
must also be explained to the participant who will be required to give consent for 
their data to be used as described in the informed consent.  
• The participant must be informed that his/her medical records may be examined 
by [CONTACT_31848], by [CONTACT_6667]/IEC members, and by [CONTACT_9326].  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
87 10.1.5.  Committees Structure  
An Independent Data Monitoring Committee (IDMC) comprised of clinical experts 
external to  [COMPANY_004] will review unblinded data at defined timepoints during the study. If 
deemed appropriate by [CONTACT_31849], or upon request by [CONTACT_31850], additional 
timepoints for review may be added.  
Details of the structure and function of the IDMC, and analys is plan for IDMC reviews, 
are outlined in the IDMC Charter, which is available upon request.  
In addition to the IDMC, the [COMPANY_004] SRT will review blinded safety data at regular 
intervals throughout the study to ensure participant safety, which includes safety  signal 
detection at any time during the study. Details of the SRT process will be available in 
relevant SRT documents. The SRT will inform the IDMC if any safety signals are 
identified.  
10.1.6.  Dissemination of Clinical Study Data  
• Where required by [CONTACT_31851], an investigator signatory 
will be identified for the approval  of the clinical study report. The investigator 
will be provided reasonable access to statistical tables, figures, and relevant 
reports and will have the opportunity to rev iew the complete study results at a 
[COMPANY_004] site or other mutually  agreeable location.  
• [COMPANY_004] will also provide all investigators who participated in the study with a 
summary of the study results and will tell the investigators what treatment their 
patients recei ved. The investigator(s) is/are encouraged to share the summary 
results with the study participants , as appropriate.  
• Under the framework of the SHARE initiative, [COMPANY_004] intends to make anonymi sed 
participant -level data from this trial available to external re searchers for scientific 
analyses or to conduct further research that can help advance medical science or 
improve patient care. This helps ensure the data provided by [CONTACT_31852]. 
Requests for access may be made through www.clinicalstudydatarequest.com.  
• [COMPANY_004] will provide the investigator with the randomisation codes for their site only 
after completion of the full statistical analysis.  
• The procedures and timing for public disclo sure of the protocol and results 
summary and for development of a manuscript for publication for this study will 
be in accordance with [COMPANY_004] Policy.  
• [COMPANY_004] intends to make anonymi sed patient -level data from this trial available to 
external researchers for scientific analyses or to conduct further research that can 
help advance medical science or improve patient care. This helps ensure the data 
provided by [CONTACT_31853]  
• A manuscript will be progressed for publication in the scientific literature if the 
results provide important scientific or medical knowledge.  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
88 10.1.7.  Data Quality Assurance  
• All participant data rel ating to the study will be recorded on printed or electronic 
CRF unless transmitted to the Sponsor or designee electronically (e.g., laboratory 
data). The investigator is responsible for verifying that data entries are accurate 
and correct by [CONTACT_31854].  
• Guidance on completion of CRFs will be provided in the CRF Guidelines.  
• Quality tolerance limits (QTLs) will be pre -defined in the QTL Plan to identify 
systematic issues that can impact participant safety and/or reliability  of study 
results. These pre -defined parameters will be monitored during and at the end of 
the study and all deviations from the QTLs and remedial actions taken will be 
summari sed in the clinical study report.  
• The investigator must permit study -related mon itoring, audits, IRB/IEC review, 
and regulatory agency inspections and provide direct access to source data 
documents.  
• Monitoring details describing strategy including definition of study critical data 
items and processes (e.g., risk -based initiatives in operations and quality such as 
Risk Management and Mitigation Strategies and Analytical Risk -Based 
Monitoring), methods, responsibilities and requirements, including handling of 
noncompliance issues and monitoring techniques (central, remote, or on -site 
monitoring) are provided in the Monitoring Plan.  
• [COMPANY_004] or a designee is responsible for the data management of this study including 
quality checking of the data.  
• [COMPANY_004] assumes accountability for actions delegated to other individuals (e.g., 
Contract Research Or ganizations).  
• Records and documents, including signed ICF, pertaining to the conduct of this 
study must be retained by [CONTACT_1732] 25 years from the issue of the final 
Clinical Study Report (CSR)/ equivalent summary unless local regulations or 
institutional policies require a longer retention period. No records may be 
destroyed during the retention period without the written approval of [COMPANY_004]. No 
records may be transferred to another location or party without written 
notification to [COMPANY_004].  
10.1.8.  Source Documents  
• Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site.  
• Data reported on the CRF or entered in the eCRF that are transcrib ed from source 
documents must be consistent with the source documents or the discrepancies 
must be explained. The investigator may need to request previous medical records 
or transfer records, depending on the study. Also, current medical records must be 
available.  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
89 • Definition of what constitutes source data and its origin can be found in [Source 
Data Acknowledgment].  
• The investigator must maintain accurate documentation (source data) that 
supports the information entered in the CRF.  
• Study monitors will perf orm ongoing source data verification to confirm that data 
entered into the CRF by [CONTACT_31855], complete, and 
verifiable from source documents; that the safety and rights of participants are 
being protected; and that the study is being conducted in accordance with the 
currently approved protocol and any other study agreements, ICH GCP, and all 
applicable regulatory requirements.  
10.1.9.  Study and Site Start and Closure  
First Act of Recruitment  
The study start date is the date on which the  clinical study will be open for recruitment of 
participants.  
The first act of recruitment is the first site open and will be the study start date.  
Study/Site Termination  
[COMPANY_004] or designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of [COMPANY_004]. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study 
supplies have been collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_31856]:  
For study termination:  
• Discontinuation of further study intervention development  
For site termination:  
• Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the  Sponsor's procedures, or GCP guidelines  
• Inadequate or no recruitment of participants (evaluated after a reasonable amount 
of time) by [CONTACT_093]  
• If the study is prematurely terminated or suspended, the Sponsor shall promptly 
inform the investigators , the IECs/IRBs, the regulatory authorities, and any 
contract research organization(s) used in the study of the reason for termination or 
suspension, as specified by [CONTACT_1214]. The 
investigator shall promptly inform the partici pant and should assure appropriate 
participant therapy and/or follow -up 
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
90 10.1.10.  Publication Policy  
• The results of this study may be published or presented at scientific meetings. If 
this is foreseen, the investigator agrees to submit all manuscripts or abstracts to 
the Sponsor before submission. This allows the Sponsor to protect proprietary 
information  and to provide comments.  
• [COMPANY_004] will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, [COMPANY_004] will generally 
support publication of multicent re studies only in their entirety and not as 
individual site data. In this case, a coordinating investigator [INVESTIGATOR_31776].  
• Authorship will be determined by [CONTACT_14346].  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
91 10.2.  Appendix 2 : Clinical Laboratory Tests  
All protocol required laboratory assessments must be conducted in accordance with the 
Laboratory Manual and the SoA (Section 1.3).  
Local laboratory results may be required in the event that the central laboratory results 
are not available in time for either study intervention administration and/or response 
evaluation to be performed – for example: when results from screening Visit [ADDRESS_31148] still be performed at the site.  
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
92 Table 5 Protocol -Required Safety Laboratory Tests  
NOTES:  
 
 
 
 
 
  
 
.  
2. Details of liver chemistry stoppi[INVESTIGATOR_21357] -up assessments after liver 
stoppi[INVESTIGATOR_31777] 7.1 and Section 10.6 All events of ALT 3 × upper 
limit of normal (ULN) and total bilirub in 2 × ULN (>35% direct bilirubin) or ALT 3 × ULN and 
international normali sed ratio (INR) >1.5, if INR measured, which may indicate severe liver injury 
(possible Hy’s Law), must be reported to [COMPANY_004] as an SAE.  
3. If alkaline phosphatase is elevated, consider  fractionating.  
4. Local urine testing will be standard for the protocol unless serum testing is required by [CONTACT_31857]/IEC.  
CCI
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
93 10.3.  Appendix 3: AEs and SAEs: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  
10.3.1.  Definition of AE 
AE Definition  
• An AE is any untoward medical occurrence in a clinical study participant, 
temporally associated with the use of a study intervention, whether or not 
considered related to the study intervention.  
NOTE: An AE can therefore be any unfavo urable and unintended sign (including 
an abnormal laboratory finding), symptom, or disease (new or exacerbated) 
temporally associated with the use of a study intervention.  
 
Events Meeting  the AE Definition  
• Any abnormal laboratory test results (haematology, clinical chemistry, or 
urinalysis) or other safety assessments (e.g., ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of t he investigator (i.e., not 
related to progression of underlying disease).  
• Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.  
• New conditions detected or diagnosed aft er study intervention administration even 
though it may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected intervention - intervention 
interaction.  
• Signs, symptoms, or the clinical sequelae of a suspect ed overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE/SAE unless it is an intentional overdose taken with possible suicidal/self -
harming intent. Such overdoses should be reported regardless of s equelae.  
• "Lack of efficacy" or "failure of expected pharmacological action" per se will not 
be reported as an AE or SAE. Such instances will be captured in the efficacy 
assessments. However, the signs, symptoms, and/or clinical sequelae resulting from 
lack of efficacy will be reported as AE or SAE if they fulfil  the definition of an AE 
or SAE.  
 
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
94 Events NOT  Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by [CONTACT_11009]’s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.  
• Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that 
leads to the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience a dmission to a hospi[INVESTIGATOR_307]).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen.  
10.3.2.  Definition of SAE  
If an event is not an AE per definition above, then it cannot be an  SAE even if serious 
conditions are met (e.g., hospi[INVESTIGATOR_31778]/symptoms of the disease under study, 
death due to progression of disease, etc.).  
An SAE is defined as any untoward medical occurrence that, at any dose, meets one or  
more of the criteria listed:  
a. Results in death  
b. Is life -threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which hypotheticall y might have caused death, if it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_15574]  
• In general, hospi[INVESTIGATOR_31779] (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_1083]/or treatment that would not have been appropriate in the 
physician’s office or  outpatient setting. Complications that occur during 
hospi[INVESTIGATOR_31780]. If a complication prolongs hospi[INVESTIGATOR_31781], the event is serious. When in doubt as to whether 
“hospi[INVESTIGATOR_11956]” occurred or was necessary, th e AE should be considered serious.  
• Hospi[INVESTIGATOR_31782] a pre -existing condition that did not 
worsen from baseline is not considered an AE.  
TMF-[ADDRESS_31149] medical occurrence that, at any dose, meets one or  
more of the criteria listed:  
d. Results in persistent or significant disability/incapacity  
• The term disability means a substan tial disruption of a person’s ability to conduct 
normal life functions.  
• This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhoea , 
influenza, and accidental t rauma (e.g. sprained ankle) which may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect   
f. Other situations:  
• Possible Hy’s Law case: ALT≥3xULN AND total bilirubin ≥2xULN (>35% direct 
bilirubin) or international normali sed ratio (INR) >1.[ADDRESS_31150] be reported as SAE  
• Medical or scientific judgment should be exercised by [CONTACT_31858]. 
These events should usually be considered serious.  
o Examples of such events include invas ive or malignant cancers, intensive 
treatment for allergic bronchospasm, blood dyscrasias, convulsions, or 
development of intervention dependency or intervention abuse.  
10.3.3.  Definition of Cardiovascular Events  
Cardiovascular Events (CV) Definition:  
Investigators will be required to fill out the specific CV event page of the CRF for the 
following AEs and SAEs:  
• Myocardial infarction/unstable angina  
• Congestive heart failure  
• Arrhythmias  
• Valvulopathy  
• Pulmonary hypertension  
• Cerebrovascular events/stroke an d transient ischemic attack  
• Peripheral arterial thromboembolism  
• Deep venous thrombosis/pulmonary embolism  
• Revasculari sation  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
96 10.3.4.  Recording and Follow -Up of AE and SAE  
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e.g. hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
related to the event.  
• The investigator will then record all relevant AE/SAE information.  
• It is not acceptable for the investigator to send photocopi[INVESTIGATOR_31783]’s 
medical records to [COMPANY_004] in lieu of completion of the [COMPANY_004] required form.  
• There may be instances when copi[INVESTIGATOR_31784]. In this case, all participant identifiers, with the exception of the 
participant n umber, will be redacted on the copi[INVESTIGATOR_31785].  
• The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/symptoms) will be documented as the AE/SAE.  
Assessment of Intensity  
The investigator will make an assessment of intensity for each AE and SAE reported 
during the study and assign it to 1 of the following categories:  
• Mild: An event that is easily tolerated by [CONTACT_2299], causing minimal 
discomfort and not interfering with everyday activities.  
• Moderate: An event that causes sufficient discomfort and interferes with normal 
everyday activities.  
• Severe: An event that prevents normal  everyday activities. An AE that is assessed 
as severe should not be confused with an SAE. Severe is a category utili sed for 
rating the intensity of an event; and both AE and SAE can be assessed as severe.  
• An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes 
as described in the definition of an SAE, NOT when it is rated as severe.  
 
Assessment of Causality  
The investigator is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE.  
• A "reasonable possibility" of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.  
• The investigator will use clinical judgment to determine the relationshi p. 
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
97 Assessment of Causality  
• Alternative causes, such as underlying diseases, concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study intervention 
administration will be considered and investigated.  
• The investigator will also consult the IB and/or Product Information, for marketed 
products, in his/her assessment.  
• For each AE/SAE, the investigator must  document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations i n which an SAE has occurred and the investigator has 
minimal information to include in the initial report to [COMPANY_004]. However, it is very 
important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to [COMPANY_004] . 
• The investigator may change his/her opi[INVESTIGATOR_9242] -up 
information and send an SAE follow -up report with the updated causality 
assessment.  
• The causality assessment is one of the criteria used when determining re gulatory 
reporting requirements.  
 
Follow -up of AE and SAE  
• The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_31859]/or causality of the AE or SAE as fully as possible. This 
may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals.  
• If a participant dies during participation in the study o r during a recogni sed follow -
up period, the investigator will provide [COMPANY_004] with a copy of any post -mortem 
findings including histopathology.  
• New or updated information will be recorded in the originally submitted 
documents.  
• The investigator will submit any updated SAE data to [COMPANY_004] within 24 hours of 
receipt of the information.  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
98 10.3.5.  Reporting of SAE to [COMPANY_004]  
SAE Reporting to [COMPANY_004]  via Electronic Data Collection Tool  
• The primary mechanism for reporting SAE to [COMPANY_004] will be the electronic data 
collection tool.  
• If the electronic system is unavailable, then the site will use the paper SAE data 
collection tool (see next section) to report the event within 24 hours and send/fax it 
to the Medical Monitor.  
• The site will enter the SAE data into the electronic system as soon a s it becomes 
available.  
• After the study is completed at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry of new data or changes to existing data.  
• If a site receives a report of a new SAE from a study participant  or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to the Medical Monitor or the SAE coordinator by t elephone.  
• Contacts for SAE reporting can be found in the SRM . 
 
SAE Reporting to [COMPANY_004] via Paper Data Collection Tool  
• Facsimile transmission of the SAE paper data collection tool is the preferred 
method to transmit this information to the Medical monitor or  the SAE coordinator.  
• In rare circumstances and in the absence of facsimile equipment, notification by 
[CONTACT_9337] a copy of the SAE data collection tool sent by 
[CONTACT_22855].  
• Initial notification via telephone does no t replace the need for the investigator to 
complete and sign the SAE data collection tool within the designated reporting time 
frames.  
• Contacts for SAE reporting can be found in the SRM . 
 
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
99 10.4.  Appendix 4: Contraceptive and Barrier Guidance  
10.4.1.  Definitions:  
Woman of Childbearing Potential (WOCBP)  
Women in the following categories are considered WOCBP (fertile):  
1. Following menarche  
2. From the time of menarche until becoming post -menopausal unless permanently 
sterile (see below)  
Notes : 
• A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.  
o A high follicle -stimulating hormone (FSH) level in the postmenopausal range 
may be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormonal replacement the rapy (HRT). However, in the absence 
of [ADDRESS_31151] 
discontinue HRT to allow confirmation of postmenopausal status before study 
enrolment.  
• Permanent sterili sation methods (for the purpose of this study) include:  
o Documented hysterectomy  
o Documented bilateral salpi[INVESTIGATOR_1656]  
o Documented bilateral oophorectomy  
For individuals with permanent infertility due to an alternate medical cause other than the 
above, (e.g., Mullerian agenesis, androgen insensitivity, gonadal dysge nesis), investigator 
discretion should be applied to determining study entry.  
 
Note:  Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview.  
 
If fertility is unclear ( e.g., amenorrhea in adolescents or athletes) and a menstrual cycle 
cannot be confirmed before first dose of study intervention, additional evaluation should 
be considered.  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
100  
Woman of Nonchildbearing Potential (WONCBP)  
Women in the following categories are c onsidered WONCBP:  
1. Premenopausal female with permanent infertility due to one of the following (for the 
purpose of this study):  
a) Documented hysterectomy  
b) Documented bilateral salpi[INVESTIGATOR_1656]  
c) Documented bilateral oophorectomy  
For individuals with permanent infertility due to an alternate medical cause other than 
the above, (e.g., Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), 
investigator discretion should be applied to determining study entry.  
Note : Documentation can come from the site per sonnel’s review of the participant’s 
medical records, medical examination, or medical history interview.  
2. Postmenopausal female  
A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.  
a) A high follicle stimulating ho rmone (FSH) level in the postmenopausal range may 
be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormonal replacement therapy (HRT). However, in the absence 
of 12 months of amenorrhea, confirmation with more than one  FSH measurement 
is required.  
b) Females on HRT and whose menopausal status is in doubt must discontinue HRT 
to allow confirmation of postmenopausal status before study enrolment.  
10.4.2.  Contraception Guidance:  
Female participants:  
CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE:  
Highly Effective Methodsb That Have Low User Dependency Failure rate of <1% per year 
when used consistently and correctly.  
• Implantable progestogen -only hormone contraception associated with inhibition of 
ovulationc 
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS)c  
• Bilateral tubal occlusion  
• Azoospermic partner (vasectomi sed or due to a medical cause)  
Azoospermia is a highly effective contraceptive method provided that the partner 
is the sole sexual partner of the woman of childbearing potential and the absence 
of sperm has been confirmed. If not, an additional highly effective method of 
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
101 CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE:  
contraception s hould be used. Spermatogenesis cycle is approximately 90 days.  
Note: documentation of azoospermia for a male participant can come from the site 
personnel’s review of the participant’s medical records, medical examination, or 
medical history interview.  
Highly Effective Methodsb That Are User Dependent  Failure rate of <1% per year when used 
consistently and correctly.  
• Combined ( oestrogen - and progestogen -containing) hormonal contraception 
associated with inhibition of ovulationc  
• oral 
• intravaginal  
• transdermal  
• injectable  
• Progestogen -only hormone contraception associated with inhibition of ovulationc  
• oral 
• injectable  
• Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse  during the entire period of risk associated with the study intervention. 
The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study 
and the preferred and usual lifestyle of the participant.  
a. Contraceptive use by [CONTACT_31860].  
b. Failure rate of <1% per year when used consistently and correctly. Typi[INVESTIGATOR_31786].  
c. Male condoms must be used in addition to hormonal contraception. If locally required, in 
accordance with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable 
contraceptive methods are limited to those which inhibit ovulation as the primary mode of 
action.  
Note: Periodic abstinence (calendar, sympto -thermal, post -ovulation methods), withdrawal 
(coitus interruptus), spermicides only, and lactational amenorrhea method (LAM) are not 
acceptable methods of contrace ption. Male condom and female condom should not be used 
together (due to risk of failure from friction)  
Male participants:  As [COMPANY_004]3511294 is a mAb  that is not anticipated to interact directly 
with deoxyribonucleic acid (DNA) or other chromosomal material a nd minimal exposure 
through semen is expected, male participants will not be required to use contraception 
during the study.  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
102 10.5.  Appendix 5: Genetics  
USE/ANALYSIS OF DNA  
China only: No genetic samples will be collected from participants in China.  
• Genetic vari ation may impact a participant’s response to study intervention, 
susceptibility, severity and progression of disease. Variable response to study 
intervention may be due to genetic determinants that impact drug absorption, 
distribution, metabolism, and excr etion; mechanism of action of the drug; disease 
aetiology; and/or molecular subtype of the disease being treated. Therefore, where 
local regulations and IRB/IEC allow, a blood sample will be collected for DNA 
analysis  
• DNA samples will be used for research related to [COMPANY_004]3511294 or asthma with an 
eosinophilic phenotype and related diseases. They may also be used to develop 
tests/assays including diagnostic tests) related to [COMPANY_004]3511294 or study interventions 
of this drug class, and indication. Genetic research  may consist of the analysis of one 
or more candidate genes or the analysis of genetic markers throughout the genome or 
analysis of the entire genome (as appropriate).  
• Additional analyses of DNA samples may be conducted if it is hypothesi sed that this 
may help further understand the clinical data.  
• The samples may be analy sed as part of a multi -study assessment of genetic factors 
involved in the response to [COMPANY_004]3511294 or study interventions of this class. The 
results of genetic analyses may  be reported in the clinical study report or in a separate 
study summary.  
• The Sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality.  
• The samples will be retained while research on [COMPANY_004]3511294 (or study interventions 
of this class) or asthma with an eosinophilic phenotype continues but no longer than 
[ADDRESS_31152] visit or other period as per local requirements.  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
103 10.6.  Appendix 6: Liver Safety: Required Actions, Monitoring and Follow -
up Assessments  
Liver Chemistry Stoppi[INVESTIGATOR_31787].  
Liver Chemistry Stoppi[INVESTIGATOR_31788] -up Assessments  
Liver Chemistry Stoppi[INVESTIGATOR_31789]-absolute  ALT  8xULN  
ALT Increase  ALT  5xULN but <8xULN persists for 2 weeks  
ALT  3xULN but <5xULN persists for 4 weeks  
Bilirubin1, 2 ALT  3xULN and total bilirubin  2xULN (>35% direct bilirubin)  
INR2  ALT  3xULN and INR>1.5  
Cannot 
Monitor  ALT  5xULN but <8xULN and cannot be monitored weekly for 2 weeks  
ALT  3xULN but <5xULN and cannot be monitored weekly for 4 weeks  
Symptomatic3 ALT  3xULN associated with symptoms (new or worsening) believed to be 
related to liver injury or hypersensitivity  
Required Actions, Monitoring and Follow -up Assessments  
Actions  Follow -Up Assessments  
• Immediately  discontinue study intervention  
• Report the event to [COMPANY_004]  within 24 hours  
• Complete the liver event form and complete 
an SAE data collection tool if the event also 
meets the criteria for an SAE2 
• Perform follow -up assessments as 
described in the Follow -up Assessment 
column.  
• Monitor the participant unti l liver chemistries 
resolve, stabili se, or return to within 
baseline (see MONITORING  below)  
MONITORING:  
If ALT 3xULN AND total bilirubin 2xULN or 
INR >1.5:  • Viral hepatitis serology4 
• Obtain INR and recheck with each liver 
chemistry assessment until the 
aminotransferases values show 
downward trend  
• Obtain blood sample for pharmacokinetic 
(PK) analysis, within a week of meeting 
increased li ver monitoring criteria.5 
• Obtain a serum creatine phosphokinase 
(CPK), lactate dehydrogenase (LDH), 
gamma glutamyl transferase [GGT], 
glutamate dehydrogenase [GLDH], and 
serum albumin.  
• Fractionate bilirubin, if total 
bilirubin2xULN  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
104 Liver Chemistry Stoppi[INVESTIGATOR_2121]  
• Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, total bilirubin and 
INR) and pe rform liver event follow -up 
assessments within 24 hours  
• Monitor participant twice weekly until liver 
chemistries resolve, stabili se or return to 
within baseline  
• A specialist or hepatology consultation is 
recommended  
For all other stoppi[INVESTIGATOR_3418] (total bilirubin 
<2xULN and INR 1.5):  
• Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, total bilirubin and 
INR) and perform liver event follow -up 
assessments within 24-72 hours  
• Monitor participant weekly until liver 
chemistries resolve, stabili se or return to 
within baseline  
RESTART/RECHALLENGE  
• Do not restart/rechallenge  participant with 
study intervention since  it is not allowed 
per protocol; continue participant in the 
study for any protocol specified follow -up 
assessments.  • Obtain complete blood count with 
differential to assess eosinophilia. This 
blood sample will be sent to the central 
laboratory to maintain the blind while 
study is ongoing. Results will be provided 
only if unblinding of a participant’s 
treatment assignment is required. Also 
note that the mechanism of action of 
[COMPANY_004]3511294 leads to lowering of 
eosinophils.  
• Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on liver event form  
• Record use of concomitant medications 
on the concomitant medica tions report 
form including acetaminophen, herbal 
remedies, recreational drugs and other 
over the counter medications . 
• Record alcohol use on the liver event 
alcohol intake form  
If ALT 3xULN AND total bilirubin 2xULN 
or INR >1.5  obtain the following in ad dition to 
the assessments listed above : 
• Anti-nuclear antibody, anti -smooth 
muscle antibody, Type 1 anti -liver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG) or gamma 
globulins.  
• Serum acetaminophen adduct assay 
should be conduct ed (where available) to 
assess potential acetaminophen 
contribution to liver injury unless 
acetaminophen use is very unlikely in the 
preceding week (e.g., where the 
participant has been resident in the 
clinical unit throughout)  
• Liver imaging (ultrasound, magnetic 
resonance, or computerised tomography) 
to evaluate liver disease; complete Liver 
Imaging form  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
105 Liver Chemistry Stoppi[INVESTIGATOR_2121]  
• Liver biopsy may be considered and 
discussed with local specialist if 
available, for instance:  
o In patients when serology raises 
the possibility of autoimmune 
hepatitis (AIH)  
o In patients when suspected DILI 
progresses or fails to resolve on 
withdrawal of study intervention  
o In patients with acute or chronic 
atypi[INVESTIGATOR_31790]:  
• If liver biopsy conducted complete liver 
biopsy form  
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin 
fractionation is not immediately available, discontinue study intervention for that participant if 
ALT ≥3xULN and total bilirubin ≥ 2xULN. Additionally, if serum bilirubin fractionation testing is 
unavailable, record presence of detectable urinary bilirubin on dipstick , indicating direct 
bilirubin elevations and suggesting liver injury.  
2. All events of ALT  3xULN and bilirubin  2xULN (>35% direct bilirubin) or ALT   3xULN and 
INR>1.5 which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported to 
[COMPANY_004] as an SAE ; the INR threshold value stated will not apply to participants receiving 
anticoagulants  
3. New or worsening symptoms believed to be related to  liver injury (such as fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, or jaundice) or believed to be related to 
hypersensitivity (such as fever, rash or eosinophilia) . 
4. Includes:  hepatitis A Immunoglobulin M (IgM) antibody; HBsAg and HB cAb; hepatitis C RNA; 
cytomegalovirus IgM antibody; Epstein -Barr viral capsid antigen IgM antibody (or if 
unavailable, heterophile antibody or monospot testing); and hepatitis E IgM antibody. In those 
with underlying chronic hepatitis B at study entry (ide ntified by [CONTACT_23977] B surface 
antigen) quantitative hepatitis B DNA and hepatitis delta antibody.  If hepatitis delta antibody 
assay cannot be performed, it can be replaced with a polymerase chain reaction (PCR) of 
hepatitis D RNA virus (where ne eded) [ Le Gal , 2005].  
5. Record the date/time of the PK blood sample draw and the date/time of the last dose of study 
intervention prior to the PK blood sample dr aw on the CRF. If the date or time of the last dose 
is unclear, provide the participant’s best approximation. If the date/time of the last dose cannot 
be approximated OR a PK sample cannot be collected in the time period indicated above, do 
not obtain a PK  sample. Instructions for sample handling and shippi[INVESTIGATOR_31791].  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
106 Liver Chemistry Increased Monitoring Criteria with Continued Study Intervention  
Liver Chemistry Increased Monitoring Criteria and Actions with Continued Study 
Intervention  
Criteria  Actions  
ALT 5xULN and  <8xULN and total 
bilirubin <2xULN or INR≤1.5 without  
symptoms believed to be related to 
liver injury or hypersensitivity, and who 
can be monitored weekly for 2 weeks.  
OR 
ALT 3xULN and <5xULN and total 
bilirubin <2xULN or INR≤1.5 without  
symptoms believed to be related to 
liver injury or hypersensitivity, and who 
can be monitored weekly for 4 weeks.  
 • Notify the [COMPANY_004] Medical Monitor within 24 hours  
of learning of the abnormality to discuss 
participant safety.  
• Participant can continue study intervention.  
• Participant must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphatase, 
total bilirubin and INR) until they resolve, stabilise  
or return to within baseline.  
• If at any time participant meets the liver chemistry 
stoppi[INVESTIGATOR_3418], proceed as described above  
• If ALT decreases from ALT 5xULN and  <8xULN 
to ≥3xULN but <5xULN, (total bilirubin <2xULN 
and INR ≤1.5) continue to monitor li ver 
chemistries weekly.  
• If, after 4 weeks of monitoring, ALT <3xULN and 
total bilirubin <2xULN and INR ≤1.5, monitor 
participants twice monthly until liver chemistries 
resolve or return to within baseline.  
References  
Le Gal  F, Gordien E, Affolabi D, Hanslik T, Alloui C, Dény  P, et al. Quantification of 
Hepatitis Delta Virus RNA in Serum by [CONTACT_31861] -Time PCR Indicates Different 
Patterns of Virological Response to Interferon Therapy in Chronically Infected Patients.  
J Clin Microbiol. 2005;43(5):2363 –2369.  
  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
107 10.7.  Appendix 7: AEs, ADEs, SAEs, SADEs, [LOCATION_003]DEs and Device 
Deficiencies: Definition and Procedures for Recording, Evaluating, Follow -
up, and Reporting in Medical Device Studies  
• The definitions and procedures detailed in t his appendix are in accordance with 
ISO [ZIP_CODE] and European Medical Device Regulation (MDR) 2017/745 for 
clinical device research (if applicable).  
• Both the investigator and the Sponsor will comply with all local medical device 
reporting requirements for me dical devices.  
• The detection and documentation procedures described in this protocol apply to 
all [COMPANY_004] medical devices provided for use in the study (see Section 6.1.[ADDRESS_31153] of [COMPANY_004] medical devices).  
10.7.1.  Definition of Medical Device AE and ADE  
Medical Device AE and ADE Definition   
• An AE is any untoward medical occurrence, in a clinical study participant, users, 
or other persons, temporally associated  with the use of study intervention  whether 
or not considered related to the investigational medical device. An AE can 
therefore be any unfavo urable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) te mporally 
associated with the use of an investigational medical device. This definition 
includes events related to the investigational medical device or comparator and 
events related to the procedures involved.  
• An adverse device effect (ADE) is an AE relate d to the use of an investigational 
medical device. This definition includes any AE resulting from insufficient or 
inadequate instructions for use, deployment, implantation, installation, or 
operation, or any malfunction of the investigational medical devic e as well as any 
event resulting from use error or from intentional misuse of the investigational 
medical device.  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
108 10.7.2.  Definition of Medical Device SAE, SADE and [LOCATION_003]DE  
A Medical Device SAE is any serious adverse event that:  
a. Led to death  
b. Led to serious deterioration in the health of the participant, that either resulted in:  
• A life -threatening illness or injury. The term ‘life -threatening' in the definition 
of ‘serious' refers to an event in which the participant was at risk of death at 
the time of the ev ent. It does not refer to an event, which hypothetically might 
have caused death, if it were more severe.  
• A permanent impairment of a body structure or a body function.  
• Inpatient or prolonged hospi[INVESTIGATOR_11956]. Planned hospi[INVESTIGATOR_17450] a pre -
existing cond ition, or a procedure required by [CONTACT_760], without serious 
deterioration in health, is not considered an SAE.  
• Medical or surgical intervention to prevent life -threatening illness or injury or 
permanent impairment to a body structure or a body function . 
c. Led to f oetal distress, f oetal death or a congenital abnormality or birth defect  
d. Is a suspected transmission of any infectious agent via a medicinal product  
SADE definition  
• A SADE is defined as an adverse device effect that has resulted in any of the  
consequences characteristic of a serious adverse event.  
• Any device deficiency that might have led to an SAE if appropriate action had not 
been taken, intervention had not occurred, or circumstances had been less fortunate.  
Unanticipated SADE ([LOCATION_003]DE) definition  
• An [LOCATION_003]DE (also identified as UADE in US Regulations 21 CFR 813.3),  is a 
serious adverse device effect that by [CONTACT_5942], incidence, severity or outcome has 
not been identified in the current version of the risk analysis report (see Section 
2.3). 
10.7.3.  Definition of Device Deficiency  
Device Deficiency Definition  
• A device deficiency is an inadequacy of a medical device with respect to its 
identity, quality, durability, reliability, safety, or performance. Device deficiencies 
include malfunctions, use errors, and information supplied by [CONTACT_3455] . 
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
109 10.7.4.  Recording and Follow -Up of AE and/or SAE and Device 
Deficiencies  
AE, SAE and Device Deficiency Recording  
• When an AE/SAE/device deficiency occurs, it is the responsibility of the 
investigator to review all documentation (e.g., hospi[INVESTIGATOR_1088], laboratory 
reports, and diagnostics reports) related to the event.  
• The investigator will then record all relevant AE/SAE/device deficiency 
information in the participant’s medical records, in accordance with the 
investigator’s normal clinical practice, and on the app ropriate form.  
• It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_004] in lieu of completion of the AE/SAE/device deficiency 
form.  
• There may be instances when copi[INVESTIGATOR_31792]. In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copi[INVESTIGATOR_31785].  
• The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis 
(not the individual signs/symptoms) will be documented as the AE/SAE.  
• For device deficiencies, it is very important that the investigator describes any 
corrective  or remedial actions taken to prevent recurrence of the deficiency.  
o A remedial action is any action other than routine maintenance or servicing of 
a medical device where such action is necessary to prevent recurrence of a 
device deficiency. This includes a ny amendment to the device design to 
prevent recurrence.  
Assessment of Intensity  
• The investigator will make an assessment of intensity for each AE/SAE/device 
deficiency reported during the study and assign it to one of the following 
categories:  
• Mild: An  event that is easily tolerated by [CONTACT_2299], causing minimal 
discomfort and not interfering with everyday activities.  
• Moderate: An event that causes sufficient discomfort and interferes with normal 
everyday activities.  
• Severe: An event that prevents  normal everyday activities. An AE that is assessed 
as severe should not be confused with an SAE. Severe is a category used for rating 
the intensity of an event; both AEs and SAEs can be assessed as severe.  
• An event is defined as ‘serious’ when it meets at  least 1 of the predefined outcomes 
as described in the definition of an SAE, not when it is rated as severe.  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
110  
Assessment of Causality  
• The investigator is obligated to assess the relationship between study intervention 
and each occurrence of each AE/SAE/device deficiency  
• A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.  
• The investigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study intervention 
administration will be considered and investigated.  
• The inve stigator will also consult the IB in his/her assessment.  
• For each AE/SAE/device deficiency, the investigator must  document in the 
medical notes that he/she has reviewed the AE/SAE/device deficiency and has 
provided an assessment of causality.  
• There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to [COMPANY_004]. However, it is very 
important that the investigator always make an assessment of causality for every 
event before the initial tran smission of the SAE data to [COMPANY_004].  
• The investigator may change his/her opi[INVESTIGATOR_9242] -up 
information and send an SAE follow -up report with the updated causality 
assessment.  
• The causality assessment is one of the criteria used when de termining regulatory 
reporting requirements.  
 
Follow -up of AE/SAE/device deficiency  
• The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_31859]/or causality of the AE/SAE/device deficiency as fully as 
possible. This may include additional laboratory tests or investigations, 
histopathological examinations, or consultation with other health care 
professionals.  
• New or updated  information will be recorded in the originally completed CRF.  
• The investigator will submit any updated SAE data to [COMPANY_004] within 24 hours of 
receipt of the information.  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
111 10.7.5.  Reporting of SAEs  
SAE Reporting to [COMPANY_004] via an Electronic Data Collection Tool  
• The primary mechanism for reporting an SAE to [COMPANY_004] will be the electronic data 
collection tool.  
• If the electronic system is unavailable, then the site will use the paper SAE data 
collection tool (see next table) in order to report the event within 24 hours.  
• The site will enter the SAE data into the electronic system as soon as it becomes 
available.  
• After the study is completed at a given site, the electronic data collection tool will 
be taken offline to prevent the entry of new data or changes to existing data.  
• If a site receives a report of a new SAE from a study participant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to the Medical Monitor or the SAE coordinator by [CONTACT_756].  
• Contacts for SAE reporting can be found in the SRM.  
 
SAE Reporting to [COMPANY_004] via Paper Data Collection  Tool  
• Facsimile transmission of the SAE data collection tool is the preferred method to 
transmit this information to the Medical Monitor or the SAE coordinator.  
• In rare circumstances and in the absence of facsimile equipment, notification by 
[CONTACT_9337] a copy of the SAE paper data collection tool sent by 
[CONTACT_22855].  
• Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE paper data collection tool within the designated 
reporting time frames.  
• Contacts for SAE reporting can be found in  the S RM. 
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
112 10.7.6.  Reporting of SADEs  
SADE Reporting to [COMPANY_004]  
NOTE: There are additional reporting obligations for medical device deficiencies 
that are potentially related to SAEs that must fulfil  the legal responsibility to notify 
appropriate regulatory authorities and other entities about certain safety 
information relating to medical devices being used in clinical studies.  
• Any device deficiency that is associated with an SAE must be reported to  [COMPANY_004] 
within 24 hours after the investigator determines that the event meets the definition 
of a device deficiency.  
• [COMPANY_004] will review all device deficiencies and determine and document in writing 
whether they could have led to an SAE. These device deficiencie s will be reported 
to the regulatory authorities and IRBs/IECs as required by [CONTACT_2091].  
• Contacts for SAE reporting can be found at the beginning of this protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774] . 
  
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
113 10.8.  Appendix 8: Anaphylaxis Criteria  
Joint National Institute of Allergy and Infectious Disease (NIAID)/ Food Allergy and 
Anaphylaxis Network (FAAN) Second Symposium on Anaphylaxis [ Sampson , 2006].  
The criteria do not make a distinction based on underlying mechanism. These criteria are 
summarised as follows:  
1) Acute onset of an illness (minutes to several hours) with involvement of the skin, 
mucosal tissue, or both (e.g., ge neralised hives, pruritus or flushing, swollen lips -
tongue -uvula), and at least one of the following:  
a) Respi[INVESTIGATOR_7798] (e.g., dyspn oea, wheeze -bronchospasm, stridor, reduced 
PEF, hypoxemia)  
b) Reduced blood pressure (BP) or associated symptoms of end-organ dysfunction 
(e.g., hypotonia [collapse], syncope, incontinence)  
2) Two or more of the following that occur rapi[INVESTIGATOR_17176] a likely allergen for 
that patient (minutes to several hours):  
a) Involvement of the skin -mucosal tissue (e.g., general ised hives, itch -flush, 
swollen lips -tongue -uvula)  
b) Respi[INVESTIGATOR_7798] (e.g., dyspn oea, wheeze -bronchospasm, stridor, reduced 
PEF, hypoxemia)  
c) Reduced BP or associated symptoms (e.g., hypotonia [collapse], syncope, 
incontinence)  
d) Persistent gastrointestin al symptoms (e.g., crampy abdominal pain, vomiting)  
3) Reduced BP after exposure to known allergen for that patient (minutes to several 
hours):  
a) Adolescents (aged 12 -17): low systolic BP (age specific) or greater than 30% 
decrease in systolic BP  
b) Adults: systol ic BP of less than 90 mm Hg or greater than 30% decrease from that 
person’s baseline  
  
TMF-[ADDRESS_31154] been excluded.
CCI
TMF-14449557  CONF IDENTIAL   206713  
Protocol Amd 02  
115 10.10.  Appendix 10: Low, Medium and High Daily Doses of Inhaled 
Corticosteroids  
Daily medium and high dose ICS options for adults and adolescents (12 years and older) 
are shown in Figure 1.  
Figure 1 Low, medium and high daily doses of inhaled corticosteroids  
  
Reproduced with permission from Global Initiative for Asthma [ GINA , 2020]).  
• The medium to high dose for Japanese adolescent subjects 15 years or younger will be ≥200 µg/day of FP 
or other ICSs of equivalent dose) as per the Japanese asthma pediatric guidelines.  
• Updates as per GINA 202 1: 
• Beclometasone dipropi[INVESTIGATOR_16847] (pMDI, extrafine particle, HFA) changed to Beclometasone dipropi[INVESTIGATOR_16847] ( DPI [INVESTIGATOR_31793], extrafine particle, HFA)  
• Budesonide (DPI) changed to Budesonide (DPI, or pMDI, standard particle, HFA ) 
• Mometasone Furoate (DPI) Low, Medium and High total daily ICS doses reference to product information 
as it depends on DPI [INVESTIGATOR_16897] .

TMF-14449557  CONFIDENTIAL   206713  
Protocol Amd 02  
116 10.11.  Appendix 11: Recommended Measures  Related to COVID -19 
Pandemic  
Overall Rationale for this Appendix:  
COVID -[ADDRESS_31155] of clinical studies. Challenges may arise 
from quarantines, site closures, travel limitations, interruptions to the supply chain for the 
study intervention  or other considerations if site personnel or study participants become 
infected with COVID -19. These challenges may lead to difficulties in meeting protocol -
specified procedures, including administering or using the study intervention  or adhering 
to proto col-mandated visits and laboratory/diagnostic testing.  
This protocol appendix outlines measures that may be applicable for any site impacted by 
[CONTACT_25963] -[ADDRESS_31156] participants’ safety, welfare and rights, and promote data 
integrity.  
STUDY PROCEDURES DURING COVID -[ADDRESS_31157] o f any travel restrictions 
implemented by [CONTACT_5737]/regional health authorities and local institutions, and individual 
benefit /risk when making enrolment  and treatment decisions for trial participants.  
Every effort should be made to adhere to protocol -specifie d assessments for participants 
on study intervention, including follow -up however when not possible, for the duration of 
these special circumstances, the following measures may be implemented for enrolled 
participants . 
• Clinical investigators should documen t in site files and in participant 
notes/Electronic Heath Records as appropriate how restrictions related to 
COVID -[ADDRESS_31158] and duration of those changes and 
indicate which trial participants were impacted and how those trial participants 
were impacted (as per the current local COVID -19 related regulatory guidance).  
• Missing protocol required data/visits due to COVID -19 should be noted in 
participant notes and recorded as a COVID -19 protocol deviation.  
• Spi[INVESTIGATOR_31772]/suspected 
COVID -19. 
Protocol Defined Procedures/Visits:  
• Where applicable country and local regulations and infrastructure for home 
healthcare allow, home healthcare may take place at a location other than the 
clinical trial site to perform study assessments, which may include collection of 
blood and urine samples, measurement of vital signs and weight, and preparation 
and administration of study drug (at the discretion of the investigator). It is the 
TMF-14449557  CONFIDENTIAL   206713  
Protocol Amd 02  
117 responsibility of the investigator to inform [COMPANY_004] when this occurs and to 
document in source notes.  
• Remote visits may be performed at the participant’s home by [CONTACT_31862] a local medical facility, unless the investigator deems that a site 
visit is nec essary.  
• Additional unscheduled safety assessments such as routine blood sampling may 
be performed at the discretion of the investigator including in the participant’s 
home, if deemed necessary.  Biological samples may be collected at a different 
location, o ther than the study site (e.g., at participant’s home) by [CONTACT_31862] a local medical facility according to standard operating procedures 
and applicable regulations (see note). Biological samples should not be collected 
if they cannot b e processed in a timely manner or appropriately stored until the 
intended use.  
• If visits to a site/home are not feasible, then the medical evaluation of the 
participant’s asthma may take place by [CONTACT_31863], phone  calls, and a web portal and/or mobile application as a way of 
communicating with and monitoring the participant’s progress. [COMPANY_004] will be 
accountable for working with the vendor to ensure the site has the required 
equipment, training and support for this mo del and should be notified as soon as 
possible by [CONTACT_31864].  
• The study investigator is responsible for ensuring that the identification, 
management, and reporting of AEs and SAEs are completed in accordance with 
the prot ocol and applicable regulations. AEs are first reported by [CONTACT_31865]/study team or may be identified by [CONTACT_31866]. In addition, mobile 
nurses may identify AEs  as well and report them to the investigator for 
evaluation. Additionally, AEs may be identified from lab reports, imaging or ECG 
reports, and other records. As determined by [CONTACT_093], the appropriate 
medical intervention, therapeutic intervention,  and/or support measures are 
instituted, as necessary.  
• The participant should be informed of the plan and any potential risks associated 
with the virtual medium and sign a revised Informed Consent Form if required. 
IRB/Ethics committee should be informed and/or approve of this change in 
approach and the process documented in study files.  
• The revised schedule of study activities  is provided in Table 6.   
Note: If the investigator wishes to conduct a trial visit at a location that has not been 
previously assessed by [CONTACT_23983], it is the investigator’s responsibility to identify an adequate 
alternate location and to notify [COMPANY_004] of the alternate location. The investi gator should 
ensure that this alternate location meets ICH GCP requirements, is well -equipped to 
perform study procedures and covered by [CONTACT_31867]. Furthermore, the 
investigator should have sufficient oversight to ensure that the staff at the a lternate 
location are trained to perform study procedures. Refer to and follow most recent local 
guidance and regulations if available or refer to FDA or EMA guidance available at time . 
TMF-14449557  CONFIDENTIAL   206713  
Protocol Amd 02  
118 Study Intervention : 
• If despi[INVESTIGATOR_31794] (see Section 6 Study Intervention a nd Concomitant Therapy), 
a maximum dose interval of 28 weeks may be used.  
• In-clinic visits are required for administration of the s tudy intervention (Week 0 and 
Week 26).  
• In some cases, trial participants who no longer have access to study intervention  or 
the investigational site may need additional safety monitoring (e.g., on withdrawal of 
an active investigational treatment).  
Data Management/Monitoring:  
• The medical problems and healthcare utili sation worksheet may be transmitted from 
and to the invest igator by [CONTACT_31868]. If copi[INVESTIGATOR_014]/scans of 
the paper worksheet are sent to the investigator by [CONTACT_31869], the participant 
should be instructed to maintain the original documents and to return them to the site 
when a visit to the site will be allowed.  
• If the eDiary device was provided to the participant, it may be returned to the site by 
[CONTACT_31870] (Visit 17 Exit 
Visit) .  
• If on -site monitoring is no longer permitted , [COMPANY_004] will consider remote Source Data 
Verification/Source Document Review (SDV/SDR) where permitted by [CONTACT_31871]/institution. Remote SDV/SDR will be proposed to study sites to meet a patient 
and/or critical quality need, e.g., to assess participan t safety or to ensure data 
integrity. In case of remote SDV/SDR, [COMPANY_004] will work with the site to ensure 
participant  privacy.  
• eCRF/CRF Final or Interim Sign off Process: The Principal Investigator (PI) is 
responsible for ensuring that the data within the eC RF casebook and any other data 
sources utili sed during the study for each study participant is complete and consistent 
with source documents throughout the study (ICH GCP 4.9.1 4.9.2). The PI [INVESTIGATOR_31795]/re -sign the eCRF from any computer/location by [CONTACT_31872] g InForm (or other 
eDC platform) using his/her unique eCRF log -in credentials. The PI [INVESTIGATOR_31796] -investigator and this must 
be documented on the Delegation of Responsibilities (DoR) Log. It is recommended 
that the PI [INVESTIGATOR_31797] a sub -investigator as a back -up for eCRF signatures. The sub -
investigator must be appropriately trained on the protocol and eCRF requirements 
(with training documented), and the DoR log updated accordingly.  
• Essential Docu ment Sign Off Process: If an investigator is unable to print and sign 
essential documents such as Protocol /Amendment signature [CONTACT_31880] [CONTACT_31873] . 
TMF-14449557  CONFIDENTIAL   206713  
Protocol Amd 02  
119 Assessments that can be Conducted Outside Clinical Study Site : 
Activities/assessments that may be conducted outside of a clinical study site are indicated 
in Table 6. 
• White boxes represent activities/assessments that are to be done during visits to the 
clinical study centre (pre-screening Visit 0, screening Visit 1, randomisation Visit 2, 
Visit 3, Visit 10, Visit 11  Exit Visit 17, and WS Visit if applicable).  
• Grey boxes represent activities/assessments during study visits ( Visits 4-9, Visits 
12-16, and the FU Visit) that may be conducted by a home healthcare professional, 
where applicable country and local regulations and infrastructure allow (at t he 
discretion of the investigator, based on safety and tolerability).  
• The FU Visit may be conducted as a remote/home visit or as a phone call.  
• During home visits, the scheduled collection of samples for laboratory and other 
assessments may be performed by  a home healthcare professional.  
 
TMF-14449557  CONFIDENTIAL   206713  
Protocol Amd 02  
120 Table 6 Schedule of Activities (SoA)  Indicating Assessments that may be Conducted Outside of a Clinical Study 
Site 
Protocol Activity  Pre-
Screenin
g Screenin
g/Run -in Intervention Period and Exit Visit (visit window is 7 days)  Follow -
up 
/Withdra
w  
(7 days)  Notes  
Visit  V0 a Visit 1 a V2b 
R* V3 V4 V5 V6 V7 V8 V9 V1
0 V1
1 V1
2 V1
3 V1
4 V1
5 V1
6 Exit 
V17 WSc  FU R* =Randomisation  
WS=Withdraw from study visit  
(see footnote c)  
FU=Follow -up visit/call (only required for 
participants not entering OLE study)  Study Week  -8 to -6 -6 to -1 0 2 4 8 12 16 20 24 26 28 32 36 40 44 48 52 26 
or 
52 56 
Study Day  -56 to -
42 -42 to -7 1 14 28 56 84 112 140 168 182 196 224 252 280 308 336 364  392 
General Eligibility Assessments  
Informed consent 
a X (X)                   Conduct at Visit 1 if not completed at Visit 
0; See footnote a.  
Genetic sample 
informed consent 
d X (X)                   Conduct at Visit 1 if not completed at Visit 
0; See footnote d.  
Demography data 
collection s  X (X)                   Conduct at Visit 1 if not completed at Visit 
0; All females must be assessed at Visit  1 
to determine childbearing potential.  
Inclusion/Exclusio
n criteria  X X                    
Historical blood 
eosinophil count   X                   See footnote e.  
Medical history   X                   Include cardiovascular (CV), CV risk 
factors, asthma, exacerbations, 
vasculitis, allergies and anaphylaxis.  
Smoking status   X                    
TMF-14449557  CONFIDENTIAL   206713  
Protocol Amd 02  
121 Protocol Activity  Pre-
Screenin
g Screenin
g/Run -in Intervention Period and Exit Visit (visit window is 7 days)  Follow -
up 
/Withdra
w  
(7 days)  Notes  
Visit  V0 a Visit 1 a V2b 
R* V3 V4 V5 V6 V7 V8 V9 V1
0 V1
1 V1
2 V1
3 V1
4 V1
5 V1
6 Exit 
V17 WSc  FU R* =Randomisation  
WS=Withdraw from study visit  
(see footnote c)  
FU=Follow -up visit/call (only required for 
participants not entering OLE study)  Study Week  -[ADDRESS_31159].  For details 
refer to study reference manual (SRM).  
eDiary registration 
and training   X                   Conduct thorough eDiary training at 
Screening Visit 1 and throughout the 
study on as -needed basis.   
Randomisation 
criteria    X                  Assess prior to randomisation; see 
footnote e.  
Efficacy Assessments  
Review for 
exacerbations   X X X X X X X X X X X X X X X X X X X Collection of exacerbations at Visit 1 is 
historical data.  
Spi[INVESTIGATOR_038] (pre - 
and post -
bronchodilator 
FEV 1)h  X X        X       X X  FEV 1=Forced expi[INVESTIGATOR_3741] 1 
second ; Spi[INVESTIGATOR_31741]/suspected COVID -19 (see 
Section 8.2.3 ). 
ACQ -5   X X X X X X X X X X X X X X X X X  ACQ -5=Asthma Control Questionnaire -5 
TMF-14449557  CONFIDENTIAL   206713  
Protocol Amd 02  
122 Protocol Activity  Pre-
Screenin
g Screenin
g/Run -in Intervention Period and Exit Visit (visit window is 7 days)  Follow -
up 
/Withdra
w  
(7 days)  Notes  
Visit  V0 a Visit 1 a V2b 
R* V3 V4 V5 V6 V7 V8 V9 V1
0 V1
1 V1
2 V1
3 V1
4 V1
5 V1
6 Exit 
V17 WSc  FU R* =Randomisation  
WS=Withdraw from study visit  
(see footnote c)  
FU=Follow -up visit/call (only required for 
participants not entering OLE study)  Study Week  -8 to -6 -6 to -1 0 2 4 8 12 16 20 24 26 28 32 36 40 44 48 52 26 
or 
52 56 
Study Day  -56 to -
42 -42 to -7 1 14 28 56 84 112 140 168 182 196 224 252 280 308 336 364  392 
HRQoL: PRO and Health Outcomes Assessments  
SGRQ    X  X  X    X    X   X X  SGRQ=St. George’s Respi[INVESTIGATOR_31742]/ANSD   =========   daily   
========= → X X X X X X X X X X   ADSD/ANSD=Asthma Daily/Nightly 
Symptom Diary; To be c omplete d daily 
during Run -in phase through Week 16, 
then to be complete d for 1 full week 
during the week preceding each visit 
thereafter.  
CCI
CCI
CCI
CCI
TMF-14449557  CONFIDENTIAL   206713  
Protocol Amd 02  
123 Protocol Activity  Pre-
Screenin
g Screenin
g/Run -in Intervention Period and Exit Visit (visit window is 7 days)  Follow -
up 
/Withdra
w  
(7 days)  Notes  
Visit  V0 a Visit 1 a V2b 
R* V3 V4 V5 V6 V7 V8 V9 V1
0 V1
1 V1
2 V1
3 V1
4 V1
5 V1
6 Exit 
V17 WSc  FU R* =Randomisation  
WS=Withdraw from study visit  
(see footnote c)  
FU=Follow -up visit/call (only required for 
participants not entering OLE study)  Study Week  -8 to -6 -6 to -1 0 2 4 8 12 16 20 24 26 28 32 36 40 44 48 52 26 
or 
52 56 
Study Day  -56 to -
42 -42 to -7 1 14 28 56 84 112 140 168 182 196 224 252 280 308 336 364  392 
Safety Assessments  
Concomitant 
Medication 
Assessment  X X X X X X X X X X X X X X X X X X X  Ensure maintenance asthma medications 
from the year prior to Screening Visit 1, 
all medications within the 3 months prior 
to Screening Visit 1 and all current 
medications are reviewed.  
Physical 
Examination   X                X X  Include height and weight for the 
complete physical exam at Screening 
Visit 1. Height can be omitted for 
subsequent visits.  
Vital Signs   X X   X   X  X X   X  X X X   
CCI
CCI
TMF-14449557  CONFIDENTIAL   206713  
Protocol Amd 02  
124 Protocol Activity  Pre-
Screenin
g Screenin
g/Run -in Intervention Period and Exit Visit (visit window is 7 days)  Follow -
up 
/Withdra
w  
(7 days)  Notes  
Visit  V0 a Visit 1 a V2b 
R* V3 V4 V5 V6 V7 V8 V9 V1
0 V1
1 V1
2 V1
3 V1
4 V1
5 V1
6 Exit 
V17 WSc  FU R* =Randomisation  
WS=Withdraw from study visit  
(see footnote c)  
FU=Follow -up visit/call (only required for 
participants not entering OLE study)  Study Week  -[ADDRESS_31160] be performed and assessed 
pre-dose . Twelve -lead ECG central over -
read values should be used at all visits 
with the exception of Visit 2 and Visit 10 
where 12 -lead ECG machine read values 
should be used.  
AE/SAE 
Assessment  X g X g X X X X X X X X X X X X X X X X X X AE=Adverse events; SAE=Serious 
adverse events; see footnote g.  
Laboratory Assessments  
Total IgE    X                   
Pregnancy Test 
(WOCBP only)   X X  X X X X X X X  X X X X X X X X Serum pregnancy test should be done at 
screening Visit 1 and Exit Visit / Withdraw 
from study visit ; urine pregnancy tests 
should be done for all other 
assessments; WOCBP=Women of 
childbearing potential; See Section 8.3.5  
for additional information . 
CCI
CCI
TMF-14449557  CONFIDENTIAL   206713  
Protocol Amd 02  
125 Protocol Activity  Pre-
Screenin
g Screenin
g/Run -in Intervention Period and Exit Visit (visit window is 7 days)  Follow -
up 
/Withdra
w  
(7 days)  Notes  
Visit  V0 a Visit 1 a V2b 
R* V3 V4 V5 V6 V7 V8 V9 V1
0 V1
1 V1
2 V1
3 V1
4 V1
5 V1
6 Exit 
V17 WSc  FU R* =Randomisation  
WS=Withdraw from study visit  
(see footnote c)  
FU=Follow -up visit/call (only required for 
participants not entering OLE study)  Study Week  -8 to -6 -6 to -1 0 2 4 8 12 16 20 24 26 28 32 36 40 44 48 52 26 
or 
52 56 
Study Day  -56 to -
42 -42 to -7 1 14 28 56 84 112 140 168 182 196 224 252 280 308 336 364  392 
CCI
TMF-14449557  CONFIDENTIAL   206713  
Protocol Amd 02  
126 Protocol Activity  Pre-
Screenin
g Screenin
g/Run -in Intervention Period and Exit Visit (visit window is 7 days)  Follow -
up 
/Withdra
w  
(7 days)  Notes  
Visit  V0 a Visit 1 a V2b 
R* V3 V4 V5 V6 V7 V8 V9 V1
0 V1
1 V1
2 V1
3 V1
4 V1
5 V1
6 Exit 
V17 WSc  FU R* =Randomisation  
WS=Withdraw from study visit  
(see footnote c)  
FU=Follow -up visit/call (only required for 
participants not entering OLE study)  Study Week  -8 to -6 -6 to -1 0 2 4 8 12 16 20 24 26 28 32 36 40 44 48 52 26 
or 
52 56 
Study Day  -56 to -
42 -42 to -7 1 14 28 56 84 112 140 168 182 196 224 252 280 308 336 364  392 
Genetics sample    =============  The genetics sample ca n be 
collected at Visit 2 or any visit 
after ============= →   See footnote d.  
Study intervention  
Administer study 
intervention    X        X          Study intervention will only be 
administered in the clinic. Any scheduled 
assessments or sample draws should be 
performed beforehand.  Monitor 
participant for at least 2h after 
administration (see Section 6.5). 
eCRF/worksheets/other  
Dispense Rescue 
medication   X X X X X X X X X X X X X X X X     
CCI
CCI
TMF-14449557  CONFIDENTIAL   206713  
Protocol Amd 02  
127 Protocol Activity  Pre-
Screenin
g Screenin
g/Run -in Intervention Period and Exit Visit (visit window is 7 days)  Follow -
up 
/Withdra
w  
(7 days)  Notes  
Visit  V0 a Visit 1 a V2b 
R* V3 V4 V5 V6 V7 V8 V9 V1
0 V1
1 V1
2 V1
3 V1
4 V1
5 V1
6 Exit 
V17 WSc  FU R* =Randomisation  
WS=Withdraw from study visit  
(see footnote c)  
FU=Follow -up visit/call (only required for 
participants not entering OLE study)  Study Week  -8 to -6 -6 to -1 0 2 4 8 12 16 20 24 26 28 32 36 40 44 48 52 26 
or 
52 56 
Study Day  -56 to -
42 -42 to -7 1 14 28 56 84 112 140 168 182 196 224 252 280 308 336 364  392 
Provide 
worksheet   X X X X X X X X X X X X X X X X    The worksheet is a medical problems and 
healthcare utili sation worksheet.  Review worksheet    X X X X X X X X X X X X X X X X X  
eDiary close out                   X X   
Complete eCRF  X X X X X X X X X X X X X X X X X X X  eCRF=electronic Case Report Form  
a. Informed Consent must be obtained prior to initiating any study assessments. Pre -screening Visit [ADDRESS_31161] be available for review of randomisation criteria.  
c. If a participant withdraws from t he study, then the Withdraw from Study (WS) Visit should be conducted [ADDRESS_31162] administered dose of study inte rvention, i.e., at 
Week 26 if the second dose of study intervention was not received, or at Week 52 if the second dose of study int ervention was received. A follow -up visit/call should also be 
conducted [ADDRESS_31163] dose of study intervention for AE/SAE assessments and pregnancy testing.  
d. Informed Consent for optional genetics research must be obtained before collecting a s ample. China only:   Genetic Informed Consent will not be collected from participants in 
China.  Genetic blood samples will not be collected from participants in China.  
e. To be randomised, participants without a historical blood eosinophil count of ≥300 cells/µL in the [ADDRESS_31164] a blood eosinophil count of ≥150 
cells/µL at Screening Visit 1. If the Screening Visit test result does not meet the blood eosinophil count eligibility criter ia, the laboratory  assessment may  be repeated, at the 
discretion of the investigator, if it is judged to be likely in the eligible range for study inclusion within the run -in period prior to Visit 2.  
f.  
 
. 
CCI
CCI
TMF-[ADDRESS_31165] i s allowed during the run -in period.  
 
TMF-14449557  CONFIDENTIAL   Protocol Amd 02  
206713  
 129 10.12.  Appendix 12: Country -specific requirements  
  
CCI
TMF-14449557  CONFIDENTIAL   Protocol Amd 02  
206713  
 130 10.13.  Appendix 1 3: Abbreviations and Trad emarks  
Abbreviations  
ACQ  Asthma Control Questionnaire  
ADA  Anti-drug antibody  
AE Adverse event  
ALT  Alanine transaminase  
ANA  Antinuclear antibodies  
ANCA  Anti-neutrophil cytoplasmic antibody  
ADE  Adverse device events  
ADSD  Asthma Daily Symptom Diary  
ANSD  Asthma Nightly Symptom Diary  
Anti-HBc Hepatitis B core antibody  
Anti-IL-[ADDRESS_31166]  
HIV Human immunodeficiency virus  
HRQoL  Health -related quality of life  
HRT  Hormone replacement therapy  
IB Investigator’s Brochure  
ICF Informed consent form  
ICH International Council on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for 
Human Use  
ICS Inhaled corticosteroid  
IDMC  Independent data monitoring committee  
IEC Independent Ethics Committee  
IFU Instruction for use  
Ig Immunoglobulin  
IL-[ADDRESS_31167]  
IRT Interactive response technology  
IUD Intrauterine device  
IUS Intrauterine hormone -releasing system  
IV Intravenous  
kg kilogram  
L Litre  
LA Long -acting  
LABA  Long -acting -agonist  
LAM  Lactational amenorrhea method  
LAMA  Long -acting muscarinic antagonist  
LDH  Lactate dehydrogenase  
LTRA  Leukotriene receptor antagonist  
mAb  Monoclonal antibody  
MAR  Missing at random  
CCI
TMF-14449557  CONFIDENTIAL   Protocol Amd 02  
206713  
 132 mcg (g) Microgram  
MDI  Metered dose inhaler  
MedDRA  Medical Dictionary  for Regulatory Activities  
mg Milligrams  
mL Millilitres  
mm Hg Millimetre of mercury  
mol Mole  
MPO  myeloperoxidase  
MSDS  Material Safety Data Sheet  
msec  Milliseconds  
NAb  Neutralising antibody  
NHANES  National Health and Nutrition Examination Survey  
NHLBI  National Heart, Lung, and Blood Institute  
NIAID  National Institute of Allergy and Infectious Disease  
NIH National Institutes of Health  
NIMP  Non-investigational medicinal product  
OCS  Oral corticosteroid  
OLE  Open -label extension  
PC20 Provocative concentration causing a 20% fall in FEV 1 
PCR  Polymerase chain reaction  
PD Pharmacodynamics  
PD 20 Provocative dose that decreases FEV 1 by 20%  
PEF Peak expi[INVESTIGATOR_31798]-filled safety syringe  
PRO  Patient -reported outcomes  
QTcF  QTc corrected by [CONTACT_6550]’s formula  
QTL  Quality tolerance limits  
R&D  Research and Development  
RNA  Ribonucleic acid  
RBC  Red blood cell  
SABA  Short -acting -agonist  
SADE  Serious adverse device event  
SAE  Serious Adverse Event  
SAP Statistical analysis plan  
SC Subcutaneous  
SDAC  Statistical data analysis centre  
SGRQ  St. George’s Respi[INVESTIGATOR_31799]-[ADDRESS_31168]  Upper Limit of Normal  
WBC  White blood cell  
WOCBP  Women of childbearing potential  
WONCBP  Women of non -childbearing  potential  
w/v Weight/volume  
μL Microlitre  
Trademark Information  
Trademarks of the GlaxoSmithKline 
group of companies   Trademarks not owned by [CONTACT_31874][INVESTIGATOR_31800]-14449557  CONFIDENTIAL   Protocol Amd 02  
206713  
 134 10.14.  Appendix 14: Protocol Amendment History  
The Protocol Amendment Summary of Changes Table for the current amendment is 
located directly before the Table of Contents.  
10.14.1.  Amendment 1: 17 -Aug-2021  
This amendment is considered to be substantial based on the criteria set forth in Article 
10(a) of Directive 2001/20/EC of the European Parliament and the Council of the 
European Union.  
Overall Rationale for the Amendment:  Amendment 01 is a global amendmen t to 
include modifications based on regulatory suggestion and additional changes were 
incorporated which align with program revisions and/or updates as listed in table below.   
Section # and Name  [CONTACT_31881], Section 
1.1 Synopsis and  
Section 2.1 Study 
Rationale  Addition of name “depemokimab”  To update the protocol with the 
recently approved generic name 
[CONTACT_31882]3511294  
Section 1.3 Schedule 
of Activities and  
Table 6 of Appendix 
11 Term “Demography and 
childbearing status” modified to 
“Demography data collection”  
 
Added text “Collection of 
exacerbations at Visit 1 is historical 
data”  
 
 
 
 
 
 
 
 
 Minor modification for more 
clarity  
Text “ -56 to -7” modified to “ -56 to -
42”, “Week -8 to –1” modified to 
“Week -8 to -6” Clarification  
Inclusion of an ECG at week [ADDRESS_31169] of 
health authority  
Only screening, randomization, 
dispensing and withdrawal visits 
need interactive response 
technology (IRT), hence corrections Visits which require IRT 
registration were clarified  
CCI
TMF-14449557  CONFIDENTIAL   Protocol Amd 02  
206713  
 135 Section # and Name  [CONTACT_31883]  [ADDRESS_31170] to the 
planned open label extension 
study  
Section 1.1 
Synopsis, Section 
4.1 Overall design 
and 
Appendix 11  Added Visits 3 and 11 as in -person 
clinic visits.  Due to the inclusion of an ECG 
at week 2 and week 28 these 
visits can not be conducted 
remotely or virtually.  
Section 4.1.1 Study 
Phases, Duration 
and Treatment Arms 
(Table 1)  Term “Clinic” modified to “Study”  Clarification  
Section 5.1 Inclusion 
Criteria  Added text in inclusion criteria 
related to pregnancy  Clarification  
Section 5.2 
Exclusion Criteria  Exclusion of participants with 
allergy/intolerance to the excipi[INVESTIGATOR_31801]3511294 in Section 6.[ADDRESS_31171] 
reversibility/hyperresponsiveness  
Section 5.3.2 
Randomization 
Exclusion Criteria  Revised QTc criteria  Revised wording for clarification  
Section 6.9.1 
Permitted 
Medications and 
Non-Drug Therapi[INVESTIGATOR_31802]-19 Vaccine  Clarification considering the 
COVID -19 pandemic situation  
Section 6.9.2 
Prohibited 
Medications and 
Non-Drug Therapi[INVESTIGATOR_31803] “ troleandomycin” from 
prohibited medication  As per the program level 
updated troleandomycin is no 
longer a prohibi ted medication  
Section 6.9.3. 
Rescue Medicine  Low dose ICS/LABA is not permitted 
as rescue medication. Rescue 
medication usage will be recorded in 
the eDiary.  Revised wording for providing 
more clarity  
Section 8.1.1 Pre -
screening Visit (Visit 
0) Only screening (Visit 1), 
randomization (Visit 2), dispensing 
(Visit 10) and withdrawal visits need 
IRT, hence corrections made 
accordingly  Visits which require IRT 
registration were clarified  
Section 8.2.2 Asthma Text deleted “Additional details  on Text removed to align with the 
CCI
CCI
TMF-14449557  CONFIDENTIAL   Protocol Amd 02  
206713  
 136 Section # and Name  [CONTACT_31884]”.  Statistical Analysis Plan  
[IP_ADDRESS].  Reversibility 
using the Maximum 
Post-Bronchodilator 
Method  Current “The procedures involv ed in 
the Maximum Post -Bronchodilator 
Method are those generated by [CONTACT_31875]  “ 
Previously “The procedures involved 
in the Maximum Post -Bronchodilator 
Method are those generated by [CONTACT_31876] ”  
 
Current “Details of reversibility 
procedure mentioned in SRM ” 
Previously “Details of reversibility 
procedure mentioned in in third 
party vendor manual ” Clarification  
Section 8.2.4. St. 
George’s Respi[INVESTIGATOR_6004] 
(SGRQ)  The SGRQ will contain 50  items 
instead of previous 51.  Clarification  
Section 8.2.10. 
Asthma Daily 
Symptom 
Diary/Asthma Nightly 
Symptom Diary 
(ADSD/ANSD)   
 
 Clarification  
Section 8.2.10. 
Asthma Daily 
Symptom 
Diary/Asthma Nightly 
Symptom Diary 
(ADSD/ANSD)  Updated the information regarding 
use of ADSD and ANSD  Correction of the timeframe for 
completing  
Section 8.3.2 Vital 
Signs  Text “Oral or skin Temperature” 
modified to “Temperature”  Clarification  
CCI
CCI
CCI
TMF-14449557  CONFIDENTIAL   Protocol Amd 02  
206713  
 137 Section # and Name  [CONTACT_9353] 8.[ADDRESS_31172] not been 
summarized  
CCI
CCI
CCI
TMF-14449557  CONFIDENTIAL   Protocol Amd 02  
206713  
 138 11. REFERENCES  
Bagnasco  D, Caminati M, Menzella F, Milanese M, Rolla G, Lombardi C, et al. One year 
of mepolizumab: Efficacy and safety in real -life in Italy. Pulm Pharmacol Ther. 
2019;58:101836.  
Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral 
glucocorticoid sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 
2014;371(13):1189 –97. 
Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy 
and safety of benralizumab for patients with severe asthma uncont rolled with high -
dosage inhaled corticosteroids and long -acting β2 -agonists (SIROCCO): a randomised, 
multicentre, placebo -controlled phase 3 trial. Lancet. 2016;388([ZIP_CODE]):2115 -27. 
Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, et al. Long -
term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1 -
year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7(1):[ADDRESS_31173] F, Boulet LP, Xie F, Young J, et al. Re slizumab for 
poorly controlled, eosinophilic asthma: a randomized, placebo -controlled study. Am J 
Respir Crit Care Med. 2011;184(10):1125 -32.  
Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. 
Reslizumab for inadequately contro lled asthma with elevated blood eosinophil counts: 
results from two multicentre, parallel, double -blind, randomised, placebo -controlled, 
phase 3 trials. Lancet Respir Med. 2015;3(5):355 -66. 
Cella D, Lai JS, Jensen SE, Christodoulou C, Junghaenel DU, Reeve BB, et al. PROMIS 
fatigue item bank had clinical validity across diverse chronic conditions. J Clin 
Epi[INVESTIGATOR_5541]. 2016;73:128 -34. 
Christodoulou C, Junghaenel DU, DeWalt DA, Rothrock N, Stone AA. Cognitive 
interviewing in the evaluation of fatigue items: resul ts from the patient -reported 
outcomes measurement information system (PROMIS). Qual Life Res. 
2008;17(10):1239 -46. 
Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International 
ERS/ATS guidelines on definition, evaluation and treatment o f severe asthma. Eur 
Respir  J. 2014;43(2):[ADDRESS_31174] ES, Albers FC, Bratton DJ, Wang -Jairaj J, Nelsen LM, et al. 
Efficacy of mepolizumab add -on therapy on health -related quality of life and markers of 
asthma control in severe eosinophilic a sthma (MUSCA): a randomised, double -blind, 
placebo -controlled, parallel -group, multicentre, phase 3b trial. Lancet. 2017;5(5):390 -
400. 
TMF-14449557  CONFIDENTIAL   Protocol Amd 02  
206713  
 139 FDA Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation 
and Proarrhythmic Potential for Non -Antiarrhythmic Drugs. 
https://www.fda.gov/media/[ZIP_CODE]/download. October 2005  
FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. 
Benralizumab, an anti -interleukin -5 receptor α monoclonal antibody, as add -on treatment 
for patients with se vere, uncontrolled, eosinophilic asthma (CALIMA): a randomised, 
double -blind, placebo -controlled phase 3 trial. Lancet. 2016;388([ZIP_CODE]):2128 -41. 
Gater A, Nelsen L, Fleming S, Lundy JJ, Bonner N, Hall R et al. Assessing asthma 
symptoms in adolescents and ad ults: qualitative research supporting development of the 
Asthma Daily Symptom Diary. Value Health 2016;19(4):440 -50. 
GlaxoSmithKline Document Number 2016N295843_03 (report date 10 -AUG -2020) or 
later; [COMPANY_004]3511294 Investigator’s Brochure (IB).  
GlaxoSmithKline  Document Number 2019N411063_00 A randomised double -blind 
(sponsor open), placebo controlled, single ascending dose, First Time in Human study in 
participants with mild to moderate asthma to assess safety, tolerability, immunogenicity, 
pharmacokinetics and  pharmacodynamics of [COMPANY_004]3511294 administered subcutaneously. 
Report date [ADDRESS_31175] on QTcF in study 205722 . Report Date 13 -JAN-2021.  
Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma 
(GINA) 2020. Available from: http://www.ginasthma.org/.  
Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. 
Mepolizumab and exacerbations of refractory eosinophilic asthma. N Eng l J Med. 
2009;360(10):973 -84. 
Harrison T, Canonica GW, Chupp G, Lee J, Schleich F, Welte T, et al. Real -world 
mepolizumab in the prospective severe asthma REALITI -A study – initial analysis. Eur 
Respir J. 2020; in press (https://doi.org/10.1183/13993003.00 151-2020).  
Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the [ADDRESS_31176]. Clin Otolaryngol. 2009;34(5):[ADDRESS_31177] George's Respi[INVESTIGATOR_6015]. Am Rev Respir 
Dis. 1992;145(6):1321 -7. 
TMF-14449557  CONFIDENTIAL   Protocol Amd 02  
206713  
 140 Juniper EF, Svensson K, Mőrk AC, Ståhl E. Measurement properties and interpretation of 
three shortened versions of the asthma control questionnaire. Resp Med. 
2005 ;99(5):553 -8. 
Khatri, S; Moore, W, Gibson, PG, Leigh R, Bourdin A, Maspero J, et al. Assessment of 
the long -term safety of mepolizumab and durability of clinical response in patients with 
severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143(5):[ADDRESS_31178] severe eosinophilic 
asthma: the COSMEX Study. Clin Ther.  2019;41(10):2041 -2056.e5.  
Lugogo N, Doming o C, Chanez P, Leigh R, Gilson MJ, Price RG, et al. Long -term 
efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi -
center, open -label, Phase IIIb study. Clin Ther. 2016;38(9):2058 -2070.e1.  
Marshall S, Madabushi R, Manolis  E, Krudys K, Staab A, Dykstra K, et al. Model -
informed drug discovery and development: current industry good practice and regulatory 
expectations and future perspectives. CPT Pharmacometrics Syst Pharmacol. 
2019;8(2):87 -96. 
Miller MR, Crapo R, Hankinson J , Brusasco V, Burgos F, Casaburi R, et al. General 
considerations for lung function testing. Eur Respir J. 2005;26(1):[ADDRESS_31179]. 2017;5(6):1572 -81.e3.  
National Institutes of Health. National Heart, Lung, and Blood Institute (NHLBI). 
Guidelines for the Diagnosis and Management of Asthma (EPR -3). Aug 2007. Available 
at https://www.nhlbi.nih.gov/health -topi[INVESTIGATOR_1102]/guidelines -for-diagnosis -management -of-
asthma  
Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al.  
Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med . 
2014;371:119 8-207.  
PASS 2020 Sample Size Software, NCSS.com. Tests for the Ratio of Two Negative 
Binomial Rates. Ch 438:1 -17. Available at https://www.ncss.com/wp -
content/themes/ncss/pdf/Procedures/PASS/Tests_for_the_Ratio_of_Two_Negative_Bino
mial_Rates.pdf  
Pavord ID , Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for 
severe eosinophilic asthma (DREAM): a multicentre, double -blind, placebo -controlled 
trial. Lancet . 2012;380:651 -9. 
Pertzov B, Unterman A, Shtraichman O, Shitenberg D, Rosengarten D,  Kramer MR. 
Efficacy and safety of mepolizumab in a real -world cohort of patients with severe 
eosinophilic asthma. J Asthma 2019. DOI:10.1080/02770903.2019.1658208.  
TMF-[ADDRESS_31180] at puberty. J Reprod Immunol. 1995;28(2):85 -109.  
Pollanen P, Setchell BP. Microvascular permeability to IgG in the rat testis at puberty. Int 
J Androl. 1989;12(3):206 -18. 
Roger JH, Bratton DJ, Mayer B, Abellan JJ, Keene ON. Treatmen t policy estimands for 
recurrent event data using data collected after cessation of randomised treatment. 
Pharmaceutical statistics. 2019;18(1):85 -95. 
Sampson HA, Munoz -Furlong A, Campbell RL, Adkinson Jr NF, Bock SA, Branum A, 
et al. Second symposium on t he definition and management of anaphylaxis: summary 
report —Second National Institute of Allergy and Infectious Disease/Food Allergy and 
Anaphylaxis Network symposium. J Allergy Clin Immunol 2006;117(2):391 -7. 
Schleich F, Graff S, Nekoee H, Moermans C, Hen ket M, Sanchez C, et al. Real -world 
experience with mepolizumab: Does it deliver what it has promised? Clin Exp Allergy. 
2020;50(6):687 -95. 
Setchell BP, Waites GMB. The blood -testis barrier. In: Hamilton DW, Greep RO, editor. 
The Handbook of Physiology, Se ction 7, Vol. V. Male Reproductive System. 
Washington, DC:American Physiological Society, 1975:143 -72.  
Setchell BP. Physiologie de la barrière sang -testicule. Andrologie. 2001;11:15 -20. 
Sohn W, Lee E, Kankam MK, Egbuna O, Moffat G, Bussiere J, et al. An o pen-label 
study in healthy men to evaluate the risk of seminal fluid transmission of denosumab to 
pregnant partners. British Journal of Clinical Pharmacology. 2016;81(2):362 -9. 
Tepper RS, Wise RS, Covar R, Irvin CG, Kercsmar CM, Kraft M et al. Asthma 
outco mes: pulmonary physiology. J Allergy Clin Immunol. 2012 Mar;129([ADDRESS_31181]): S65 -
87. 
Wang Y, Zhu H, Madabushi R, Liu Q, Huang SM, Zineh I. Model -Informed Drug 
Development: Current US Regulatory Practice and Future Considerations. Clin Pharmol 
Ther. 2019;105(4 ):899 -911. 